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Abstract 
There are a number of diseases that are caused by, or depend on, irregular 
angiogenesis. In cancer, tumors require new vasculature in order to proliferate. In 
neovascular age-related macular degeneration (NVAMD), aberrant angiogenesis can 
result in leakage that damages the retina, causing progressive blindness in patients. Other 
ocular diseases, such as macular edema and proliferative diabetic retinopathy, also 
depend on diseased blood vessels, impairing the sight of many millions of people around 
the world. Therefore, blocking these pathologies has been, and continues to be, an 
important target of research and therapy. 
Peptide delivery and genetic therapy are two promising strategies for the 
treatment of a number of diseases. Gene therapy can be used to replace lost function both 
in the case of inherited and acquired diseases, such as in cancer. Here, a non-viral 
polymeric strategy is described for the delivery of DNA. Poly(beta-amino esters) (PBAE) 
are a class of cationic, hydrolytically degradable polymers that can electrostatically 
complex with genetic material to form gene delivery nanoparticles. The modular structure 
of the PBAEs allows for the creation of a library of structures with varying transfection 
abilities. These PBAEs are used to deliver both reporter and functional genes. Polymer 
structures that optimally transfect cancer cell types, such as small cell lung cancer, and 
endothelial cell types, such as human retinal endothelial cells, are identified. The delivery 
of a functional gene in vivo shows inhibition of tumor growth in a mouse model. The 
delivery of reporter genes allows for the identification of PBAEs that can preferentially 
transfect retinal endothelial cells over retinal epithelial cells in vitro. Therefore, it is 
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shown that PBAEs can be a useful platform to deliver DNA both directly to cancer cells 
and to endothelial cells as a treatment for angiogenesis dependent diseases. 
Peptides have a number of favorable therapeutic properties, such as high 
specificity. Certain serpin-derived and collagen-IV derived peptides have been shown to 
have potent in vitro and in vivo anti-angiogenic properties. However, peptides are often 
difficult to translate to the clinic due to high biological clearance and poor biodistribution. 
Here, the use of nanoparticle and microparticle formulations are described that can 
counter these limitations and extend the activity of anti-angiogenic peptides by controlled 
release over time. A number of poly(lactide-co-glycolide) (PLGA) based nanoparticle 
systems are also developed for the release and passive targeting of the collagen-IV 
derived peptide for cancer applications. A composite polymeric microparticle system, 
using PBAE and PLGA, is developed for the treatment of NVAMD. This delivery system 
is able to release the serpin-derived peptide and inhibit neovascularization in a clinically 
relevant mouse model over many months. A PLGA microparticle system is also 
optimized for the release of the collagen-IV derived peptides, with improved long-term 
efficacy observed in the clinically relevant mouse model. 
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Chapter 1 
Introduction to the Thesis 
 
1.1 Outline of the Thesis 
The field of drug and gene delivery is discussed in chapters 2 and 3. Chapter 2 
focuses on drug delivery as it pertains to angiogenesis in disease. Anti-angiogenic 
therapies for diseases dependent on aberrant angiogenesis are discussed, with a focus on 
eye diseases and cancer. Chapter 3 details electrostatic methods that can be used to 
enhance gene delivery in a number of applications. 
The thesis is broken up into three aims. In Aim 1, a strategy for targeting and 
treating the vasculature, using polymeric non-viral gene delivery, is described. In this aim, 
a library of poly(beta-amino ester)s (PBAE) is characterized and employed to transfect 
both cancer (small cell lung cancer) and endothelial (human umbilical and human retinal) 
cells. The transfection is done with both reporter genes and then later functional genes. 
Aim 2 then explores another approach to anti-angiogenic therapy by the delivery of a 
peptide therapeutic in a biodegradable microparticle system. The focus of this aim is 
neovascular age-related macular degeneration (AMD), with the goal of creating a long-
term treatment option. In Aim 3, additional anti-angiogenic therapies are created through 
the use of a different anti-angiogenic peptide and both microparticle and nanoparticle 
systems. A microparticle system is first developed with the goal of further improving the 
long-term efficacy and translatability of an ocular drug delivery system to treat 
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neovascular AMD as well as macular edema. Peptide encapsulation in, and presentation 
on, nanoparticles is the focus of the second half of Aim 3, with goal of delivering this 
peptide-based nanotherapeutic to treat solid tumors. In vivo data is presented that shows 
promise for future therapeutic systems. 
 
1.2 Specific Aims of the Thesis 
Aim 1: To develop a library of biodegradable poly(β-amino esters) for nanoparticle 
based non-viral gene delivery for angiogenesis dependent diseases 
PBAEs have previously been shown to be effective at transfecting a number of 
cell types. Here the goal is identify specific structures that could be useful for transfecting 
small cell lung cancer (H446), human umbilical vein endothelial (HUVEC), and human 
retinal endothelial (HREC) cell lines. The first step was to synthesize and characterize 
both the polymers and nanoparticles, including performing gel-permeation 
chromatography (GPC), nuclear magnetic resonance (NMR), nanoparticle tracking 
analysis (NTA), dynamic light scattering (DLS). A focus of the characterization was to 
develop a new protocol for estimating the number of plasmid per nanoparticle (NP). This 
protocol is described in chapter 4. The number of NPs in solution was quantified by 
NTA. Using the assumption that all plasmid are complexed into NPs, supported by gel 
electrophoresis data, the number of plasmids per particle can be calculated. In 
collaboration with Dr. Christine Hann’s lab, these PBAEs were used to target small cell 
lung cancer, as described in chapter 5. A library of PBAEs was first screened against 
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H446 cells. Those with highest transfection level, as measured using a luciferase assay, 
without causing toxicity, were selected to test in a xenograft animal model. In this model, 
p53 was delivered with PBAEs intratumorally and a reduction in tumor growth was 
observed. Chapter 6 describes a collaboration with Dr. Elia Duh’s lab, in which PBAEs 
were screened on HUVECs and HRECs, as well as on RPEs. We observed that certain 
structures might have an ability to transfect one cell type over another. Additionally, 
there were PBAEs that were able to transfect all these cell types better than currently 
commercially available reagents, such as Lipofectamine 2000 and FuGene HD. More 
globally, while there was a good correlation of transfection by PBAEs between the two 
endothelial cell types, this correlation was much lower when comparing the endothelial 
and epithelial cell types. This cell type tropism can potentially be taken advantage of in 
vivo in the development of gene delivery therapies. 
 
Aim 2: To develop poly(lactide-co-glycolide) and poly(β-amino esters) 
microparticles for anti-angiogenic, hydrophilic, serpin-derived peptide delivery to 
treat neovascular age-related macular degeneration 
Dr. Aleksander Popel’s lab has previously discovered and developed peptides 
with potent anti-angiogenic properties. These peptides have been shown to inhibit cell 
proliferation, adhesion, and migration, as well as reduce tumor growth in vivo in various 
mouse models. The use of these peptides to treat choroidal neovascularization (CNV) has 
been more recently explored. However, peptides are usually poor therapeutics due to 
relatively fast clearance and degradation rates. Due to the likely need for intravitreal 
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injections to treat CNV, reducing the number of such injections is a desired clinical goal. 
Therefore, chapter 7 describes a new therapeutic consisting of a novel serpin-derived 
peptide encapsulated within a biodegradable microparticle was developed. The peptide 
used here is a negatively charged serpin-derived peptide. In the first step, this peptide is 
complexed with biodegradable and cationic PBAEs, then encapsulated in poly(lactide-co-
glycolide) PLGA microparticles, which are also biodegradable in water. These particles 
were characterized using NTA, DLS, scanning electron microscopy (SEM), as well as by 
quantifying the release rate of the peptide in vitro. Subsequently, this system was tested 
in a laser induced CNV mouse model in collaboration with Dr. Peter Campochiaro’s lab. 
Injections of samples and controls were done on day zero, after which choroidal 
neovascularization was induced over several months in replicate batches of mice. For 
each time point, laser-induced choroidal neovascularization began two weeks before final 
assay time. We evaluated whether the amount of peptide available at each time point, 
through release form the microparticle, could reduce the amount of CNV. We observed a 
statistical significant reduction over the course of 14 weeks in the mouse model. 
 
Aim 3: To develop PLGA-based microparticles and nanoparticles for anti-
angiogenic, hydrophobic, collagen-IV derived peptide delivery 
Developing particle-based therapeutics that utilized biomimetic, hydrophobic, 
collagen-IV derived peptides was the focus in Aim 3. This peptide has a number of 
properties that lend it to be more translatable to the clinic. It has a monotonic response 
curve, has a strong anti-angiogenic effect that can block both VEGF-mediated and non-
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VEGF-mediated angiogenesis, and its target is known. Chapter 8 describes the 
investigation of this peptide, along with the microparticle system used to deliver this 
peptide. In order to optimize the release system for this peptide, PLGA with varying L:G 
ratio was used. Once one PLGA polymer was selected, this system was evaluated in both 
a laser-induced choroidal neovascularization mouse model and as a TET-Opsin genetic 
inducible macular edema mouse model. Promising results have been observed in terms of 
the particle-peptide therapeutic’s ability to reduce CNV, possibly reverse CNV, and 
prevent leakage-induced retinal detachment. Long-term efficacy was also observed in the 
microparticle system in a CNV mouse model for at least four months.  
In order to deliver these peptides for cancer applications, systemic administration 
leading to tumor targeting is required. Chapter 9 describes the various nanoparticle (NP) 
formulations that were developed to encapsulate peptide, including PBAE/peptide self-
assembled nanoparticles, PLGA nanospheres, PLGA nanoellipsoids, and PLGA-PEG 
micelles. Based on biodistribution experiments, the PLGA-PEG NPs can passively reach 
solid tumors in a breast cancer subcutaneous mouse model due to the biophysical 
properties of the nanoparticle. 
 
 
This chapter was originally published as Bhise NS, Shmueli RB, Sunshine JC, Tzeng SY, Green JJ. “Drug 
Delivery Strategies for Therapeutic Angiogenesis and Antiangiogenesis.” Expert Opin Drug Deliv. 2011 
Apr;8(4):485-504. 
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Chapter 2 
The Role of Angiogenesis in Disease and as a Target for 
Therapeutics 
 
2.1 Introduction 
Vascular perfusion is essential for adequate nutrient, waste and gas exchange for 
all tissues in the human body. Many diseases stem from insufficient blood perfusion, 
resulting in a shortage of oxygen, termed hypoxia. Angiogenesis is an important 
mechanism of physiological vascularization in adults, whereby new blood vessels sprout 
from existing ones by a coordinated interaction of endothelial cells with angiogenesis-
inducing signals, like growth factors (GFs), hypoxic conditions, and extracellular matrix 
(ECM) components, specifically adhesion molecules [1]. Vasculogenesis is a 
neovascularization process that involves recruitment of circulating vascular progenitor 
cells, originating from the multipotent hemangioblast precursor cell residing in bone 
marrow or peripheral blood, instead of local endothelial cells as in case of angiogenesis 
[2]. Traditionally, vasculogenesis was considered to occur only during embryonic 
development of the circulatory system [3], and neovascularization in adults was believed 
to occur via angiogenesis or arteriogenesis, a process of flow-induced remodeling of pre-
existing blood vessels. However recent studies have suggested that circulating endothelial 
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progenitor cells can be recruited by cytokines to induce limited vasculogenesis in 
ischemic areas in adults [4]. 
Angiogenesis is also critical in pathologic states such as psoriasis [5], 
atherosclerosis [6, 7], rheumatoid arthritis [8, 9], diabetes [10], cancer [11], and ocular 
neovascularization [12] in age-related macular degeneration (AMD) and diabetic 
retinopathy. Normal angiogenesis is usually focal and self-limited, whereas in pathologic 
processes, aberrant angiogenesis is often persistent and widespread [13].  
A wide range of pro- and anti-angiogenic processes act in concert to orchestrate 
angiogenesis (Figure 2.1). Among the many GFs implicated in angiogenesis such as 
vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF) and fibroblast growth factors (FGFs) [14], VEGF has 
been identified as the most crucial. VEGF is relatively specific to endothelial cells, and 
has a non-redundant role during the “angiogenic switch” (the critical point where tumors 
begin to induce angiogenesis) [14, 15]. VEGF regulates several endothelial cell functions, 
including
 
mitogenesis, vascular tone (inducing hypotension), and vessel permeability [16], 
as well as inducing the production
 
of plasminogen activators and proteases that help to 
degrade the basement membrane and allow for formation of new blood vessels [17]. 
Hypoxia, the hypoxia inducible factor HIF-1, and other GFs and cytokines, regulate the 
transcription of erythropoietin and VEGF [16]. The vasoactive and angiogenic functions 
of VEGF
 
are mediated primarily through VEGFR-2 [16]. VEGFR subsequently activates 
multiple signaling pathways (Ras/MAPK, FAK, PI3K/Akt, PLCγ) [18], which leads to 
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angiogensis. Additional GFs such as bFGF, PDGF, and TGFβ help to stabilize newly 
formed blood vessels by recruiting pericytes and smooth muscle cells [1, 19].  
2.1.1 Tumor Angiogenesis and Therapy 
Overexpression of oncogenes or downregulation of tumor-suppressive genes 
resulting in aberrant, proliferative cells is essential, but not sufficient, for the 
development of a lethal tumor. Tumor angiogenesis is crucial for the growth and 
persistence of tumors and metastases. This was first described in 1971 by Judah Folkman, 
who observed that tumors could only grow to 2 mm in diameter without the growth of 
new blood vessels [11]. Two millimeters is the distance that oxygen can diffuse through 
tissue [20]; tumors need blood vessels to supply the oxygen and nutrients necessary for 
survival and proliferation [11]. Folkman further postulated in 1971 that a “tumor-
angiogenesis factor” (TAF) induces blood vessel growth and that inhibition of TAF may 
halt tumor progression, which he termed “antiangiogenic therapy” [11].  
Compared with cancer cells, endothelial cells in malignant tumors are genetically 
stable, nonmalignant, and rarely drug resistant, making them a relatively stable target 
[21]. Destroying the tumor vasculature can also amplify a drug's antitumor effect on a 
per-cell basis [22]. Anti-angiogenesis can initially help to “normalize” tumor vasculature, 
increase tumor perfusion, and alleviate tumor hypoxia, thereby increasing the efficacy of 
conventional anti-cancer
 
therapies if both anti-angiogenic and anti-cancer therapies are 
carefully scheduled [23]. At later time points, VEGF inhibition induces tumor hypoxia as 
more of the tumor vasculature is starved [24].  
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Many angiogenic inhibitors have been developed, and several such as 
bevacizumab [25], ranibizumab [26], pegaptanib [27], aflibercept [28], cetuximab [29, 
30], panitumumab [31], trastuzumab [32, 33], gefitinib [34], erlotinib [35], sorafenib [36, 
37], sunitinib [38, 39], temsirolimus [40], and everolimus [41] (Table 2.1) have passed or 
are close to passing FDA approval and are being utilized in therapy for various cancers 
and AMD. In addition, a large number of chemotherapeutics developed for cancer were 
later shown to have anti-angiogenic properties, especially when given often at lower 
doses in “metronomic chemotherapy” [42]. However, the current therapies on the market 
mostly target VEGF, its receptor, or the tyrosine kinases that phosphorylate its receptor. 
Since angiogenesis is a result of the interplay between several pro- and anti-angiogenic 
factors, simultaneous targeting of several pro-angiogenic signaling cascades (rather than 
just VEGF) should be one of the most promising anti-angiogenic approaches [15].  
2.1.2 Age-related Macular Degeneration Biology and Therapy 
AMD is the leading cause of blindness in the elderly and is marked by loss of 
central vision. It is the most common of a large number of inherited and acquired diseases, 
collectively called macular degeneration (MD) [43]. AMD can be further split into two 
main forms, exudative/wet (or choroidal neovascular) and non-exudative/dry. Wet AMD 
is less common but is a leading cause of blindness [44]. Dry AMD results from atrophy 
of retinal pigment epithelium (RPE), which leads to photoreceptor atrophy [45]. The wet 
form is an advanced form of AMD and is treatable with anti-angiogenic drugs. Choroidal 
neovascularization (CNV), the formation of new blood vessels from the choroids of the 
eye, leads to leakage of blood and serum, which damages the retina by stimulating 
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inflammation and scar formation. This damage to the retina causes central vision loss and, 
eventually, blindness if left untreated. 
Neovascular AMD results from an interplay of genetic, metabolic, and 
environmental factors [46]. However, while the exact causes remain an active research 
area, it is known that angiogenesis and vascular imbalance play a central role in this 
disease, importantly involving VEGF. Many cells of the eye produce VEGF, including 
RPE cells, pericytes, endothelial cells, glial cells, Muller cells, and ganglion cells [47]. In 
addition to stimulating blood vessel growth, VEGF can also stimulate endothelial cells to 
produce matrix metalloproteinases (MMPs), which can degrade extracellular matrix and 
allow new vessels to grow into tissue [47]. It has been demonstrated that VEGF 
overexpression in mouse models and in human studies leads to CNV [46]. Other 
molecular factors are also important in AMD, including pigment epithelium-derived 
factor (PEDF), basic fibroblast growth factor (bFGF) and angiopoietins [47]. Stimuli due 
to hypoxia, ischemia, inflammation, and oxidative stress (all of which can accumulate 
with age) can influence the production and balance of these factors.  
Recent successful treatments of AMD have been developed that target these relevant 
effectors, specifically treating blood vessel growth by targeting VEGF. As with cancer 
treatments, improved clinical results might be achieved through combination therapy that 
targets multiple GFs. 
 
2.2 Drug Delivery Systems 
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Synthetic and biological materials have been studied in the development of safe 
and effective drug delivery systems. The chemical and physical properties of synthetic 
materials, including polymers, are often easier to control, but their biocompatibility must 
be carefully assessed. Biological materials already possess many desired properties but 
may be more difficult to modify or manufacture as well as being potentially 
immunogenic. Strategies under current investigation in the field of drug delivery are 
discussed below and summarized in Table 2.2, with particular focus on those that 
promote or suppress angiogenesis. 
2.2.1 Drug-Agent Conjugates 
 Perhaps the simplest drug delivery system in concept is the direct conjugation of a 
drug to a delivery agent. Because poly(ethylene glycol) (PEG) has been shown to 
increase circulation time after systemic delivery, several therapeutics have been 
PEGylated with the goal of avoiding biological clearance mechanisms, some of which 
have been translated to the clinic or are in clinical trials. Also in use are antibody-drug 
conjugates (ADCs) for specific targeting, such as blocking angiogenesis by using 
cytotoxic drugs bound to antibodies against markers of tumor vasculature [48]. Adhesive 
peptide moieties like Arginine-Glycine-Aspartate (RGD) sequences can be used to 
localize a drug carrier to desired tissues [49, 50]. Because RGD sequences bind to 
integrins, this method has been used to target vasculature and suppress angiogenesis [51]. 
Other delivery conjugates bind to a therapeutic in order to increase solubility or improve 
biodistribution, as in the case of Abraxane™, in which the cancer drug paclitaxel is 
bound to albumin in order to increase its solubility and thereby reduce solvent-mediated 
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toxicity [52]. 
2.2.2 Implanted Drug-Loaded Materials 
 Another strategy for drug delivery is the use of implanted depots, usually made of 
biological or synthetic polymers that are loaded with a therapeutic. An advantage of this 
type of system is its suitability for localized delivery. Generally, as in the case of the 
GLIADEL
®
 wafer made of poly(carboxyphenoxy propane:sebacic acid) discs loaded 
with bis-chloronitrosourea (BCNU) and used to treat glioblastoma multiforme (GBM) 
[53, 54], the depot is implanted directly at the site of the tissue to be treated. This 
eliminates the need for targeting mediated by specific interactions between chemical or 
biological moieties. Furthermore, drug-loaded depots can themselves be substrates for 
cell growth, as in the case of GF-loaded hydrogels [55-57]. These can be used as tissue 
engineering scaffolds that provide specific cues for cell survival and proliferation, wound 
healing, or angiogenesis [58, 59]. One concern with implantable reservoirs is the 
potential for local inflammation or foreign body response [60, 61]. They are also limited 
for use in systemic drug delivery [62, 63] unless the loaded drug can freely permeate 
through the matrix. 
2.2.3 Micro- and Nanoparticles for Drug Delivery 
 An alternative to large, implanted drug reservoirs is a micro- or nanoparticulate 
system. In many cases, these are small enough to be injected, reducing injury due to 
surgical implantation. Among the frequently investigated synthetic polymers are 
polyesters, including poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly( -
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caprolactone) (PCL), and derivatives or copolymers of the above, like poly(lactic-co-
glycolic acid) (PLGA). These degrade hydrolytically under physiological conditions [64, 
65] and are biocompatible in vitro and in vivo [66]. They are used in nanoparticulate 
delivery of proteins, small molecules, and genes [67, 68], as well as microparticulate 
delivery of proteins and small molecules [66, 69, 70]. In one case, VEGF and 
dexamethasone were released slowly from PLGA particles to encourage angiogenesis 
while minimizing local inflammation [71]. The drug release kinetics, degradation, 
biodistribution, and clearance of synthetic particles are dependent on several factors, 
including size, geometry, charge, surface chemistry, encapsulation procedure, and the 
encapsulated drug itself [72-75]. Other than direct injection, particles can also be 
embedded within a larger mesh, thereby providing localized delivery similar to 
implantable systems while also allowing for a wider biodistribution as particles are 
released by diffusion or degradation of the mesh [76-78]. One difficulty with particulate-
based systems, however, is their tendency to be cleared relatively quickly through the 
liver, spleen, and kidneys in a size-dependent manner [79, 80]. Though circulation time 
can be lengthened (by PEGylation to form "stealth" particles [81]) and their targeting can 
be tailored (by changing the size or geometry of the particles and changing the surface 
chemistry [74, 82, 83], for many systems, an ideal in vivo distribution has yet to be 
achieved. 
 Amphiphilic lipids, surfactants, or block copolymers constitute another form of 
drug delivery. Self-assembly of amphiphiles into colloids causes micelle formation, in 
which a lipophilic core is isolated from the surrounding aqueous phase by an external 
hydrophilic shell or corona [84]. A bilayer of these molecules can form vesicles classified 
 
14 
as liposomes with hydrophilic moieties both at the core and in the surrounding corona, 
while the lipophilic moieties associate within the bilayer. The biphasic character of these 
molecules allows them to serve as vehicles for either hydrophilic or lipophilic drugs [85-
87] and techniques can tailor the particles' size, lamellarity, fluidity, and hydrophobicity 
[88-91]. Liposomes were found to be effective in targeting the mononuclear phagocyte 
system (MPS) because they were easily captured by MPS cells and removed from 
circulation [92, 93]; this short lifetime in the bloodstream is a disadvantage, however, for 
targets beyond the MPS. Altering surface charge or size, conjugation of surface 
molecules like PEG, and coadministration of suppressive drugs have been shown to 
alleviate this problem to some degree [89, 94, 95]. Similar to the surfactant- and lipid-
based micelles and liposomes are nanocapsules and polymersomes. Nanocapsules have a 
lipophilic interior consisting of the lipophilic block of a copolymer, which serves as a 
drug reservoir and is surrounded by a hydrophilic core, while polymersomes are 
composed of bilayers, similar to liposomes [96]. Nanocapsules and polymersomes are 
made of semi- or totally synthetic copolymer amphiphiles, which can be of greater 
molecular weight than naturally-occurring lipids [97]. These differences impart a more 
fluid, dynamic character to liposomes and micelles that are suitable for many biological 
processes [98], while nanocapsules and polymersomes often display more stability than 
fluidity [99], in addition to the flexibility granted by the ability to control chemical 
properties of the polymers [97, 98]. 
Cationic biomaterials, including both synthetic and biological polymers, have 
been used to form complexes with nucleic acids for the purpose of nanoparticulate gene 
delivery. Cationic moieties in polymers, including polyethyleneimine [100, 101], 
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chitosan [102], polyamidoamines [103], and poly( -amino esters) [104, 105], can interact 
with anionic DNA, RNA, or oligonucleotides. The polycations mediate transport into cell, 
through degradative cellular compartments, and into the cytoplasm, nucleus, or other 
compartments where the cargo is active [101]. These materials have recently been studied 
for their potential to treat or cure many diseases, including those whose genetic basis is 
known but whose downstream molecular effectors are hard to target. Polymeric gene 
delivery has gained attention as an alternative to viral gene delivery, which suffers from 
limited cargo capacity, immune response, and the possibility of insertional mutagenesis 
[106]. Recent work on polymeric gene delivery to human endothelial cells, for example, 
has demonstrated virus-like efficacy along with minimal cytotoxicity [107-109]. In 
addition to these particles' potential to therapeutically regulate any gene of known 
sequence, gene delivery can also be used as a first step in cell-based drug delivery 
systems.  
2.2.4 Cell-Based Delivery Systems 
Ex vivo gene delivery can be used as a precursor to cell-based, pro-angiogenic 
drug delivery. In one study, human mesenchymal stem cells (hMSCs) were transfected 
with polymeric particles to express VEGF at high levels and subsequently seeded onto 
polyester scaffolds in order to promote angiogenesis in vivo [110]. Success in a similar 
system was seen with VEGF-expressing endothelial cells and adipose-derived stromal 
cells [111]. Cell-based systems are attractive because drug dose and release kinetics can 
be controlled over long periods of time of up to nearly a year [112], provided that the cell 
stably expresses the desired therapeutic. Other studies have used cells as a method of 
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delivering nanoparticles, allowing for a two-stage release of drugs or proteins [113], 
particles that serve as MRI contrast agents [59], or particles that enhance radiation 
therapy [114].  
Delivery of cells can also be combined with other biomaterials such as hydrogels 
or other polymer capsules [110-112, 115] that encapsulate cells. In one study, Chinese 
hamster ovary (CHO) cells transfected with VEGF cDNA and subsequently encapsulated 
in alginate and poly(l-lysine) microspheres were shown to increase angiogenesis after 
implantation in mice [116]. Cell-based therapies, however, pose additional safety 
concerns, including the potential for inflammation, immune response or rejection of the 
graft, and unanticipated host-donor cell interactions. There are also questions of which 
cells to use and how to harvest enough for therapeutic purposes and dose regulation, 
especially for cases in which the secreted protein might have an off-target effect on the 
secreting cell itself [117-119]. 
2.2.5 Nondegradable Particles 
 While a great deal of research has focused on biodegradable particles, 
nondegradable particles are also studied for delivery of therapeutics. Mesoporous silicon 
microparticles can be loaded with proteins and other therapeutics, including insoluble 
drugs [120], and their microstructure allows surface interactions to be minimized, 
reducing damage to a drug during the loading process [121]. Drug delivery systems like 
these can be nested, such as with mesoporous microparticles that encapsulate 
nanoliposomes that are themselves loaded with small interfering RNA to create 
multistage delivery systems [122]. Another class of nondegradable particles is metal 
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nanoparticles, notable for their monodispersity, small sizes, and magnetic and thermal 
properties. Iron oxide nanoparticles have been used as MR contrast agents as they 
accumulate passively in tumor vasculature [123, 124] and can be encapsulated in lipids or 
polymeric particles[125]. They can also be conjugated to ligands like RGD that can 
actively target the particles to areas of high angiogenesis, such as tumors [126]. Gold 
nanoparticles, in part due to their relative biocompatibility, have been used as vehicles for 
gene or drug delivery [127, 128] and for thermal therapy [129]. While many of these 
particulate systems allow greater control over fabrication and processing variables, many 
of them are also limited by their toxicity [130, 131]. 
 
2.3 Anti-angiogenic Drug Delivery Systems  
2.3.1 Anti-Cancer Drug Delivery Concepts and Systems 
A key concept when considering the development of controlled release 
formulations for anti-angiogenic therapy is that many angiogenesis inhibitors have a 
biphasic dose-response curve [132]. As a result, maximum tolerated dose is not the 
paradigm to use for anti-angiogenic therapy [15]. As an example, a high dose regimen 
(120 mg/kg/day) of sunitinib leads to a compensatory increase in pro-angiogenic proteins 
and reduced survival and increased metastases in a mouse model, while a lower dose 
regimen (40-60 mg/kg/day) has the opposite, beneficial effect [133, 134]. Combinations 
of therapies, such as blocking the signaling of more than one GF, has also been shown to 
be more effective in some cases (Figure 2.2A-B). For example, researchers have used 
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simultaneous administration of antibodies against both VEGFR-2 and PlGF to suppress 
tumor growth as well as an anti-angiogenic antibody to enhance the efficacy of a 
conventional chemotherapy drug. This can be especially useful when a certain type of 
tumor is known to be resistant to one treatment but not another, or when treatment with a 
low dose of two therapies is less toxic to healthy cells than a high dose of either one the 
individual therapies [135]. In other cases, combination therapy is no more effective than 
the single therapy (Figure 2.2C), highlighting the importance of a systems level 
understanding of the effect of one pathway on another [136]. 
Nanoparticles can be effective in targeting tumor vasculature due to specific and 
non-specific biochemical and biophysical mechanisms. One of the advantages of 
nanoparticle-mediated delivery is due to the enhanced permeability and retention (EPR) 
effect (Figure 2.1). Nanoparticles that are ~50-200 nm have been shown to accumulate in 
tumors, provided they have a long circulation time, as a result of the leaky vasculature 
and absence of a draining lymphatic system present in the tumor bed [137-139]. Active 
targeting of endothelial molecules that are upregulated in response to high levels of 
angiogenesis can also be used for additional specificity. The size exclusion caused by 
leaky vasculature, as well as the increased angiogenesis at tumor sites, has been exploited 
to image tumor angiogenesis via metallic nanoparticles [140]. In this case, the passive 
targeting of nanoparticles via the EPR effect was enhanced by active targeting via -v- -
3 integrin on the nanoparticles. Another example of an approach combining EPR with 
remote activation is that of metallic nanoshells, which accumulate in tumor vasculature 
prior to being activated externally by near-infrared light for thermal ablative therapy 
[129]. Other formulations include the conjugation of integrin and VEGF receptor 
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antagonists, which target sites of angiogenesis and also suppress signaling through 
receptors to inhibit vessel growth [141].  
The charge of a drug or delivery vehicle affects its ability to penetrate into tissue, 
accumulate in desired sites, and escape rapid clearance from the bloodstream [142, 143]. 
Experimental anti-angiogenic therapies have included cationic liposomes, which can 
target neovasculature, to deliver the cancer drugs oxaliplatin [144] or paclitaxel [145], 
with or without pegylation to increase circulation time. Both of these exhibited not only 
the expected anti-tumor activity from the platinum analog drugs, but also a marked anti-
angiogenic effect. 
The abnormal vasculature of tumors, while potentially useful for drug delivery 
applications, can also be a hindrance. For example, one study found that tumor vessels 
composed of cells with heterogenous mutations caused preferential extravasation of 90-
nm liposomes (Figure 2.3) [146]. This could potentially contribute to tumor recurrence 
from the cells in the part of the tumor mass that were not exposed to extravasating drug-
loaded vehicles. Another challenge to cancer drug delivery is the increased interstitial 
pressure in the tumor space [147] and decreased perfusion near the center of the tumor 
mass [148]; as a result, most unmodified particles or other delivery agents can penetrate 
only a small distance. Peptide sequences that cause tumor penetration have been 
identified [149], and efforts are being made to use this principle to enhance the effect of 
peptides to tumor endothelium [150]. Also contributing to the problem of low tumor 
penetration is the high expression of certain collagens by tumor endothelial cells [151]. 
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The difficulties in targeting the core of tumors further motivates the approach of targeting 
tumor vasculature, as it is more easily reached. 
Recent studies exploring overexpressed genes [152] on tumor endothelium have 
shown that the collagens that may prevent tumor penetration can also be used as targets 
for drug delivery. For example, a di-Fab' fragment-PEG conjugate called CDP791 which 
targets VEGFR-2 was recently shown to prevent VEGF signaling and reduce 
angiogenesis in a phase II clinical trial for the treatment of non-squamous non-small-cell 
lung cancer [153]. A review of these delivery challenges makes it clear that simultaneous 
targeting of multiple barriers may improve the likelihood of success of anti-angiogenic 
treatments delivered to tumors. 
2.3.2 AMD Drug Delivery Concepts and Systems 
There are currently two anti-VEGF treatments approved in the US for AMD: 
pegaptanib and ranibizumab. Bevacizumab, which is approved for some cancers, is also 
routinely used off-label for AMD. Bevacizumab is a murine recombinant, humanized, 
monoclonal antibody that has been shown to bind to and inhibit all known isoforms of 
VEGF [46]. Ranibizumab is an antibody fragment developed from the same murine 
anitbody as bevacizumab, also binding to all known isoforms of VEGF [46]. The 
constant region was eliminated, to improve retinal penetration and reduce inflammation 
response. Specific amino acids were substituted to increase its binding affinity to VEGF 
[46]. It is administered via intravitreal injections once per month and has a half-life of 
three days [154]. Both have been found to work similarly well, although off-label 
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bevacizumab use is considerably less expensive (about $50 per dose as compared to 
about $2000 per dose) [155, 156]. 
Long-term anti-VEGF therapy can cause detrimental effects, however, and 
frequent intravitreal injections could damage the eye [43]. These treatments do not help 
all patients, as approximately 20% still lose vision over time. Newer treatments include 
VEGF-TRAP, a recombinant protein that targets VEGF rather than the VEGF receptor 
[157], and a recently completed phase III trial has found it to be comparably effective to 
ranibizumab. 
Improving the route of drug delivery to the back of the eye is a central challenge 
that needs to be addressed. There are various routes of entry into the eye, including 
topical application, transscleral delivery, intravitreal injection, and systemic delivery. 
Topical application is the least invasive of these methods. However, drugs delivered 
topically must cross corneal epithelial layers, avoid aqueous humor clearance 
mechanisms, and diffuse all the way to the posterior eye [158]. Transscleral delivery is 
relatively less invasive and provides a more direct route to the posterior segment as 
compared to topical application. It still must pass a number of barriers, including tissue 
penetration, avoiding clearance due to circulation, and avoiding metabolic activity of 
these cellular barriers [159]. 
Intravitreal injections allow drugs or implants to be delivered directly into the 
vitreous. This method is also the most invasive, can cause trauma to the eye, and as a 
result leads to reduced patient compliance [158]. Systemic delivery has the advantage of 
being easier for patients than intravitreal or transscleral delivery, as well as the potential 
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ability to delivery higher doses. The limitations include increased risks for side effects in 
other tissues, as well as the difficulty of crossing the blood-retinal barrier [160]. 
Currently approved drugs are usually delivered via intravitreal injections, as this is the 
most direct route. However, depending on the delivery platform, other routes might be 
used. For example, a drug delivery reservoir implanted in the sclera [161] contains a 
controlled-release membrane fabricated from cross-linked polyethylene glycol with 
interconnected collagen microparticles embedded within the membrane (Figure 2.4). A 
constant and controllable release rate was obtained by tuning the membrane's chemical 
and physical properties. 
Extending the half-life of the therapeutic is also key as it can reduce the dosage, 
frequency of injections, costs, and negative patient outcomes. As previously mentioned, 
PEGylation can increase half-life, as in the case of pegatanib, a currently approved AMD 
therapy. This PEGylated aptamer, made of short RNA strands with 3D conformation, 
binds to one specific isoform of VEGF [27]. 
In another strategy, an anti-angiogenic integrin antagonist, C16Y, peptide was 
encapsulated within PLA/PLA-PEO nanoparticles [162]. Intravitreal injections led to 
improved anti-angiogenic outcomes attributed to the increased half-life of the peptide in 
the eye. Additionally, nanoparticles were observed to penetrate the retina and localize to 
retinal pigment epithelial layer. The identification of a number of other anti-angiogenic 
peptides has also been achieved through computational and experimental methods [163]. 
These peptides inhibit proliferation and migration of HUVECs, as well as reduce tumor 
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size in in vivo cancer models [164]. Encapsulation of these novel agents in particles may 
enable combinatorial delivery, long-term activity, and enhanced efficacy.  
There has been extensive work on drug depots in the context of ocular drug 
delivery for anti-angiogenesis. Molokhia et al. developed a capsule drug ring (CDR) that 
can be implanted in the peripheral lens capsule during cataract surgery [165]. This semi-
permeable poly(methyl methacrylate) depot can release bevacizumab and other drugs in a 
continuous and controlled fashion and may allow for the replacement of intravitreal 
injections. This system is still being tested in animal models and there are clinical trials 
underway for other implantable drug delivery systems. An intravitreal polymeric non-
biodegradable matrix insert system has been utilized for the delivery of fluocinolone 
acetonide to treat diabetic macular edema [166]. The inserts released the drug 
consistently for over a year in patients. Other implants degrade over time, reducing any 
possible future complications in the eye [167]. Systemic delivery may also be possible by 
temporarily easing the blood-retinal barrier [168], as shown in the delivery of RNAi to 
mice. 
 
2.4 Conclusion 
Angiogenesis is crucial not only to normal biology but also to many diseased 
states, including cancer, AMD, and ischemia. Drug delivery paradigms are being 
developed that combine well-studied principles of material transport and 
pharmacokinetics with novel biomaterials and fabrication methods. Some of these 
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therapeutic systems have been translated to the clinic with success. However, additional 
research is needed to further optimize the delivery of drugs currently available and to 
identify new treatment modalities.  
 
2.5 Expert Opinion 
 Advanced drug delivery systems can benefit therapeutic angiogenesis and anti-
angiogenesis by increasing specificity, prolonging duration, and combining multiple 
components together. As additional information is gleaned on a systems level view of 
angiogenesis, precision delivery in both time and space of multimodal agents to control 
angiogenesis will become increasingly important. Drug delivery systems are the enabling 
technologies to translate this information into new therapies. 
 Numerous targets have been identified for anti-angiogenic therapies, including 
growth factors and their receptors and ligands localized on tumor vasculature. In the case 
of cancer, despite the ever-increasing understanding of cancer biology and drug delivery, 
current therapies are still plagued by inefficiency, systemic toxicity, and tumor recurrence. 
Because there are so many factors that contribute to excessive tumor angiogenesis and 
growth, and because great flexibility is granted through drug delivery approaches, it will 
be advantageous to consider engineered systems and more than a single pathway to 
decrease angiogenesis in tumors for maximal therapeutic effect. For example, (1) the 
conjugation of targeting ligands to drugs can increase specificity; (2) encapsulation of 
multiple drug-agent conjugates in liposomes or polymer nanoparticles can protect the 
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drugs and facilitate extravasation from the bloodstream and into tumor tissue; (3) control 
of physicochemical properties can further narrow the tissues targeted by the particle and 
also increase efficiency; (4) the particle itself can be protected from clearance by 
conjugation of “stealth” molecules or secondary encapsulation in microparticles or 
scaffolds. Furthermore, potentially hundreds of lead drug molecules can be formulated 
together in different combinations into systems that control release dosages and the order 
of drug release. Similarly in AMD, drug delivery strategies could enable codelivery of 
agents for increased potency and reduce the need for repeated intravitreal injections. Such 
anti-angiogenic approaches for both cancer and AMD are now being explored clinically 
to increase both efficacy and specificity. 
 The goal of pro-angiogenic therapies is to successfully deliver key angiogenic 
factors that stimulate revascularization of an ischemic site. In the context of ischemic 
diseases, reperfusion improves the function of the diseased organ; whereas in the case of 
tissue engineered constructs and tissue implantation, revascularization enhances graft 
survival. A critical aspect of developing any therapeutic angiogenesis strategy is to 
optimize the dose, duration of expression, and timing of factor administration. According 
to preclinical data, in nonischemic tissues, induction angiogenesis may be required for a 
period of weeks or months to allow maturation of newly formed capillaries; in an 
ischemic environment, this period of dependence on pro-angiogenic stimulation may be 
longer [169]. A leading failure of many potential therapies is the limited duration of 
angiogenic agent expression in the targeted diseased area. Furthermore, improper 
targeting of angiogenic factors can have deleterious side-effects, including retinopathy 
and buildup of atherosclerotic plaque. To address these issues, it is critical to develop 
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controlled and targeted delivery strategies that can prolong the duration of factor 
exposure. The clinical success of a pro-angiogenic therapy may require a patient-specific 
tailored delivery strategy that accounts for factors such as age, level of tissue damage, 
route of administration, and the native in-vivo environment. Rationally designed 
biodegradable 3D matrices can that act as depots for growth factors and present stimuli to 
communicate with endogenous angiogenic cells are promising technologies. 
Combinatorial strategies that use such smart delivery platforms in conjunction with 
angiogenesis-stimulating cells and growth factors need to be further explored to expedite 
the successful translation of pro-angiogenic therapies. For both pro-angiogenic and anti-
angiogenic approaches, the use of biomaterials to encapsulate biological molecules and 
cells greatly enhances efficacy and will lead to many future clinical therapies.    
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2.7 Tables 
Table 2.1. Angiogenic Inhibitors. 
Drug (Trade name) Target Type of molecule FDA approved 
target(s) 
Bevacizumab 
(Avastin
®
) [25] 
anti-VEGF 
receptor 
humanized mAb mCRC, NSCLC, 
advanced breast 
cancer 
Ranibizumab 
(Lucentis
®
) [26] 
anti-VEGF 
receptor 
mAb fragment wet AMD 
Pegaptanib 
(Macugen
®
) [27] 
anti-VEGF 
receptor 
pegylated anti-
VEGF aptamer 
wet AMD 
Aflibercept (VEGF 
Trap) [28] 
Binds/sequesters 
VEGF-A and 
PLGF 
fusion protein wet AMD 
Cetuximab 
(Erbitux
®
) [29, 30] 
anti-EGFR chimeric IgG1 
mAb 
mCRC, head and neck 
cancer in KRAS-wt 
patients 
Panitumumab 
(Vectibix
®
) [31] 
anti-EGFR fully humanized 
IgG2 mAb 
mCRC 
Trastuzumab  
(Herceptin
®
) [32, 33] 
anti-HER-2 humanized IgG1 
mAb  
Breast cancer 
Gefitinib (Iressa
TM
) 
[34] and 
Erlotinib 
(Tarveca
®
) [35] 
RTKI of EGFR oral small 
molecule 
NSCLC, pancreatic 
cancer in EGFR+ 
patients 
Sorafenib 
(Nexavar
®
) [36, 37] 
RTKI of VEGFR-
1,2,3, PDGFR-ß, 
and Raf-1 
oral small 
molecule 
aRCC, advanced 
hepatocellular 
carcinoma 
Sunitinib 
(Sutent
®
) [38, 39] 
RTKI of VEGFR-
1,2,3, PDGFR- ß, 
and RET 
oral small 
molecule 
aRCC, GIST 
Temsirolimus 
(Torisel
®
) [40] 
mTOR* oral small 
molecule 
aRCC 
Everolimus 
(Afinitor
®
) [41] 
mTOR* oral small 
molecule 
aRCC 
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*inhibits cell division, halts growth signaling, and reduces hypoxia inducible factor (HIF-
1 and HIF-2 alpha) and VEGF expression. Abbreviations: Metastatic colorectal cancer 
(mCRC), Non-Small Cell Lung Cancer (NSCLC), Advanced Renal Cell Carcinoma 
(aRCC), Age-Related Macular Degeneration (AMD), Vascular Endothelial Growth 
Factor (VEGF), Epidermal Growth Factor Receptor (EGFR), Receptor Tyrosine Kinase 
Inhibitor (RTKI), Monoclonal antibody (mAb) 
 
Table 2.2. Drug delivery systems and representative examples and applications thereof. 
Delivery 
System 
Examples Clinical uses / Potential 
applications 
Free drug Small molecule drug against 
receptor tyrosine kinase [133] 
Sunitinib: advanced renal cell 
carcinoma 
Whole antibody against VEGF 
[25] 
Bevacizumab: Metastatic 
colorectal cancer (mCRC), non-
small cell lung cancer (NSCLC), 
advanced breast cancer 
Antibody Fab' fragment against 
VEGF [26] 
Ranibizumab: Exudative age-
related macular degeneration 
(AMD) 
Whole protein rhPDGF [170] Becaplermin: Pro-angiogenesis in 
diabetic ulcers 
Protein with VEGFR-binding 
domains and Fc antibody region 
[163] 
VEGF-TRAP: Anti-angiogenesis 
in tumors and exudative AMD 
Protein regulating ocular blood 
vessel growth [171] 
adPEDF: AMD 
Drug-
delivery 
agent 
conjugates 
RGD sequences bound to drug 
[172] 
EMD 121974 (Cilengitide): Drug 
targeted to vasculature for 
melanoma, glioblastoma, prostate 
cancer 
Interferon alpha bound to PEG 
[173-175] 
Pegasys: antiviral 
PegIntron: antineoplastic 
Fab' fragment against VEGFR-2 
conjugated to PEG [153] 
CDP791: Inhibit VEGF signaling 
in non-squamous non-small-cell 
lung cancer 
Pegylated RNA aptamer targeting 
VEGF [27] 
Pegaptanib: Exudative AMD 
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Implanted 
depots 
VEGF, bFGF, or TGF  
encapsulated in collagen or 
gelatin hydrogels [55, 56, 58, 59] 
Pro-angiogenic tissue engineering 
scaffolds 
Cannula depot injection of 
anecortave acetate [47] 
Controlled release formulation of 
angiostatic steroid for AMD 
Liposomes Cationic liposomes containing 
paclitaxel or oxaliplatin [144, 
145] 
Targeting to tumor vasculature for 
cancer chemotherapy 
RGD-conjugated liposomes 
containing doxorubicin [50] 
Biodegradabl
e micro- and 
nanoparticles 
PLGA, PLA, PCL, 
polyanhydride, alginate, or 
gelatin particles [64-67] 
Injectable or embedded vehicles for 
long-term delivery of proteins, 
mucleotides, or small-molecule 
drugs 
DNA, RNA, or oligonucleotides 
complexed with polycations [101] 
Self-assembled nanoparticles for 
gene delivery 
Nondegradab
le 
nanoparticles 
Gold or iron-oxide nanoparticles 
[123-125, 127, 129] 
Magnetic imaging, drug delivery, 
thermal therapy 
Mesoporous silicon 
microparticles [120, 122] 
Intravenous delivery of therapeutics   
Cell-based 
systems 
VEGF-transfected CHO cells 
embedded in biodegradable 
polymer [116] 
Pro-angiogenic factors secreted by 
cells within tissue engineering 
scaffolds 
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2.8 Figures 
 
 
Figure 2.1. This schematic diagram depicts the angiogenic and anti-angiogenic responses 
at a capillary level. The cancer cells in tumor tissue secrete angiogenic growth factors 
that bind to their respective receptors on the endothelial cells lining the capillaries, 
leading to recruitment of disorganized blood vessels infiltrating into the tumor. This 
leaky vasculature allows entry of the systemically injected vector (eg. a PEGylated 
nanoparticle) into tumor tissue, while the vector cannot pass across the mature walls of 
normal tissue vessels. This results in passive targeting  of the tumor by the enhanced 
permeability and retention (EPR) effect.  Anti-angiogenic drugs, like VEGF-TRAP and 
bevacizumab, block the angiogenic effect of the growth factors. Therapeutic angiogenesis 
for treatment of ischemic diseases or vascularization of a tissue engineered construct is 
achieved by controlled local delivery of pro-angiogenic factors using a synthetic delivery 
scaffold (eg. fibrin hydrogel loaded with non-covalently or covalently bound growth 
factors). 
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Figure 2.2. (A1-3) Antibodies against PlGF and VEGFR2 inhibit tumor angiogenesis 
compared to nonspecific antibody IgG1., particularly in combination (A4). PlGF antibody 
also enhances the effect of gemcitabine, measured by tumor volume (B), and inhibits 
excessive recruitment of macrophages; the latter is not enhanced by coadministration of 
anti-VEGFR-2 (C). Adapted with permission from Elsevier: Fischer et al., Cell, 2007 
[135]. 
 
 
Figure 2.3. Tumor vasculature is highlighted by green fluorescence, overlaid with red-
fluorescent liposomes. The two sections shown are 50 m apart in the tumor tissue, with 
a large difference in liposome migration from one part of the tumor to the other. Scale 
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bar: 50 m. Adapted with permission from Macmillan Publishers Ltd: Brown et al., 
Nature Medicine, 2001 [146]. 
 
 
Figure 2.4. (A) Transscleral drug delivery device. (B) Device made with TEGDM 
reservoir and PEGDM/Col membrane which can be loaded with various drug solutions. 
(C) Capsule sutured onto rabbit eye sclera 3 days after implantation. Arrowhead indicates 
suture site. (D) Distribution of model drug FD40 (green) around implantation site at day 
3. Cell nuclei dyed stained blue. FD40 reaches retinal pigment epithelium (RPE). Retina 
(RE), choroids (CO), sclera (SC). Adapted with permission from Elsevier: Kawashima et 
al, Biomaterials, 2010 [161]. 
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Chapter 3 
Electrostatic Surface Modifications to Improve Gene Delivery 
 
3.1 Introduction 
Biomaterials have been developed for use in many fields including tissue 
engineering and drug delivery. There are many types of biomaterials, including 
macromolecules, synthetic polymers, and lipid systems [1, 2]. Biomaterials have been 
designed to respond to and interact with biological systems in a variety of ways. For 
example, in tissue engineering, which includes the regeneration and replacement of 
damaged and diseased tissues, biomaterials support a specific function of the target tissue. 
In drug delivery, biomaterials need to have the required encapsulation and release 
profiles necessary to treat the particular disease with a particular drug. A hydrophobic 
biomaterial may be preferred for delivery of a small molecule hydrophobic drug for 
cancer therapy, whereas a hydrophilic cationic biomaterial may be preferred for gene 
delivery. Gene delivery is particularly challenging as the drug cargos (nucleic acids) are 
large, highly charged, and degradable. Fortunately, the charged, polyvalent nature of 
nucleic acids enables various strategies for forming electrostatically associated coatings, 
complexes, and films. This review highlights how biomaterials can be used for particle-
based and surface-based gene delivery and how electrostatic coatings can further enhance 
efficacy. 
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3.2 Biomaterials 
Synthetic polymers are a popular biomaterial choice for drug and gene delivery. 
The ability to control the properties of synthetic polymers facilitates rational design. For 
example, polymers that contain positive charges are made so that they can 
electrostatically bind to negatively charged nucleic acids such as DNA molecules. These 
materials can be used directly to encapsulate cargos or as coatings for particles and 
devices. Examples of some of the commonly used biomaterials investigated for gene 
delivery are shown in Figure 3.1. Polyethylenimine (PEI) [3] is a polymer that is 
composed of multiple units of ethylenimine in both linear and branched arrangements. 
The branched PEI polymer contains primary, secondary and tertiary amines at a ratio of 
1:2:1, while the linear polymer is composed of all secondary amines except for primary 
amines at the end groups. These amines are responsible for the positive charges that are 
necessary to bind to DNA. PEI is an off-the-shelf polymer for gene delivery that can 
condense DNA into nano-sized complexes and facilitate some amount of in vitro and in 
vivo gene transfer [4]. Further modifications to PEI have been made to increase its 
performance at various points of the gene delivery process [5-7]. Polyamidoamine 
(PAMAM) [8] is a dendrimer system composed of amidoamine bonds. The dendrimer is 
built by adding esters and amines to different core molecules that have amine 
functionalities.  
 Many types of degradable biomaterials have been created including hydrolytically 
degradable esters such as polylactic acid (PLA) [9, 10], polyglycolic acid (PGA) and co-
polymers [11], polycaprolactone (PCL) [12], and others [13]. The physical properties of 
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the materials tune its degradation and rates of drug release. Poly(beta-amino ester)s 
(PBAE) [14-16] are a class of polymers that are both positively charged and 
hydrolytically degradable. They are synthesized from the conjugate addition of amine to 
diacrylates. The type of monomer diacrylates and amines can be varied to achieve 
different polymer properties. Poly(ester-anhydrides) [17] are often used to form 
microparticles that can encapsulate drugs or genetic material and degrade through surface 
erosion rather than the bulk erosion exhibited by PLA/PGA microspheres. Lipid based 
systems such as 1,2-Dioleyl-3-triethylammoniumpropane (DOTAP) can also form 
liposomes or lipoplexes that encapsulate drugs or nucleic acids [18]. The cationic head, 
linker region and hydrophobic tails can be modified to alter delivery properties. 
Natural polymer based systems have also been studied as they are often 
biocompatible and degradable [19]. For example, poly-L-Lysine (PLL) [20] is a linear 
polymer made from the amino acid lysine and it is a highly positively charged 
macromolecule due to the basic primary amine at the end of the lysine residue. Other 
natural-based biomaterials include sugars such as chitosan [21, 22], dextran [23], and 
cyclodextrins [24]. Combining natural polymers with synthetic polymers can improve 
drug delivery or tissue engineering functionality. 
 
3.3 Nucleic Acid Delivery 
A particularly promising, but challenging drug delivery cargo are nucleic acids 
such as DNA and various types of RNA including antisense RNA, siRNA, isRNA, and 
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miRNA [25, 26]. Genetic material is relatively large compared to most therapeutics. This 
makes it more difficult to transport within the body, into a cell, within a cell and into the 
nucleus. Viral vectors such as adenovirus [27] or lentivirus [28] have been developed for 
therapeutic gene delivery as they have evolved to do this very efficiently. However, there 
are continuing safety concerns with their use such as the potential for tumor induction 
[29] and the generation of immune responses [30].  Once the nucleic acid-containing 
particle is formed, it must remain stable and enable internalization within target cells. 
Common pathways for nano-formulations to enter the cell are via clathrin and caveolae-
mediated endocytosis [31]. If the DNA/delivery particle is too large it will not be able to 
enter the cell. As the cell surface is negatively charged, particles need to be neutral or 
positively charged in order to promote cell interactions and efficient internalization. 
For intracellular delivery, internalization is necessary, but not sufficient. There 
must also be efficient escape from the endosomal compartment to the cytoplasm to be 
active in the cell [32]. One proposed mechanism by which many of the polymer systems 
facilitate endosomal escape is through a proton-sponge mechanism. In this model, the 
basic nature of the polymer buffers the hydrogen ions pumped into the vesicle by the cell. 
To maintain electroneutrality, chloride ions flux into the endosome as well, creating 
osmotic pressure. The cell continues to attempt to acidify the vesicle until the vesicle 
finally ruptures due to the swelling of the endosome with water, releasing the particle 
[33]. Additional endosome escape mechanisms include the use of viral-based proteins 
that puncture the lipid bilayer, allowing particle escape.  
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Once in the cytoplasm, the encapsulated cargo must then be released from the 
particle in an efficient manner [34]. The delivery system needs to reach a balance 
between binding and dissociation with DNA. The system needs to bind tightly enough for 
particle formation, but must be able to unpack to release the DNA when in the cytoplasm 
or nucleoplasm. One method is for the release of DNA to be triggered by a stimuli that is 
present inside the cell, but not outside, such as a reducing environment.  
An additional requirement for DNA delivery is transport of the DNA into the 
nucleus following cargo release [35]. It has been reported that the ability of DNA to cross 
the nuclear pore complex can be enhanced by binding nuclear localization sequence 
(NLS)-signal peptides to the DNA that allow the DNA to be picked up by the 
nucleoporin active transport system [36]. Gene expression can occur transiently from an 
episomal plasmid or targeted integration can be designed [37]. Although longer acting, 
integration of the exogenous DNA carries the risk of insertional mutagenesis and cancer 
cell generation.  
The delivery of genes holds potential to treat both genetic diseases and acquired 
diseases such as cancer. While significant progress has been made in the field, non-viral 
biomaterial-mediated gene delivery is still much less effective than viral gene delivery 
[38]. New biomaterials continue to be developed to enhance efficacy and safety [39, 40]. 
Recent approaches to finding new synthetic polymers for gene delivery include polymer 
library approaches. High-throughput synthesis and screening techniques were used to 
search over two thousand different polymer structures for gene delivery [16]. Lead 
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structures, poly(beta-amino ester)s, are biodegradable and rival adenovirus for gene 
transfer to human primary cells in vitro [41].  
 
3.4 Coated Particles for Delivery 
3.4.1 Nanoparticles 
Nanoparticles are particles with length scales from 1-1000 nm. They can be “hard” 
nanoparticles primarily composed of gold [42-44], silver [45], or other inorganic 
materials [46-48] or they could be “soft” nanoparticles such as polyplexes [49, 50], 
liposomes [51], lipidoids [52], or other organic molecules. Beyond spheres, they can also 
be crafted into various shapes such as crystals or prisms [53]. Novel processing methods 
can enable printing of nanoparticles into more complex shapes such as cylinders, “hex 
nuts,” or toroids [54]. New kinds of therapies are being packaged into these nanoparticles 
[55]. The use of nanoparticle systems can allow for improved drug targeting, specific 
intracellular delivery, and potentially more control over delivery profiles.  
Targeting is especially important in cancer drug delivery since the therapeutic is often 
intentionally cytotoxic. Targeting of cancer cells with nanoparticles is often done by 
targeting specific cancer cell surface receptors. Specific interactions can be achieved by 
modifying the delivery vehicle with specific peptides, proteins, or antibodies that bind to 
the surface receptors [56]. More recently, some groups have used aptamers, which are 
RNA and DNA molecules with the ability to bind to specific targets with high affinity 
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[57]. Cancer gene therapy can also obtain additional specificity by delivering genes that 
only a cancer cell would be able to efficiently transcribe via transcriptional targeting [58]. 
3.4.2 Microparticles 
While microparticles have been typically used as drug reservoirs for controlled 
release of drugs, peptides, and proteins [59], they can also be used for intracellular 
delivery. Although most cells cannot take-up microparticles, immune cells such as 
macrophages can internalize them. Thus, the size of a particle can also affect targeting 
and a microparticle system can specifically deliver drugs or genes to cells of the immune 
system. Delivering antigen-coding genes can be useful for vaccine purposes. Cationic 
PLGA particles have been shown to significantly increase in vivo antibody responses to 
create better vaccine systems [60]. Positively charged surfactant molecules were added to 
PLGA during the microparticle fabrication process, resulting in positively charged PLGA 
particles. The positively charged surface allowed for adsorption of DNA molecules onto 
the particle surface. In this case, DNA plasmids that code for HIV proteins were used in 
order to improve vaccination response. Poly(beta-amino ester)s can also be blended with 
PLGA microparticles to provide pH triggered release and enhanced efficacy [61]. Singh 
et al., review microparticle systems used for vaccine applications [62]. 
3.4.3 Types of Coatings 
Various particulate formulations have been used to deliver drugs, whether that 
cargo is small molecules, protein, sugars, or genetic material [63-66]. The surfaces of 
these particles have been modified in various ways to improve delivery. Covalent 
modifications, such as PEGylation and polysaccharide coats, have been used to improve 
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particle stability in serum in vitro and in vivo [67, 68]. These alterations reduce the 
interactions of the particles with the various serum proteins that can cause aggregation or 
degradation of the particles. Enhanced stability can also be achieved used electrostatic 
coatings. For example, Trubetskoy et al. showed that polyacrylic acid can be used to coat 
polyethylenimine/DNA or cationic lipid/DNA complexes and thereby prevent serum 
inhibition of the complexes [69]. The polyacrylic acid provides electrostatic shielding 
from the serum proteins, increasing in vivo gene delivery following systemic injection, 
and reducing toxicity.  
Virus particles have also been coated with polymers to improve their in vivo 
stability. Adenovirus has been coated with polymers that protect the viral particles from 
interaction with specific blood components and reduces interaction with the immune 
system [70]. A hydrophilic polymer, N-(2-hydroxypropyl) methacrylamide (HPMA)-
based copolymer, was functionalized in order to bind to the viral surface. The binding 
included both covalent and electrostatic interactions to further increase the coating 
stability. The polymer also contained reducible disulfide bonds that would allow the 
coating to be degraded so that transfection can still occur. Additional modifications have 
included specific receptor targeting elements [71]. In another electrostatic coating 
approach, PEI was used to modify the surface of baculoviral vectors [72]. These coating 
modifications can therefore allow viral gene delivery to overcome some of the limitations 
mentioned earlier in the review. 
Targeted delivery to cells has been achieved by functionalizing the surfaces of 
particles so that they can interact more favorably with specific cells. These targeting 
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molecules can be covalently bound to the particles [73] or can be coated to the particles 
via electrostatic interactions [74]. These targeting molecules are often proteins or protein 
fragments that bind to a specific cell receptor, such as transferrin, epidermal growth 
factor (EGF), and Arginine-Glycine-Aspartic Acid (RGD) domains [73, 75-77]. In the 
case of gene delivery, one problem with covalent modification with targeting ligands is 
that this changes the functionality of polymer moieties and efficacy can decrease [76, 77]. 
A coating approach avoids this potential issue. A schematic for multilayer 
electrostatically coated particles is depicted in Figure 3.2. 
In one example of an electrostatic coating approach, positively charged poly(beta-
amino ester)/DNA nanoparticles were coated with negatively charged peptides [74]. 
Peptides were chosen such that they contained a stretch of anionic amino acids (Glutamic 
Acid residues), a linker (Glycine residues), and a ligand (Arginine-Glycine-Aspartic 
Acid). Addition of the peptide coating was found to neutralize the particle charge and 
promote gene delivery to human umbilical vein endothelial cells. Interestingly, it was 
only when the surface charge was neutralized, and the non-specific delivery of the 
nanoparticles reduced, that the presence of the ligand impacted gene delivery. However, 
once neutralized, nanoparticles coated with polyglutamic acid-polyglycine-RGD peptides 
had up to an order of magnitude higher gene delivery efficacy than the same particles 
coated with the scrambled sequence polyglutamic acid-polyglycine-RDG peptides [74]. 
Thus, the sequence of the ligand and the overall charge of the particle were important for 
intracellular deliver of the particles.   
As a complementary strategy, negatively charged particles can be coated with 
cationic polymers to improve their delivery properties. For example, Lee et al. [78] 
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showed that gold nanoparticles thiolated with siRNA could subsequently be coated with 
PBAEs to achieve significantly enhanced cytoplasmic delivery of the siRNA. In this 
work (depicted in Figure 3.3), gold-siRNA nanoparticles were unable to mediate gene 
silencing alone, but when coated with polymer, silencing increased to >95% using the 
same dose of gold-siRNA nanoparticles. Interestingly, small structural differences to the 
PBAEs used as coatings, dramatically changed the silencing behavior of the gold-siRNA 
particles. The most effective polymers were those that had terminal tertiary amine groups. 
In other work Fuller et al. [79] showed that PEI could be used as a cationic polymer to 
coat negatively charged fluorescent silica particles to enable enhanced intracellular 
delivery and endosomal escape. This system enabled the combination of both imaging 
and gene delivery within the same nanoparticles.  
In vivo, it has also been shown that tissue targeting can be tuned via electrostatic 
coating [80]. In this study, cationic polymer/DNA nanoparticles were coated with anionic 
peptides and following tail-vein injection, gene delivery was directed away from the 
lungs and to the spleen and bone marrow or alternatively to liver cells depending on the 
coating amount and type. Following systemic administration, cationic particles can 
potentially aggregate with blood constituents that embolize in the vascular beds of the 
lung [69, 81, 82]. These coatings were shown to prevent aggregation with erythrocytes 
and prevent lethality following injection as compared to uncoated polymeric particles.  
Thus the effectiveness of charged nanoparticles, either cationic or anionic, can be 
greatly improved by single coats of an oppositely charged biomaterial that incorporates 
new functionality to the nanoparticle. This functionality could consist of improved serum 
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resistance, cell or tissue targeting, efficient internalization, endosomal escape, controlled 
release, and reduced toxicity. 
3.4.4 Multilayer Particle Coating 
Multiple electrostatic layers can be deposited on a particle using a layer-by-layer 
(LbL) approach (Figure 3.2). For this method, successive and alternating anionic and 
cationic layers are added to a particle core [83, 84]. After each layer is added, 
centrifugation allows for isolation of the particles so that further layers can be added. In 
some formulations, DNA is added as one of the anionic layers [85]. Using this approach, 
the layers were observed to disassemble inside the cell, where the DNA molecules then 
have access to the nucleus. In another system, DNA was added first as an internal layer 
adsorbed to a core. After multilayers were formed with spermidine and DNA coats, the 
core substrate was subsequently dissolved away so that the DNA becomes an internal 
encapsulated layer within a capsule [86]. In other work, DNA has also been encapsulated 
within chondroitin sulfate/poly(-L-arginine) LbL particles [87]. DNA was first added to 
the core particle and then alternating layers of chondroitin sulfate and poly(-L-arginine) 
polyelectrolytes were added subsequently to create a core/shell structure. The core was 
then dissolved so that only the DNA was left encapsulated and free inside the 
polyelectrolyte shell. Many of these systems are on the micrometer scale, which can 
reduce the ability of cells to take up the particles. Reducing the size of these LbL 
particles would therefore improve delivery of DNA. One such example uses liposomes as 
the substrate onto which polyelectrolyte layers, such as DNA, can be added [88]. 
Additionally, polyplexes have been used as a substrate onto which further layers are 
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added electrostatically [89]. In this case, the extra PEI layer increased transfection 
activity further, presumably because the increased amount of PEI enabled greater 
endosomal escape. A negatively charged poly(acrylic acid) layer was added in between 
the PEI layers in order to construct the multilayer particle. Examples of multilayer 
coatings are summarized in Table 3.2. 
 
3.5 Multilayer Coated Non-Particulate Substrates for Delivery 
In addition to particles, other surfaces can also be coated for controlled release 
and drug delivery. The sequential addition of positively and negatively charged 
polyelectrolytes to form a multilayered structure is a general approach that can be applied 
to diverse fields including optics, separations, and drug delivery [90]. Many different 
materials can be incorporated into these multilayers. These multilayers can then also be 
used as substrates themselves onto which cells can adhere. Surface mediated gene 
delivery can be useful as a mechanism for efficient gene transfer and as an enabling 
technology for tissue engineering [91]. Growing transfected cells on a surface can enable 
the release of soluble drugs, such as proteins, and has other potential advantages over 
particulate systems. One such advantage is spatial control of release of the therapeutic 
molecule. Surface-mediated delivery also allows for more efficient delivery since there is 
a much higher local concentration of drug available to the cells. The reverse system has 
also been developed where a live cell can serve as the substrate for multilayer coating [92, 
93]. 
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 Multilayer electrostatic coatings have been used by researchers to tune the release 
of various biomolecules from substrates. One common method of fabricating such 
multilayer surfaces is an electrostatic-based layer-by-layer approach as shown in Figure 
3.4. The first step is to coat a charged substrate with a layer of oppositely charged 
polyelectrolytes. The substrate can range from an inorganic material of any shape to 
biological tissue surfaces [94, 95]. The substrate is then washed to remove excess 
polyelectrolytes. Another layer of polyelectrolytes is added next which has an opposite 
charge to that of the first layer. Once again the surface is washed to remove the excess. 
This process cycle can then be repeated until the desired multilayer structure is achieved. 
Many different polyelectrolytes can be used, which gives flexibility and control over the 
type of surface and release characteristics that can be attained. Table 3.2 summarizes 
some of the multilayer structures discussed in this section. 
3.5.1 Controlled Delivery via Multilayer Structures  
 Drug release from the multilayered surfaces has been achieved via different 
mechanisms. Polyelectrolyte layers that are hydrolytically degradable allow for 
controlled release in aqueous environments, such as in the body [96]. Therapeutic 
polysaccharides, such as heparin, have been used for negatively charged layers, along 
with poly(beta-amino esters) as positively charged layers.  PBAE hydrolysis rate is 
dependent on the pH of the solution and this controls the degradation of PBAE based 
multilayers. With this system, drugs are released more slowly at lower pH solutions as 
expected. Other hydrolytically degradable polymers can be used in similar systems. 
Wood et al. showed that rather than relying on hydrolytic degradation, these multilayer 
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films can have triggered release based on an applied voltage [97]. The key development 
was using Prussian Blue, a non-toxic FDA-approved material, to assemble the films. 
Electric current can similarly tune release of encapsulated insulin from hydrogen-bonded 
gels composed of poly(ethyloxazoline) and poly(acrylic acid) multilayers [98].  
Multilayer structures that exhibit pH dependent swelling have also been designed 
[99]. PH-dependent swelling was achieved by using a combination of polyelectrolyte 
layers, one of which contains pH responsive functional groups, and the other which has 
hydrophobic domains. The swelling behavior allows for encapsulation of various drug 
delivery cargos and release that is highly tuned to environmental stimuli. Polypeptides 
can also be used to construct similar multilayer films, including those with pH responsive 
triggered release [100]. Loading of the layers with a drug is a function of solution pH and 
by varying the polypeptide polyelectrolyte layer composition, one can tune pH triggered 
response of the multilayer. 
These methods can be extended for the controlled release of multiple drugs from 
one film [101, 102]. In one example, a hydrolytically degradable layer is used to control 
the overall release profile of a therapeutic polysaccharide and small hydrophobic 
molecule. In this case, one of the drugs (the polysaccharide) also serves a structural role 
as a polyelectrolyte that composes the multilayer. The other drug is encapsulated in 
polymeric micelles that are incorporated within the multilayer. The two delivered drugs 
can act synergistically to improve therapeutic activity [102]. This approach could be 
extended for multi-stage gene delivery. For multi-drug release, it is important to control 
interlayer diffusion. One such strategy is to add covalently cross-linked barriers between 
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the two main polyelectrolyte layers [101]. The cross-linked barriers are also 
polyelectrolyte layers as well so that they can be seamlessly added during multilayer 
fabrication. Researchers found that one bilayer of cross-linked barrier is sufficient to 
block interlayer diffusion. However, the base layers underneath the barrier influence how 
well the barrier blocked diffusion. 
A spray method can be used instead of the dip method to apply each 
polyelectrolyte layer in order to decrease processing time. Spraying can also be used to 
introduce asymmetry into multilayers which can be useful for drug delivery and other 
applications such as purification or biocatalytic membranes [103]. The spraying method 
is based on electrospinning technology, which involves the use of an applied voltage 
between the polyelectrolyte solution and surface to create a micrometer or nanometer 
sized fiber deposited onto the surface. 
3.5.2 Delivery of DNA via Multilayer Structures 
These multilayer structures can be useful for gene delivery in particular, where 
DNA acts as both one of the negatively charged polyelectrolyte structural layers and the 
drug of interest. For example Zhang et al. showed release of functional DNA from 
multilayered films [104]. In this study, the addition of an extra gene delivery agent 
(Lipofectamine) was required to permit intracellular delivery of the released DNA into 
mammalian cells, but this work demonstrated that the multilayer could serve as a DNA 
transfection reservoir. Building on this result Jewell et al. showed that PBAE/DNA 
multilayers could degrade into PBAE/DNA associated complexes that enable gene 
delivery at areas physically close to the multilayer coatings [105]. Figure 3.5 
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demonstrates how this system can enable spatial control of gene expression through 
quartz slides that were coated with PBAE polymer and enhanced green fluorescent 
protein (EGFP) DNA. Gene expression is high in areas adjacent to the slide surface, but 
low in areas further away. In principle, the breakdown products of the multilayer films 
themselves could serve as in situ gene delivery agents. Combinations of multiple 
biomaterials, each with specific intracellular gene delivery function (DNA condensation, 
endosomal escape, nuclear import, etc.), may prove to be the most effective. 
DNA and PEI have been used to create multilayer structures using an electrospun 
polymeric mesh as a substrate [106]. Cells were cultured on these multilayered meshes 
and transfection was observed. Such a system can be useful for drug delivery and tissue 
engineering applications. Using a bioreducible polyelectrolyte provides another method 
for controlled delivery [107]. Disulfide bonds within a poly(amido amine) polymer 
enable degradation in the presence of a reducing environment. Alternating layers of the 
cationic polymer and plasmid DNA were deposited on a stainless steel mesh, which is a 
similar system to a stent. Increased and longer lasting transfection was observed as 
compared to the non-reducible controls. The release and gene expression of this system 
over 12 days is shown in Figure 3.6. The authors hypothesized that the plasma 
membrane might provide a reducing environment, so that polymer degradation can take 
place upon interaction with the cell surface. Significant gene expression was achieved in 
both fibroblasts (NIH-3T3) and smooth muscle cells (SMC). 
Another method of delivery is the incorporation of pre-formed DNA nanoparticles 
embedded into a layer-by-layer structure [108]. In one study, poly(L-lysine) and 
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hyaluronic acid were used as the positively and negatively charged polyelectrolyte layers, 
respectively. Plasmid DNA was complexed with various formulations of PLL and 
cyclodextrin. This combination approach, a multilayer structure embedded with DNA 
complexes, allows for both tunable release of the complexes and improved 
protection/uptake of the pre-formed nanoparticles. 
 
3.6 Conclusion 
Electrostatic coatings are useful to modify the surfaces of particles and substrates 
for gene delivery. In the case of particles, these coatings can improve multiple steps of 
delivery including improved serum resistance, cell targeting, cellular uptake, endosomal 
escape, controlled release, and reduced toxicity. In the case of substrates, these 
electrostatic modifications can enable spatial and temporal control of release. These 
methods can also be used to facilitate triggered release either from environmental cues 
(pH) or an external source (electric field). Electrostatically adsorbed multilayers permit 
the creation of more complicated structures such as hollow capsules and surfaces that can 
release multiple therapeutic components over differing time scales. As these coatings and 
films can be constructed using a wide array of biomaterials and gentle processing 
conditions, they can have widespread applications to drug delivery and tissue engineering. 
 
3.7 Expert Opinion 
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Physical and chemical properties of particles and substrates can be controlled 
through the modification of their surfaces with polyelectrolytes. These modifications are 
especially promising to the fields of drug and gene delivery. A major strength of this 
approach is its suitability for a wide range of biomaterials including peptides, sugars, 
polymers, and nucleic acids. Indeed, any macromolecule with a multivalent charge is 
amenable to this technology.  
 In some applications, coated nanoparticles were utilized for enhanced intracellular 
delivery. Specific intracellular delivery bottlenecks improved through electrostatic 
biomaterial coatings include cell targeting, cellular uptake, and endosomal escape. This 
work can be extended to include coatings with moieties for active transport through the 
cell, nuclear uptake, and other intracellular functions. Multilayered particles could be 
constructed that contain specialized biomaterials for each layer rather than the same two 
alternating layers throughout the coating. These customized layers could enable enhanced 
intracellular delivery or more precise multidrug release. 
 One natural extension of this work, and something that is already appearing in the 
literature [109, 110], is the use of nucleic acids other than DNA. Small interfering RNA 
(siRNA), immunostimulatory RNA (isRNA), micro RNA (miRNA), small activating 
RNA (saRNA), and antigene RNA (agRNA) are all examples of nucleic acids that would 
be very promising for both encapsulated cargos and coatings for particles and surfaces. 
There are many applications of this technology including cancer therapy [56] and 
targeting [111]. In addition, these materials can be used for immunotherapy and as 
vaccines, enabling controlled delivery of the immune stimulating molecules [112, 113]. 
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In another application, multiple combinations of nucleic acids within the same particle 
may be especially interesting in creating new tools for efficient non-viral reprogramming 
of differentiated cells to induced pluripotent stem cells [114]. 
 Encapsulation of cells within polyelectrolytes may enable protection and control 
of the cells. For example, a cell could be engineered to have a particular affinity for 
another cell or biomacromolecule through its electrostatic coatings. Such cells could 
potentially enable increased cell-cell interactions in the formation of engineered tissues, 
novel mechanisms for the recognition of pathogens, or aid in wound healing. In the case 
of stem cell engineering, such an approach may enable the controlled differentiation 
and/or reprogramming of the encapsulated cells within the multilayer coating. This 
approach could be useful for tissue engineering and regenerative medicine. 
 Multilayer films could also be designed not just for how they behave as films, but 
also how their breakdown products behave. For example, polyelectrolyte layers of the 
film could be therapeutics themselves or be prodrugs that degrade into therapeutic 
molecules. They could also form in situ particles or structures that then have functionality 
even after the multilayer degrades (such as self-assembly into targeted nanoparticles).  
These coatings and films could also be used to coat virtually any device including stents 
and stent-like devices. 
 These biomaterials and approaches can also be utilized to combine drug delivery 
with imaging to create new theranostics and multifunctional nanomedicines [115]. With 
such a system, one could visualize the spatial and temporal delivery of the therapeutic 
agent. It could also be used to better tune ligand coatings or stimuli responsive coatings 
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for improved in vivo function. Putting these two elements together, a triggered diagnostic 
signal and drug release profile could be engineered to occur in the presence of a target 
compound or environment. 
 Although this technology is promising and there are many interesting applications, 
challenges remain before there can be broad clinical application. Ensuring safety is 
critical and may be a challenge as the fields of gene therapy and nanotechnology have 
already had their share of safety-related setbacks. One way that electrostatically coated 
nanoparticles can improve safety is through specific targeting. By targeting certain tissues 
or aberrant cells (cancer) with increased specificity compared to uncoated non-viral 
particles or to viral particles, off-target serious adverse events can be reduced. Proper 
coatings can also facilitate long circulation times and increased efficacy with a lower 
dose of active drug, further increasing safety. Biodegradable and biocompatible materials, 
like many of the polymeric materials discussed, are key to minimizing toxicity. In the 
case of gene therapy clinical trials, it is important that the DNA itself is also designed 
with safety in mind so that it is maximally effective and minimally immunogenic. One 
way to achieve this is by the elimination of toll-like receptor signaling CpG motifs in the 
DNA vector backbone or through utilization of a minicircle DNA vector free of bacterial 
backbone elements. Choosing the appropriate biomaterials, animal models, and 
manufacturing procedures will all be crucial as well. Nonetheless, given the versatile and 
powerful approach of electrostatic coatings and multilayers, including increasing spatial 
and temporal precision, many new therapeutics and diagnostics based on this technology 
will likely appear in the future.   
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3.9 Tables 
Table 3.1. Electrostatic surface modifications of particle systems for gene delivery. 
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Table 3.2. Multilayered particles and films. 
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3.10 Figures 
 
Figure 3.1. Biomaterials used to form particles and coatings for gene delivery. 
 
 
72 
 
Figure 3.2. Fabrication of a multilayer particle. Synthesis begins with a charged colloidal 
substrate. Oppositely charged polyelectrolytes are added in solution in a cyclic fashion. 
After the addition of each polyelectrolyte there is a wash and centrifugation step. As a 
final step, targeting ligands can be electrostatically added (yellow triangles). The 
colloidal substrate can be left encapsulated for delivery or can be chemically degraded 
and removed to form a hollow core. 
 
 
Figure 3.3. SiRNA modified gold-nanoparticles (orange sphere) are electrostatically 
coated with cationic polymers (PBAEs) to enhance cell transfection. Reproduced with 
permission from Nano Letters. Copyright ACS 2009 [78].   
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Figure 3.4. Multilayered coatings can be added to structures such as glass slides, stents, 
and organic tissues. In each case, an oppositely charged polyelectrolyte is added to a 
charged surface followed by a wash step to remove excess polyelectrolyte. The next layer 
of oppositely charged polyelectrolytes can then be added and this cycle can be repeated 
as needed. 
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Figure 3.5. Fluorescence microscopy image showing localized transfection of COS-7 
cells. The white lines show the approximate boundary between targeted and non-targeted 
delivery areas. The targeted areas are the quartz substrate functionalized with 
multilayered films of a PBAE polymer (seen in Figure 3.1) and pEGFP.  Reproduced 
with permission from Journal of Controlled Release. Copyright Elsevier 2005 [105]. 
 
 
Figure 3.6. Cumulative transfection of NIH-3T3 (a) and SMC (b) cells with SEAP-DNA 
(secreted alkaline phosphatase based luminescence). Three surfaces were used: stainless 
steel mesh coated with DNA/reducible polymer multilayer (■), DNA/PEI multilayer (●), 
and control non-coated mesh (▲). Reproduced with permission from Biomaterials. 
Copyright Elsevier 2009 [107]. 
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Chapter 4 
Methods and Characterization of Polymeric Gene Delivery 
Nanoparticles 
 
4.1 Introduction 
Gene delivery is attractive both to treat genetic diseases [1] and as a technology 
for regenerative medicine [2]. For successful clinical translation of a cell-based gene 
therapy approach [3], it is important to address two key challenges: 1) to develop safe and 
effective gene delivery vectors [4] and 2) to find a replenishable and genetically matched 
source of cells [5, 6]. Non-viral gene delivery is a safer alternative to viral vectors [7-10]. 
Cationic polymers condense DNA via electrostatic interaction with the negatively 
charged DNA backbone to form self-assembled complexes on the order of ~100 nm and 
are commonly termed polyplexes or polymeric nanoparticles. Polyethylenimine (PEI) is a 
widely-used off-the-shelf cationic polymer that forms polymeric nanoparticles with DNA 
and is non-degradable [11]. Poly(beta-amino ester)s (PBAEs) are a newer class of 
cationic polymers that similarly form polymeric nanoparticles, but are hydrolytically 
degradable [12]. End-modification of PBAEs has shown improved gene delivery efficacy 
in certain cell types [13-15]. 
 
85 
Recently, human fibroblasts have been successfully reprogrammed to induced 
pluripotent stem cells (iPSCs) [16] that offer potential applications in regenerative 
medicine as a replenishable source of autologous stem cells [16-18]. Many 
reprogramming studies utilize viral vectors that have higher efficiency but are unsafe for 
clinical applications, while non-viral methods, such as nanoparticle-based methods, have 
reported low reprogramming efficiency [6]. Reprogramming requires transfection of a 
combination of plasmids that encode reprogramming factors [6, 19]. Since the number of 
plasmids complexed per particle affects transfection efficiency, a quantitative 
determination of this number would benefit the development of nanoparticle-based gene 
delivery strategies, especially for co-delivery of multiple plasmids to the same target as 
required in factor-based reprogramming. 
Few studies have investigated the composition of gene delivery nanoparticles in 
terms of the number of plasmids associated with a single nanoparticle, and the assays 
used have had significant drawbacks that affect the estimation [20-23]. In the present 
study, we developed a novel assay to easily quantify the number of plasmids within 
polymeric nanoparticles in physiologically relevant aqueous conditions using a 
nanoparticle tracking analysis technique. We investigated PEI and six formulations of 
PBAEs optimized for gene delivery to human primary fibroblasts (IMR90). We studied 
how small modifications, including to the polymer structure and polymer to DNA weight 
ratio, affect the composition of the nanoparticles in terms of plasmids associated per 
particle and its implications in co-transfection of multiple plasmids to the same cells. 
Particles effective at transfecting primary human fibroblasts had 30-120 plasmids per 
particle, depending on polymer structure. Nanoparticles that contain a high level of 
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plasmids per particle (120 vs. 30) proved promising for coexpression. This quantitative 
understanding has implications for co-delivery of therapeutic genes and for stem cell 
reprogramming using nanoparticles. 
 
4.2 Materials and Methods 
4.2.1 Polymer synthesis and nanoparticle formation 
Details of the polymer synthesis and nanoparticle formation method have been 
previously described [13]. Briefly, diacrylate terminated base polymers (BxSx) were first 
synthesized at 90˚C by conjugate addition of acrylate and amine monomers for 24 hours. 
As a second step, the base polymers were end-capped with amine containing small 
molecules at room temperature in DMSO to form amine terminated end-capped PBAE 
versions (BxSxEx). To form nanoparticles, PBAE stock solutions of 100 mg/mL in 
DMSO and EGFP-N1 DNA stock of 1 mg/mL in deionized (DI) water were both diluted 
separately in 25 mM, pH 5 sodium acetate (NaAc) solution at concentrations required to 
achieve polymer to DNA weight ratios (wt/wt) of 40, 60 and 100 and mixed vigorously at 
a 1:1 ratio, with final concentrations at 0.006 or 0.06 mg DNA/mL. The nanoparticles 
were formed through self-assembly during a 10-minute incubation. PEI-based 
nanoparticles at a 2 wt/wt ratio were prepared similarly, but using a 150 mM, pH 5.5 
sodium chloride solution. 
4.2.2 Cell Transfection 
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IMR90s maintained in Eagle’s Minimum Essential Medium supplemented with 
10% FBS were plated at a density of 1.8x10
5
 cells per well and transfected at 6 µg 
DNA/100 µl particles per well in a 6-well plate. After incubating the cells with 
nanoparticles for 4 hours, the media was aspirated and replaced with fresh media and the 
fluorescence expression was analyzed using microscopy after 48 hours. See 
supplementary methods for a step-by-step protocol. 
4.2.3 Nanoparticle characterization by NTA and TEM 
A Nanosight LM10 equipped with a sensitive CCD camera was used for 
characterizing the nanoparticles by NTA. Two hundred microliters of diluted 
nanoparticle solution was loaded into the sample chamber using a 1 mL syringe, the 
chamber connected to a 405 nm laser source was placed on the Nanosight microscope 
stage, and a 60 s movie containing the Brownian motion tracking of the scattering 
centroids (particles) was recorded using the NTA software (Version 2.0). The movie was 
processed using the manufacturer recommended auto settings with manual adjustment of 
the gain, blur and brightness as recommended. The particle solution was diluted in DI 
water to adjust the sample concentration to 10
7
-10
9
 particles/mL. For TEM studies, 
nanoparticles were formed by complexing with EGFP-DNA as described earlier and 10 
µL of these particles was placed on a formvar/carbon coated copper grid (FCF400-Cu, 
Electron Microscopy Sciences). The nanoparticles were dried for 2 hours and then 
imaged in a Philips/FEI BioTwin CM120 Transmission Electron Microscope at the JHU-
SOM Microscope Facility. The images were processed using ImageJ software. See 
supplementary methods for a step-by-step protocol. 
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4.2.4 Plasmid per particle distribution calculations 
The known total plasmid concentration was multiplied by the volume fraction of 
each 1 nm-spaced particle-size class to get the number of plasmids in each 1 nm-spaced 
particle-size class. This plasmid number was divided by the number of particles in that 
particle-size class to get the number of plasmids per particle for each particle-size class. 
The particle per plasmid distribution was determined for all replicates, the replicates were 
averaged and the average was rounded off to the nearest whole number to plot a graph of 
number of plasmids per particle (at each 1-nm spaced particle class) against the 
concentration of particles that contain that given number of plasmids. Both the mode and 
mean of the distribution were calculated, where the peak of the distribution represents the 
mode plasmid per particle number for each formulation. The mean of 1 nm distribution 
matched the mean obtained from overall average calculations. 
 
4.3 Results and Discussion 
 The structures of the polymers used in this study are shown in Figure 4.1. We 
focused on six end-capped PBAE formulations: B4S4E7, with base polymer synthesized 
at a 1.2:1 monomer ratio and formulated at 40 weight polymer to weight DNA (wt/wt), 
B4S4E7 (1.2:1, 60 wt/wt), B5S3E7 (1.05:1, 60 wt/wt), B5S3E7 (1.05:1, 100 wt/wt), 
B4S5E7 (1.2:1, 100 wt/wt), and B5S5E1 (1.2:1, 100 wt/wt). The nanoparticles were 
formed by complexing polymers with enhanced green fluorescent (EGFP-N1) plasmid 
DNA in 25 mM, pH 5 sodium acetate (NaAc) solution. The 25 kDa branched PEI-based 
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control nanoparticles were prepared in 150 mM, pH 5.5 sodium chloride (NaCl) solution 
at 2 wt/wt ratio (N/P ratio of 16). 
The nanoparticles were used for transfecting human fetal fibroblasts (IMR90) 
with EGFP and DsRed plasmids. The cells were transfected in three different conditions, 
a) transfection with complexes containing both EGFP and DsRed plasmids for 4 hours, b) 
transfection with exclusively EGFP containing complexes for 2 hours, followed by 
transfection with the same dose of exclusively DsRed containing complexes for 2 hours 
after media change and c) transfection with exclusively EGFP containing complexes for 4 
hours, followed by transfection with the same dose of exclusively DsRed containing 
complexes for 4 hours after a gap of 24 hours.  
The nanoparticles were analyzed by nanoparticle tracking analysis (NTA) using a 
Nanosight LM10 that tracks the random Brownian motion of individual nanoparticles 
suspended in an aqueous solution. The particle characterization performed using NTA 
was confirmed by dynamic light scattering (DLS) using Malvern Zetasizer NanoZS. 
Unlike the intensity-based distribution of particle size given by DLS, NTA gives a direct 
number-averaged distribution of the particle hydrodynamic diameter by tracking 
individual particles in real-time as light scattering centroids using a sensitive CCD 
camera. The number mean particle size (diameter in nanometers) and absolute particle 
concentration (number of particles/mL) were determined using NTA. 
All polymers used in this study formed monodisperse particle size distributions as 
verified by a unimodal distribution by NTA (Figure 4.2A). Transmission Electron 
Microscopy (TEM) was also performed with dried nanoparticles and gave comparable 
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sizes to the hydrated nanoparticles (Figure 4.2B). The samples were analyzed by gel 
electrophoresis to evaluate whether 100% of plasmid was complexed into particles at the 
wt/wt ratios used for NTA measurements. Each lane in the gel contained nanoparticles 
formulated at a particular wt/wt and the first lane contained a control sample of free DNA 
by itself (Figure 4.S1). The gel electrophoresis results validate that free DNA is not 
present in these samples and all plasmid for these formulations is complexed within 
nanoparticles. The known mass (calculated from concentration and total volume) and 
molecular weight of the EGFP-N1 plasmid (4.7 kilobase pairs, kbp) used for particle 
formulation was used to calculate the number of plasmids/mL. As all of the DNA was 
complexed within nanoparticles and all the nanoparticles were monodisperse, the ratio of 
plasmids/mL to particles/mL (concentration measured using NTA) determines the 
average number of plasmids per particle. The analysis was performed for PEI and the six 
different PBAE formulations to study the effect of varying polymer structure and wt/wt 
ratio on the number of plasmids associated per nanoparticle.  
NTA tracks individual nanoparticles so that number fractions can be directly 
calculated. The nanoparticle sizes were binned rounding to the nearest nanometer, and the 
following equations were used to determine average nanoparticle size (Table 4.1). The 
number mean diameter, d , reported by NTA is determined using eq.1. The mean volume 
based-diameter, , was calculated using eq.2 and used to estimate the average 
theoretical maximum number of plasmids per particle. This average quantity gives the 
average volume of a particle randomly selected (or taken up by the cell) from the 
population of particles. 
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Single condensed plasmid size was estimated from literature data to determine the 
average plasmid volume. Dividing the average particle volume by the volume of a 
condensed plasmid determines the average theoretical maximum number of plasmids per 
particle. Based on branched 25 kDa PEI saturated DNA condensate sizes and cationic 
thiol-detergent compacted single plasmid DNA dimensions reported in previous 
publications, the diameter used for a single condensed 5 kbp plasmid DNA can range 
from 20-40 nm [24, 25]. The choice of a plasmid size from within this range can 
dramatically affect the theoretical maximum calculation. Therefore, a likely minimum 
condensed plasmid size was calculated using the result that the distance between DNA 
helices in DNA condensates is 2.7 nm [26]. This value has been reported to range from 
2.4-2.8 nm [27, 28], but this variation has a smaller effect on the calculations than 
varying the plasmid diameter. Assuming a cylindrical shape, the volume of a minimum 
condensed plasmid can then be calculated to be 9140 nm
3
 ( = π*(2.7/2 nm)
2
*(0.34 
nm/base pair)*(4.7 kbp), where 0.34 nm equals the length of a DNA rod per base pair 
[29] and each plasmid contains 4.7 kbp). A volume of 9140 nm
3
 corresponds to an 
equivalent spherical diameter of 25.9 nm. In general, the actual number of plasmids per 
particle for any sized particle is less than the theoretical maximum. This may be due to 
 
92 
nanoparticle volume taken up by extra polymer that is not tightly associated to condensed 
DNA as well as a possible range in the degree of plasmid condensation.  
Another important point is that there is a distribution of plasmid/particle numbers, 
reflecting the distribution of particle sizes observed within a population. Therefore, there 
will be particles with plasmid/particle numbers both greater than and less than the 
average numbers. An example of the profiles can be seen in Figure 4.2C, as well as in 
supplemental Figure 4.S2, which together show the plasmid per particle distribution data 
for all formulations as determined by calculating the number of plasmids per particle for 
each 1 nm increment (see methods). 
 Table 4.2 shows the particle per plasmid quantification. Each nanoparticle 
condition was fabricated and analyzed in at least duplicate independent batches and each 
of these replicates included a minimum of 500 completed tracks by NTA to ensure good 
statistics for the number of particles and their size. The 25 kDa branched PEI-based 
nanoparticles had 90±10 plasmids per particle on average as calculated by NTA with an 
average theoretical maximum estimate of 267 plasmids per particle. The average 
plasmids per particle counts, calculated by NTA, for the six PBAE formulations ranged 
from 30±2 to 120±20 and the average theoretical maximum average estimates ranged 
from 80 to 195. Similar to PEI-based nanoparticles, B4S4E7 nanoparticles at 60 wt/wt 
had 110±10 plasmids per particle and at 40 wt/wt, 120±20 plasmids per particle as 
calculated by NTA. Changing the polymer to DNA weight ratio, from 40 to 60 wt/wt for 
B4S4E7-based nanoparticles and 60 to 100 wt/wt for B5S3E7-based nanoparticles did 
not significantly change the number of plasmids associated per particle. Interestingly, 
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B4S4E7 nanoparticles, which are highly effective at transfecting IMR90 cells, have the 
highest plasmid per particle counts in the PBAE-DNA nanoparticles tested. This indicates 
that, in addition to polymer structure, plasmid per particle count maybe an important 
parameter to determine the transfection efficacy of PBAE-based nanoparticles for a 
specific cell type. A study conducted by Ogris et al. correlated DNA/PEI (with or without 
transferrin ligand) complex size with transfection efficiency [30]. Greater average 
intensity of green fluorescent protein (GFP) expression per cell was found following 
transfection with larger sized particles compared to smaller sized particles. This may be 
due in part to the larger particles containing more plasmids per particle than the smaller 
particles.  
The three B4-based nanoparticles have similar plasmids per particle counts (90-
120) and the three B5-based nanoparticles have similar plasmids per particle counts (30-
45). Intriguingly, the B4-based nanoparticles have approximately 3-fold the DNA 
carrying capacity per particle even though the structure of B4 and B5 differ by only a 
single carbon to the repeating backbone and both B4-based and B5-based nanoparticles 
have similar ~100 nm particle size as measured by NTA analysis. This finding highlights 
how the number of plasmids/particle is an important parameter for consideration in 
nanoparticle design and characterization and it can be tuned through changes to 
biomaterial structure. 
A critical barrier to the generation of induced pluripotent stem cells and to 
achieving high reprogramming efficiency with non-viral vectors is the low probability of 
uptake and expression of multiple plasmids (carrying multiple reprogramming factors) by 
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the same cell. Accordingly, co-transfection experiments using EGFP and DsRed plasmids 
were conducted in IMR90s to gain insight into the process of delivering multiple plasmid 
types intracellularly using nanoparticles. Similar co-delivery is seen with PBAE-based 
nanoparticles as with Lipofectamine 2000, a leading commercially available transfection 
agent, but with higher cell viability for the PBAE-based nanoparticles. Gene expression 
following co-delivery with nanoparticles containing multiple plasmids differs from 
delivery of the same genes in the same type of nanoparticles when formulated and 
administered separately. Figure 4.3 shows that if the two plasmids are mixed together 
before nanoparticle self-assembly to form co-delivery particles, more cells coexpress the 
two plasmids together (orange-yellow cells) than when the two plasmids are formulated 
and delivered separately with the same type of nanoparticles on two different days (green 
and red cells, Figure 4.3A). When the nanoparticles are formulated separately and 
administered together on the same day, the trend of reduced co-delivery also holds 
(Figure 4.3B). 
In the case of nanoparticles that contain both GFP and DsRed plasmids, most of 
the cells exhibit coexpression (yellow/orange cells). When the same type of nanoparticles 
are used on the same day at the same dose, but containing exclusively GFP and then 
exclusively DsRed, very few cells exhibit coexpression (yellow/orange cells) and instead 
individual plasmid expression is strongly seen as either EGFP (green cells) or DsRed (red 
cells). Cells also do not exhibit coexpression (yellow/orange cells) of the GFP and DsRed 
plasmids in the separate particles when they are administered 24 hours apart. Thus, for 
certain applications, co-delivery within the same nanoparticles is critical to ensure 
coexpression. Schwake et al. presented a stochastic model of transfection to predict co-
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transfection ratio and plasmid expression level distribution in Lipofectamine and PEI 
complexes [31]. They studied co-transfection of pre-mixed plasmids encoding yellow 
fluorescent protein (YFP) and cyan fluorescent protein (CFP) and post-mixed plasmids 
(complexes contains either CFP or YFP plasmid) and observed that the co-transfection 
ratio was higher (21.9%) in pre-mixed than in post-mixed complexes (12.9%), which 
could also be predicted by their mathematical model [31]. This observation is consistent 
with our observations in the co-transfection experiments in IMR90 cells. Choosing 
nanoparticles that contain a high level of plasmids per particle (120 vs. 30) may be a 
promising strategy to maximize coexpression. Flow cytometry analysis of the co-
transfected cells (same day, same particle) showed that B4S4E7-based nanoparticles 
achieved coexpression in 15.8±0.5% of live cells, whereas B5S3E7-based nanoparticles 
achieved coexpression in 3.3±1% of live cells (Figure 4.S3). 
Previous studies on the number of plasmids contained within gene delivery 
nanoparticles have been limited [20-23]. In studies using cryo-TEM, X-ray scattering, 
and DLS to evaluate lipopolyamine-DNA complexes, up to 7 plasmids (6.4 kbp) per ~50 
nm lipoplex particle and 13 plasmids (3.7 kbp) per 50-100 nm lipoplex particle were 
calculated [21, 23]. In making these calculations, the particles were assumed as 
monodisperse spheres although size showed irregularities. Based on the periodicity of 
ordered microdomains of the particles, half the TEM volume of the ~50 nm spheres was 
assumed to be occupied by DNA and the number of plasmids was calculated by dividing 
this volume by the density of DNA as 1.66 g/cm
3
. In this manner, as the length of DNA 
was shortened, the number of plasmids per particle was calculated to increase linearly up 
to 55 plasmids per lipoplex particle when the DNA was 0.9 kbp in size.
24
 This study, 
 
96 
which analyzed lipoplexes and did not include polymeric nanoparticles, is dependent on 
the observation of ordered microdomain structure and did not look at the effect of varying 
biomaterial structure on nanoparticle composition and properties. 
In an alternative strategy, Ho et al. reported the use of quantum dot (QD) labeling 
combined with regular TEM for estimation of plasmids per particle in chitosan-based 
nanoparticles [20]. The number of quantum dots per polyplex nanoparticle can be 
determined by the ratio of fluorescence signal from a single polyplex compared to a 
single QD and by counting the electron-dense regions of QDs within a polyplex in a 
TEM image. Estimating 0-3 QD per plasmid, ~30 plasmids per particle were calculated 
for a ~60 nm particle [20]. While this QD technique works very well as a novel tool to 
evaluate intracellular stability and DNA unpacking, it has limitations in easily estimating 
plasmids per particle as the DNA must be first labeled and this may change its self-
assembly properties with certain materials, unlabeled DNA that may be encapsulated is 
not directly detected, counting QDs per particle by TEM becomes more difficult as the 
number of plasmids increases due to potentially overlapping plasmids and QDs in the 2D 
image, and other simplifying assumptions.  
 A third approach at measuring plasmids per particle was developed by Collins et 
al. who studied (Lys)16 containing peptide/DNA complexes and quantified the number of 
plasmids per particle in physiologically relevant aqueous solution [22]. However, the 
technique used, Flow Particle Image Analysis, is only amenable to sizing larger, micron-
sized particles. A polylysine-based Polymol peptide was found to form ~1 µm particles 
that contained an estimated 70,000 6.0 kbp plasmids per particle. These microparticles 
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are approximately 10-fold larger than the nanoparticles used in the current study, and 
hence, their volume is ~10
3
-fold greater. 
For all formulations described in this manuscript, calculated plasmid per particle 
counts were lower than the estimated theoretical maximum value, but of the same order 
of magnitude. The calculated values determined from this novel NTA method are similar 
in some ways to the numbers previously reported in literature including an average of 30 
plasmids per particle for chitosan-DNA nanoparticles [20] and 13 plasmids per particle 
for lipopolyamine-DNA lipoplex nanoparticles [21]. These are both close to the low 
range of the PBAE nanoparticles described. However, we also show that other PBAE 
nanoparticles as well as PEI nanoparticles can have a much higher DNA carrying 
capacity of ~100 plasmids per particle. This higher DNA loading may be especially 
important for the co-delivery of genetic therapeutics for the treatment of diseases such as 
cancer or as an enabling tool for stem cell reprogramming. 
 Although TEM is routinely used for nanoparticle characterization, and can be 
used to estimate particle concentration, there are drawbacks of using this method. They 
include errors introduced by processing effects such as dehydration and aggregation of 
“soft” self-assembled particles that are typically hydrated in their native state, limited 
sample size per image for sufficient statistics, consumption of the sample by the assay, 
and relatively high cost and time consumed for sample collection and analysis. DLS is 
unable to measure particle concentration and reports size that is biased towards larger 
particles. Thus, a new technique is required. Here, we show that NTA is a technique that 
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is able to meet this need. In addition to its utility at measuring number-averaged size and 
concentration of nanoparticles, the assay is also quick and non-destructive of the sample. 
In comparison to viruses, which are natural nanoparticles, the polymeric 
nanoparticles are found to contain up to 100-fold more copies of their delivery genome 
than viruses contain. For example, while adenovirus particles and the polymer-based 
nanoparticles evaluated here both contain double stranded DNA, are both ~100 nm in 
size, and have been shown to have comparable efficacy in vitro to certain human cells 
[32], this work shows that each synthetic nanoparticle is dramatically less efficient in 
delivery. Future work is needed to improve the efficiency of synthetic nanoparticles for 
non-viral gene delivery. 
 In conclusion, a quick, easy and robust assay for quantifying the number of 
plasmids per nanoparticle in physiologically relevant aqueous solution was developed. 
PBAE-based and PEI-based polymeric nanoparticles were analyzed by varying their 
polymer structure and polymer to DNA weight ratio. The plasmids per particle values 
ranged from 30 to 120 plasmids per particle and depended on polymer structure. More 
plasmids per particle led to higher co-expression following gene delivery. To our 
knowledge, this is the first study to report characterization of polymeric nanoparticles in 
terms of plasmids per particle in aqueous conditions. Characterization of polymeric 
nanoparticles in terms of the number of plasmids per particle can allow for improved 
design to non-virally co-deliver multiple plasmids to the same target, a requirement for 
certain gene therapies and for factor-based stem cell reprogramming. 
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4.5 Tables 
Table 4.1. Nanoparticle size averages of the seven formulations. Z-average determined 
by dynamic light scattering (DLS), with all other sizing determined by nanoparticle 
tracking analysis (NTA). Error reported is standard error of the mean. 
 
 
Table 4.2. The average number of plasmids per nanoparticle for the seven nanoparticle 
formulations as determined by nanoparticle tracking analysis (NTA). 
 
  
 
101 
4.6 Figures 
 
Figure 4.1. The chemical structures of the PBAEs and PEI used in this study. 
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Figure 4.2. Size distribution and plasmid per particle distribution data of PBAE (B4S4E7 
and B5S3E7, both 60wt/wt) based nanoparticles. (a) particle size from nanoparticle 
tracking analysis (b) particle size from transmission electron microscopy (c) plasmid per 
particle distribution from nanoparticle tracking analysis. 
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Figure 4.3. Co-transfection data in IMR90 human fibroblasts. B4S4E7 and B5S3E7-
based nanoparticles were used to deliver EGFP and DsRed plasmids within the same 
particles on the same day as well as (a) within separate particles on separate days and (b) 
within separate particles on the same day. Lipofectamine 2000 was used as a positive 
control.  
A
. 
B
. 
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4.7 Supplementary Methods 
1.) Cell Seeding. 
1.1) Do not allow cells to grow to overconfluency. Use early passage cells when 
transfecting primary cells. 
1.2) Twenty-four hours prior to transfection, trypsinize the cells, count the cells using a 
hemocytometer, and dilute the cell suspension with media to achieve the desired cell 
density (cells/volume). Seed cells into clear tissue culture-treated flat-bottom 96-well 
plates using a reservoir and multichannel pipettes. The chosen density should give 70-
80% confluency on the day of transfection. For example, as displayed in Table 4.SM1, 
cells were diluted to 25 to 50 cells/µL for the transfection data shown here. 
 
2.) Cell Transfection. 
2.1.) Dilution of polymer and DNA stocks. Thaw polymer and DNA stock solutions at 
room temperature (RT). Dilute polymer stock solution and DNA stock solution, 
separately in clear 96-well plates using a twelve-channel pipette, with the appropriate 
solvent to concentrations required to obtain the desired polymer weight to DNA weight 
ratios (wt/wt). In this case, the chosen solvent is 25 mM sodium acetate buffer (pH=5.2). 
2.1.1.) DNA dilution. Typically, DNA stored at 1 mg/mL is diluted in sodium acetate 
buffer to a concentration of 0.03 to 0.06 mg/mL in a clear non-tissue culture-treated 96-
well plate (one well for a single formulation). Table 4.SM2 shows the typical DNA 
dilution protocol for a single formulation used to transfect four replicate wells in a 96-
well plate seeded with cells from Step 1. 
2.1.2.) Polymer dilution. The 100 mg/mL polymer/DMSO solution is diluted in sodium 
acetate buffer according to the concentration required to obtain the desired polymer to 
DNA wt/wt ratio. The range of wt/wt ratios typically used for gene delivery with 
poly(beta-amino ester)s (PBAEs) is 20 to 100. PBAE polymers are first diluted to 10 
mg/mL, followed by the dilution protocol as shown in Table 4.SM3. The polymer 
dilutions can be performed in a clear non-tissue culture-treated 96-well plate that matches 
the sample orientation of the DNA dilution plate. 
2.2.) Nanoparticle formation. Add the PBAE solution to an equal volume of the plasmid 
DNA solution using a twelve-channel pipette and mix vigorously. Let the mixture 
incubate at RT for 10 minutes to allow self-assembly. 
2.3.) Nanoparticle transfection. Following self-assembly, 20 µL nanoparticles are added 
per well to the culture medium dropwise using the twelve-channel pipette. Replicate 
wells are left untreated or are transfected with commercially available reagents as 
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controls. The transfected cells are incubated at 37˚C for two to four hours and then the 
wells are replaced with fresh media (100 µL/well).The choice of incubation time will 
depend on the cell line, culture conditions, and transfection system. The difference in 
transfection efficiency and cell toxicity as a result of varying incubation period will be 
quantified by the analysis protocol described in Step 3. 
 
3.) Analysis of Transfection Efficiency and Cell Toxicity. 
Transfection efficiency is analyzed visually with a fluorescence microscope and 
quantified using a flow cytometer forty-eight hours post-transfection. Cell toxicity is 
analyzed visually with a fluorescence microscope and quantified using the CellTiter 96® 
AQueous One assay twenty-four hours post-transfection. 
3.1.) Fluorescence microscopy. Visually analyze the wells for the expression of the 
transfected reporter gene (for example, EGFP or DsRed) using the appropriate 
fluorescence channel. Acquire images for each well, choosing fields of view that 
appropriately represent the transfection efficiency for the particular formulations (Figure 
4.SM1). Make a note of any cell toxicity observed visually. 
3.2.) Flow Cytometry.  
3.2.1.) Use multichannel pipettes to prepare the 96-well plate for flow cytometry. Wash 
with PBS, trypsinize with 30 L/well of trypsin/EDTA, neutralize with 170 L FACS 
buffer (PBS + 2%FBS), pipette up and down in each well, including around edges, and 
transfer the entire 200- L volume of each well into corresponding wells in a round-
bottom or V-bottom 96-well plate.  
3.2.2.) Centrifuge the plate at 130g for 5 min at 4 C.  
3.2.3.) Remove 170 L media from each well and pipette to resuspend cells while 
avoiding bubbles. To use a viability stain like propidium iodide (PI), add 10 L of FACS 
buffer+PI (50:1 FACS buffer:PI dilution; PI stock concentration 1 mg/mL) to each well. 
Immediately place on ice and cover from light. 
3.2.4.) Start the C6 Accuri flow cytometer, the HyperCyt® 96-well attachment, and the 
HyperView® software. Use HyperView® Design and Protocol tabs to choose the 
appropriate plate type, plate layout, and other settings such as shake/sip/rinse/shake time. 
For the above protocol, the following parameters were used, a pre-plate prime for one 
minute, and a pre-plate shake for 30 seconds at 2400rpm. Sip time was set for 15 seconds 
at 15 rpm, a probe rinse every well for 2 seconds, and an interwell shake every 12 wells 
for 12 seconds at 2400 rpm. The interwell shake is important to keep the cells dispersed 
in the media, as well as for improved ability to process the data by including timed breaks 
between groups of wells (in this case 12 seconds). 
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3.2.5.) Use HyperView® Well Identification tab to process the data and separate into the 
appropriate well (Figure 4.SM2). In order to identify the individual wells, it can help to 
use the software’s noise filter, as well as including a base even filter under the advanced 
settings. 
3.2.6.) Quantify percentage of positively transfected live cells by appropriate gating to 
separate different populations (Figure 4.SM3).First view the flow data on a FSC vs.SSC 
scatter plot in order to separate cells from debris (Figure 4.SM3A). If propidium iodide 
(PI) was used, gate the individual cell population and view that data on a FSC vs. FL3plot 
in order to separate live cells from dead cells and gate the live cells. In order to quantify 
the number of transfected cells, view the live cell population on the appropriate channels, 
for example, GFP can be seen in FL1. Using the untreated population, gate the untreated 
cells in order to identify the background signal (Figure 4.SM3B).The positively 
transfected cells can then be isolated using this gate and by viewing the transfected 
populations using both scatter and contour plots (Figure 4.SM3C and 4.SM3D). There 
may be a continuum of positively transfected cells, as different cells will be transfected to 
different degrees of fluorescence. 
3.3.) CellTiter 96® AQueous One assay 
3.3.1.) Transfect another plate in exactly the same manner for cell toxicity measurements. 
3.3.2.) Premix 1 mL of the CellTiter 96® AQueous One assay solution with 10mL fresh 
media. Remove media from cells and use a multichannel pipette to add 110 uL of the 
premixed solution+media per well. 
3.3.3.) Measure the absorbance at 490 nm every one hour interval from 1 to 4 hours until 
the absorbance from the well with untreated condition is in the linear range of the assay. 
Include four control wells with only solution+media for a background absorbance reading. 
3.3.4.) Average the absorbance values from the four replicate wells per condition and 
subtract the average background absorbance from each average. Normalize the corrected 
average for each treated condition to the corrected average of the untreated condition to 
determine the percent cell viability. 
 
4.) Nanoparticle sizing with NTA and plasmid per particle calculations. 
4.1.) Prime the fluidics system of the Nanosight NS500 by running the diluent pump 
forward at approximately 1/5th the max speed and the sample pump backward at 
approximately 1/10th the max speed. Continue until the fluidics system is flushed with 
diluent. 
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4.2.) Prepare the nanoparticles to be analyzed. In the case of PBAEs, separately dilute the 
stock plasmid DNA (1 mg/mL) and stock PBAE (100 mg/mL) in sodium acetate buffer 
(25 mM, pH 5) in eppendorf tubes. 
4.3.) Dilute the plasmid DNA concentration to 0.06 mg/mL. Polymer concentration can 
vary depending on the required weight-weight ratio of polymer to DNA (for example, for 
60 wt/wt particles, polymer is diluted to 3.6 mg/mL). 
4.4.) Add the polymer solution to an equal volume of the plasmid DNA solution and mix 
vigorously. Incubate the mixture at room temperature for 10 minutes to allow self-
assembly. 
4.5.) Dilute the nanoparticle solution 100-fold into PBS in order for the nanoparticle 
concentration to be in the appropriate range for NTA and to obtain a final volume of at 
least 500 µL. 
4.6.) Load the sample into the Nanosight by placing the loading tube into the sample 
eppendorf tube (Figure 4.SM4A). Make sure not to introduce air bubbles. 
4.7.) In capture mode, increase the camera level until particles can be seen. Adjust the 
focus so that the particles look smooth (Figure 4.SM4A and 4.SM4B). 
4.8.) While in standard mode, adjust the camera level past the point that all particles can 
be seen on screen. Then decrease the camera level to the lowest level such that the 
particles can all still be observed. If an intermediate camera level is needed, go into 
advanced mode and modify the camera shutter and gain to the appropriate levels. 
4.9.) Visually check to make sure there are between 20 – 100 particles on the screen. An 
ideal number for nanoparticle tracking is approximately 50 particles. If there are too 
many or too few, flush the NS500, adjust the dilution into PBS, and re-load the sample. 
4.10.) Adjust the capture duration according to the standard mode table. Typically 30 – 
60 seconds is an appropriate capture length (Figure 4.SM4B). 
4.11.) To load the next sample, flush the system, then re-load the new sample. 
4.12.) Once videos are captured, proceed to the processing stage by opening a video file. 
4.13.) There are a number of parameters that can be tuned in order to best process a video 
(Figure 4.SM4C). The goal is to select parameters that best capture each particle on the 
screen, as indicated by a red cross mark on the screen over each particle (Figure 4.SM5). 
4.14.) Increase the screen gain to better see the particles. Under the standard or advanced 
mode, select the auto adjust for the parameters by clicking the appropriate boxes. In the 
case that the auto settings do not adequately select particles, unclick the box and 
manually set the parameters (Figure 4.SM4C). 
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4.15.) Once all the particles are picked on screen, click the process button of the software 
to process the video file (Figure 4.SM4C). This provides the particle size distribution, 
size averages, as well as particle concentration. 
4.16.) In order to make certain that the particle concentration is accurate, change the PBS 
dilution, such as by increasing dilution by 2x, and repeat the above procedure. Measuring 
multiple dilutions of the same sample is recommended to ensure that the concentration 
measurement of the sample is accurate. A good range for measurement is 10
7
-10
9
 
particles/mL. 
4.17) Verify that all plasmids are incorporated into nanoparticles by running gel 
electrophoresis of the nanoparticles and evaluating whether any free DNA is present. If 
not all plasmids are encapsulated, use standard techniques to measure DNA absorbance 
in order to quantify total encapsulated plasmids. 
4.18.) To calculate the average number of plasmids per particle, divide the total 
encapsulated plasmid concentration by the NTA measured particle concentration. In 
order to estimate the plasmid per particle sample distribution, first use the NTA particle 
size histogram to calculate the volume fraction of each 1-nm bin of particle. Multiply this 
volume fraction distribution by the total plasmid amount to obtain the number of 
plasmids in each bin. Divide these numbers by the number of particles in each bin to 
obtain the number of plasmids-per-particle for each particle size. 
 
4.7.1 Supplementary Methods (SM) Tables 
 
Table 4.SM1. Typical cell plating protocol for a 96-well plate format. 
Wells/Plate Volume/Well (µL) Cells/Well 
96 100 2,500 to 5,000 
 
Table 4.SM2. Typical DNA dilution protocol for a 96-well plate format. 
Wells
/Plate 
Volume/
Well (µL) 
Particle 
Volume/
Well (µL) 
DNA/Well 
(µg) 
DNA 
(µg/ µL) 
DNA 
stock 
(µL) 
NaAc 
(µL) 
96 100  20 0.6 to 1.2 0.03 to 0.06 3.0to 6.0 47 to 44 
 
Table 4.SM3. Typical polymer dilution protocol for a 96-well plate format. 
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Polymer:
DNA 
(wt/wt) 
Particle 
Volume/
Well (µL) 
# Replicate 
Wells 
DNA/ 
Well (µg) 
Polymer/
Well (µg) 
Polymer/ 
DMSO 
stock (µL) 
NaAc 
(µL) 
20 20 4 0.6 to 1.2 12 to 24 1.2 to 2.4 55 
40 20 4 0.6 to 1.2 24 to 48 2.4 to 4.8 55 
60 20 4 0.6 to 1.2 36 to 72 3.6 to 7.2 50 
100 20 4 0.6 to 1.2 60 to 120 6.0 to 12 50 
 
 
4.7.2 Supplementary Methods (SM) Figures 
 
Figure 4.SM1. Single color channel fluorescence imaging of HRECs transfected with 
PBAE. (Left) GFP fluorescence, colored green; (Middle) Brightfield image; (Right) 
Composite image. 
 
 
Figure 4.SM2. Hypercyt software well identification step after data collected. (Left) 
Example of problematic data due to low counts or issue with the fluidics; (Right) 
Example of clean data, with easily identified wells. 
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Figure 4.SM3. FlowJo gating for cells transfected with EGFP plasmid. (A) FSC vs. SSC 
for untreated cells; (B) FL1 vs. FL3 for untreated cells; (C, D) FL1 vs. FL3 for cells 
transfected with PBAE. Both pseudo-color density (C) and (D) contour plots are useful to 
determine the location to draw gates. 
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Figure 4.SM4. Screenshot of parts of the Nanosight nanoparticle tracking analysis 
software, version 2.2. (A) The fluidics control; (B) Capture mode, used to capture video 
of the nanoparticles; (C) Processing mode available after opening a previously captured 
video. Red boxes highlight functions discussed in the protocol. 
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Figure 4.SM5. Example of Nanosight video capture and analysis. Screenshots of sample 
before video capture for sample that is not diluted enough (A), and with appropriate 
dilution (B); Screenshots of analysis mode with particle detection threshold set too low 
(C) and set appropriately (D), with red cross hairs identifying all particles appropriately. 
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4.8 Supplementary Figures 
 
Figure 4.S1. Gel electrophoresis data of the six PBAE-based nanoparticle formulations at 
different polymer to DNA weight ratios (wt/wt – 20,40,60,100,140,180) and PEI-based 
nanoparticles control at 2 wt/wt prepared by complexing polymer with EGFP plasmid. 
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Figure 4.S2. Plasmid per particle distributions from nanoparticle tracking analysis. 
Figure shows the plasmid per particle distribution data for the rest of the formulations as 
determined by calculating the number of plasmids per particle for each 1 nm increment of 
particle size. The peak of the distribution represents the mode plasmid per particle 
number for each formulation. The mean of 1 nm distribution was also determined and 
found to be equal to the mean obtained from overall average calculations. For all 
formulations, the mode was lower than the mean indicating that a few particles may 
contain a lot of the plasmids and other particles contain fewer plasmids. 
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Figure 4.S3. Flow cytometry (FC) and fluorescence microscopy (FM) images of IMR90 
cells co-transfected with DsRed and EGFP plasmids using B5S3E7 (FC-bottom panel, 
FM-left image) and B4S4E7 (FC-top panel, FM-right image) based nanoparticles. 
15.8±0.5% cells were co-transfected by B4S4E7 based nanoparticles as compared to 
3.3±0.5% co-transfected by B5S3E7 based nanoparticles. The polymer B4S4E7 with a 
high plasmid/particle count (~120) is more effective at co-transfection than B5S3E7 with 
a low plasmid/particle count (~30).   
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Chapter 5 
Poly(beta-aminoester) Nanoparticle Delivery of p53 has 
Activity Against Small Cell Lung Cancer In Vitro and In Vivo 
 
5.1 Introduction 
 Small cell lung cancer (SCLC) represents 15% of all lung cancer cases and has 
one of the highest case-fatality rates of all cancers with nearly as many deaths as 
diagnoses per year. In 2011 over 25,000 deaths were attributable to this disease in the US 
alone [1]. The median survival of patients diagnosed with SCLC is less than 1 year. This 
statistic has not changed significantly over the past 3 decades despite over 52 randomized 
phase 3 clinical trials evaluating numerous cytotoxic chemotherapies [2]. The 
combination of etoposide and cisplatin has been the standard first-line therapy for SCLC 
since the 1980s. In 2003 topotecan became the only drug approved for treatment of 
patients with relapsed SCLC. New therapeutic approaches are needed to improve long-
term survival in this disease. 
 SCLC exhibits certain recurrent genetic alterations most notably inactivation of 
the tumor suppressor genes, TP53 and RB. TP53 encodes a transcription factor whose 
targets regulate cell cycle progression, senescence, DNA repair and apoptosis [3, 4]. 
TP53 mutations are the most common genetic alteration in human cancer, occurring in 
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over 50% of cases [5, 6]. Wild-type (WT) p53 activity can also be abrogated by 
endogenous MDM2 or viral proteins; the human papilloma virus E6 protein, SV-40 large 
T antigen and adenovirus E1B-55kDa proteins can bind and attenuate p53 activity 
resulting in cellular transformation [7-9]. In transgenic mouse models disruption ofTP53 
results in increased susceptibility to tumor development, most notably lymphomas and 
sarcomas. Restoration of p53 in these models results in potent antitumor activity in a cell-
type specific manner; TP53 re-expression induces apoptosis in autochthonous 
lymphomas but senescence in sarcoma and hepatocellular carcinoma models [10, 11].  
 In SCLC, TP53 alterations are prevalent; among 67 independent SCLC cell lines 
and 231 primary SCLC tumors TP53 was mutated in 90% and 74% of cases respectively 
[12]. Support for the critical role of TP53 in SCLC pathogenesis also derives from 
transgenic mouse models, in which Cre-mediated loss of TP53 and RB results in murine 
SCLC which shares histopathologic features of human SCLC including neural cell 
adhesion molecule (NCAM; CD56) expression, and elaboration of neuroendocrine (NE) 
markers such as synaptophysin and chromogranin [13]. In this genetic background, 
AdenoCre placed under the control of the NE cell-specific calcitonin/calcitonin-gene 
related peptide (CGRP) promoter, but not a Clara-cell specific promoter, resulted in 
murine SCLC, implicating pulmonary NE cells as the putative cell of origin for SCLC 
[14]. In vitro, Adachi et al, has demonstrated that expression of WT p53 in a p53-null 
SCLC cell line results in apoptosis [15]. As loss of TP53 appears to be critical in SCLC 
development, restoration of functional p53 may have therapeutic efficacy. 
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 Adenovirus is the one of the most widely studied gene therapy vectors; in non-
small cell lung cancer (NSCLC), adenoviral-mediated TP53 (Ad.p53) delivery has been 
evaluated in several early-phase clinical trials [16, 17]. Intratumoral (IT) delivery of 
Ad.p53 in combination with chemotherapy was found to be safe and histological 
examination of tumor tissue revealed apoptosis in Ad.p53 treated samples [16]. A phase 
II study, however, failed to show increased response or local benefit of combined Ad.p53 
and chemotherapy over chemotherapy alone [17]. Adenoviral gene therapy has also been 
evaluated preclinically in SCLC models. Adenoviral delivery of a siRNA targeting the 
hepatocyte growth factor receptor, c-Met, in the H446 SCLC cell line resulted in 
decreased proliferation in vitro and tumor growth inhibition (TGI) in vivo [18]. Similarly, 
adenoviral delivery of fragile histidine triad complex, a putative tumor suppressor gene 
often mutated in SCLC, induced apoptosis in multiple SCLC cell lines [19]. 
 The use of viral vectors has been limited by safety concerns including insertional 
mutagenesis and toxicity as well as limited cargo capacity and manufacturing challenges 
[20, 21]. Many patients have pre-existing humoral immunity to adenovirus, or rapidly 
develop neutralizing antibodies, limiting the potential of adenoviral therapies. Alternative 
approaches to gene delivery, using non-viral biomaterials such as inorganic nanoparticles, 
cationic lipids, liposomes, polymers, and peptides, have been limited by low efficicency, 
resulting in limited efficacy [22-24]. 
We have developed highly effective biomaterials for non-viral gene delivery to 
hard-to-transfect cells [23, 25- -amino ester) (PBAE) polymers are 
biodegradable due to ester linkages throughout the polymer backbone which allows for 
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lower toxicity and release of DNA intracellularly. Through their secondary and tertiary 
amines, these polymers are also able to buffer the endosome, which facilitates endosomal 
escape [29, 30]. Additionally, subtle changes to PBAE structure can improve specificity 
of transfection and these polymers have been adapted for gene delivery to various cell 
types including HUVECs, human retinal endothelial cells and human mesenchymal stem 
cells as well as glioblastoma multiforme, ovarian, prostate and pancreatic cell lines [25, 
27, 31-33]. 
 In this study, we sought to develop non-viral nanoparticles which could deliver 
therapeutic genes with high efficiency to SCLC cells. We synthesized an array of PBAEs 
using combinatorial chemistry [34] and found several polymers with transfection 
efficiencies comparable to commercially available agents in SCLC cell lines. These 
polymers may be generally useful as efficient gene-delivery vectors. As a proof of 
principle for this approach, we used two PBAE polymers to assess the activity of WT 
TP53 delivery to the p53-mutant H446 SCLC cell line in vitro and in vivo.  
 
5.2 Materials and Methods 
5.2.1 Plasmids, Chemicals and Reagents 
Unless otherwise stated, all reagents were purchased from Sigma Chemical 
Company (St. Louis, MO USA) or Fisher Scientific (Pittsburgh, PA USA) in the highest 
available purity. The CMV-GFP (EGFPN1) and CMV-LUC plasmids were purchased 
from Elim Biopharm (Palo Alto, CA). p53-CMV-GFP plasmid (Addgene, San Diego, 
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CA) contained CMV-promoter regulating the fusion of two gene segments: WT p53 and 
EGFPN1 backbone. 
5.2.2 Monomers Reagents 
Monomers used for polymer synthesis were the following: from Acros Organics 
[1-(3-aminopropyl)pyrrolidine (E8)], Alfa Aesar [1,4-butanediol diacrylate (B4), 1-(3-
aminopropyl)-4-methylpiperazine (E7)], Fluka [2-(3-aminopropylamino)ethanol (E6), 3-
amino-1-propanol (S3), 4-amino-1-butanol (S4), 5-amino-1-pentanol (S5)], Monomer-
Polymer and Dajac Laboratories [1,3-propanediol diacrylate (B3), 1,5-pentanediol 
diacrylate (B5)], Sigma-Aldrich [1,3-butanediol diacrylate (B3m)], and TCI America 
[1,3-diaminopentane (E3), 2-methyl-1,5-diaminopentane (E4), (PEO)4-bis-amine (E5)] 
and as previously described [34]. 
5.2.3 Preparation of Cy5 labeled dsRED DNA 
pDsRed-Max-N1 DNA (Promega, Madison, WI) was labeled with Cy5 
fluorophore using the Label IT Cy 5 Tracker kit (Mirus, Madison, WI) as per 
manufacturer’s protocol and stored at -20 C in light protective conditions.  
5.2.4 Cell lines 
All cell lines were obtained from American Type Culture Collection (ATCC) and 
grown in complete RPMI [RPMI 1640 (Quality Biologicals, Gaithersburg, MD) 
supplemented with 10% fetal bovine serum, L-glutamine, pen/strep, sodium pyruvate, 
HEPES, and sodium bicarbonate] per ATCC recommendations.  
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5.2.5 Synthesis of poly(β-amino esters) (PBAEs) 
The PBAEs were synthesized in a two-step reaction procedure (Figure 5.1). In 
the first step, the base polymers were synthesized by mixing diacrylates (B) with amino 
alcohols (S) at a molar ratio of 1.1:1 or 1.2:1. The reaction was performed in glass 
scintillating vials with teflon stir bars at 90
o
C for 24 hours. The base polymer was then 
dissolved in anhydrous dimethyl sulfoxide (DMSO) to 167 mg/mL. In the second step of 
the reaction, 480 µL of the base polymer solution is mixed with 320 µL of 0.5 M end-
capping amine (E) in 1.5 mL eppendorf tubes and allowed to react in a shaker for 24 
hours. Polymers were then divided into smaller volumes and stored at frozen and with 
desiccant until needed. These polymers were characterized with gel permeation 
chromatography and proton nuclear magnetic resonance as previously described [34]. 
Select polymers, including polymers used in vivo, were made in larger quantities and 
further purified. In this case, after the base polymer reaction step, the polymers are 
dissolved in tetrahydrofuran (THF), instead of DMSO, and then end-capped as above, but 
with end-capped monomers also diluted in THF. Once the reaction is complete, the 
polymer is mixed with 4x the volume of ethyl ether. These mixtures were vortexed 
vigorously and then centrifuged at 4 krpm for 5 minutes, after which the supernatant 
containing unreacted monomer and organic solvents was removed. This process was then 
repeated a second time and the purified polymers dried under vacuum for 2 days. The 
polymers were then dissolved in anhydrous dimethyl sulfoxide and kept frozen with 
desiccant as described above. 
5.2.6 Nanoparticle Preparation 
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For each transfection, PBAE:DNA nanoparticles were prepared by separately 
dissolving PBAE polymer and DNA in 25 mM sodium acetate (pH 5.0). The polymer and 
DNA solutions were mixed in equal volumes, gently pipetted and incubated for 10 min at 
RT. A range of w/w ratios were evaluated for the high-throughput screen and are 
described in the High-throughput screening of PBAE polymer library section found in the 
Supplemental Data. For all other experiments, PBAE:DNA ratios of 75 w/w and 30 w/w 
ratios were for in vitro and in vivo studies, respectively. Polymer and DNA stocks were 
stored at -20 C and thawed on ice before mixing and treating the cells. For Cy5-DsRed 
experiments, 0.1ug of Cy 5 labeled DsRED was included in the DNA mixtures and 
PBAE:DNA nanoparticles were prepared as described above.  
5.2.7 Nanoparticle characterization 
Plasmid DNA and PBAEs were separately diluted in 25 mM sodium acetate 
buffer to 0.06 mg/mL and either 1.8, 3.6, or 4.5 mg/mL, respectively (corresponding to 
PBAE:DNA weight/weight, wt/wt, ratios of 30, 60, or 90). Equal volumes of the DNA 
and PBAE solutions were mixed and incubated for 10 minutes at room temperature. The 
resulting solution of nanoparticles was then used either for sizing or DNA complexation 
studies. In the case of sizing, the samples were further diluted in PBS and loaded into a 
Nanosight NS500 nanoparticle tracking analysis (NTA) instrument. The solutions were 
diluted anywhere from 50x to 200x, so that the nanoparticle concentrations were 
appropriate for NTA analysis [35]. NTA videos were captured for 60 seconds and 
analyzed using the NTA software, version 2.1. To further examine the ability of the 
polymers to bind to the DNA, the nanoparticle solutions were run on a gel using 
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electrophoresis and compared to naked DNA. A 1% agarose gel with 0.1 µL/mL 
ethidium bromide was made. The naked DNA solution was mixed with a 30% glycerol 
loading buffer with bromophenol blue dye, while the nanoparticle solutions were mixed 
with the loading buffer without the dye to prevent interference between the dye and 
PBAE-DNA interaction. The gel was run for 30 min at 100V and imaged using the UVP 
BioDoc-It Imaging Center. 
5.2.8 Transfection protocol 
Adherent cells: H446 cells were seeded at low density and allowed to adhere 
overnight. PBAE:DNA nanoparticles were added to cells followed by gentle shaking. 
After 4 hours, the media was replaced with fresh media and the cells were incubated at 
37 C for 44 h. 
Suspension cells (H146, H187): Cells were seeded in complete RPMI overnight 
then incubated with PBAE/DNA nanoparticles for 4 h with gentle shaking. After 4 h, 
cells were centrifuged at low speed for 2 min, fresh media was added and the cells further 
incubated at 37 C for next 44 hours.  
5.2.9 Fluorescence microscopy 
GFP positive cells were analyzed using a Motic AE31 inverted microscope using 
a FITC 480nm filter. Cy5 labeled cells were visualized and analyzed using a Zeiss Axio 
Observer microscope fitted with a Cy5 specific filter (emission wavelength of 690nm).  
5.2.10 Flow cytometry 
 
127 
GFP fluorescence was used to indicate successful transfection, propidium iodide 
(PI) was used for dead cell discrimination, and Cy5 fluorescence to indicate successful 
nanoparticle association using a FACSCalibur flow cytometer (BD Biosciences, 
Rockville, MD). Briefly, adherent cells were trypsinized, centrifuged and resuspended in 
500 µL of fresh media and analyzed by flow cytometry. A total of 10,000 cells were 
acquired per analysis. All analyses were run with triplicate samples. Data analysis was 
performed using BD CellQuest Pro software (BD Biosciences).  
5.2.11 Western blot 
Whole cell extracts were prepared using RIPA buffer containing protease and 
phosphatase inhibitors and clarified by low-speed centrifugation. The protein extracts 
were quantitated by BCA assay, resolved by SDS-PAGE on 4-12% Bis-Tris gels and 
transferred to PVDF membranes. Membranes were blotted with a 1:500 dilution of 
primary antibodies to p53 (Santa Cruz Biotechnologies), p21 (Calbiochem), anti-GFP 
(Abcam) and actin (Santa Cruz) and detected using HRP-conjugated secondary 
antibodies and visualized by ECL per protocol (Pierce).  
5.2.12 Cell cycle analysis 
Cells were prepared at 48 and 72 hrs post-treatment for cell cycle analysis 
following a standard PI staining protocol and analyzed by flow cytometry using a 
FACSCalibur flow cytometer and CellQuest Pro software. Each assay was run in 
triplicate and all data is presented as the mean +/- SEM.  
5.2.13 Annexin V staining 
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To determine early apoptotic events, cells were assessed for Annexin V positivity. 
Cells were plated and transfected as described above. At the indicated time after 
transfection cells were detached from the tissue culture plates using Accutase (Sigma), 
stained with Annexin V Cy5 (BD Biosciences) per manufacturer’s directions and 
analyzed on a FACSCalibur flow cytometer. Cisplatin (10uM) treated cells were used as 
a positive control. Each assay was run in triplicate and all data is represented as the mean 
+/- SEM. 
5.2.14 Fluorescence-activated cell sorting (FACS) 
Cells were sorted using a using a FACS Aria II (BD Biosciences) into GFP-
positive and GFP-negative populations 18 hrs post-transfection. Untreated cells passed 
through the sorting machine were used as an additional control. Post-sort analysis was 
completed within 2 hrs of collection, cells were replated in complete RPMI and assessed 
at 48 and 72hrs post-transfection. 
5.2.15 In vivo experiments 
Three-to-four week old athymic female nude mice were injected subcutaneously 
with 1.5x10
6
 H446 cells suspended in PBS and mixed 1:1 in matrigel (BD Biosciences). 
Once tumor volumes reached 200 mm
3
, the mice were randomized [N=3-4] into three 
groups: 1) Untreated, 2) 457:CMV-LUC, 3) 457:CMV-p53-LUC. The PBAE:DNA 
nanoparticles were prepared at 30 w/w; 50 µg of DNA was used per IT injection and the 
mice were treated twice a week for 3 weeks. Tumor measurements, using a digital caliper, 
and weights were collected twice a week. Tumor volume was calculated as follows: 
tumor volume (mm
3
) = [length (mm) x width (mm)
2
]/2. Toxicity was monitored by 
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weight loss and animal activity following ACUC protocols. Tumor growth curves are 
presented as mean +/- SEM. The area under curve (AUC) was calculated using GraphPad 
Prism estimating total AUC from day 1 to day 18 for respective treatment groups. The 
percentage inhibition in tumor growth was compared among all the treatment groups over 
the total time course of the study. Statistical significance was then determined by two-
way ANOVA followed by Bonferroni post-hoc test. (* p ≤ 0.001 CMV-p53-LUC vs. 
CMV-LUC; 
#
 p ≤ 0.01 CMV-p53-LUC vs. untreated). All animal experiments were 
performed following JHU Animal Care and Use Committee regulations.  
 
5.3 Results 
We generated a polymer array of 30 structurally distinct PBAEs and over 120 
nanoparticle formulations (Figure 5.1). This array contained base polymers composed of 
four backbone monomers that differed by single carbons between the acrylate groups (B3, 
B3m, B4, and B5 corresponded to 3 carbons, 3 carbons + 1 methyl group, 4 carbons, and 
5 carbons respectively) and three side chain monomers (S3, S4, and S5 that differed by 
having 3, 4, and 5 carbons respectively between amine and alcohol groups). These base 
polymers were terminated with one of six amine-containing small molecule end-groups. 
Structures were validated by GPC and NMR [34]. We performed a high-throughput 
luciferase-based screen of the PBAE array to identify leading polymers optimized for 
efficient transfection of SCLC cells. Gene delivery of exogenous luciferase plasmid 
resulted in luminescence that was quantified and normalized to untreated cells (Figure 
5.S1). The leading candidate polymers, such as 456 (Figure 5.1), were able to transfect 
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H446 cells several orders of magnitude better than other nanoparticle formulations, and 
resulted in transfection efficiencies as high or higher than both positive controls, 
FuGENE HD and Lipofectamine 2000. The size of the leading PBAE/DNA nanoparticles 
was examined using nanoparticle tracking analysis [35] and quantified by nanoparticle 
number-average size (Figure 5.2A). DNA encapsulation and binding by the leading 
polymers was determined by gel electrophoresis, demonstrating that at the optimized 
PBAE:DNA weight:weight ratios used in our study, the DNA is completely complexed 
by the polymers (Figure 5.2B). In general, the nanoparticle diameters range from 100-
200 nm, with the range for the leading polymers, a more narrow 100-150 nm. It has been 
previously reported that within this range, the size of the particle does not correlate 
strongly with transfection efficacy [29].  
 The extensive luciferase-based screen identified PBAEs that could induce high 
levels of expression, but to identify those PBAEs which could transfect the highest 
percentage of cells, we used a GFP-based analysis. We selected 32 of the top candidates 
from the initial screen and quantitated the transfection efficiency by fluorescence 
microscopy and flow cytometry (Figure 5.3A-B). Two of the top polymers, 456 and 457, 
exhibited transfection efficiencies of approximately 40%, comparable to the 
commercially available transfection agent, Fugene-HD (Figure 5.3C, grey bars). The 
majority of the polymers also induced higher level GFP expression, quantitated by 
geometric mean fluorescence, compared with Fugene HD (Figure 5.3C, black bars). We 
adapted our transfection protocol for suspension cells and found that 456 polymers could 
transfect H146 and H187 SCLC cell lines with effieciencies of 33 ±3% and 22±2%, 
respectively (Figure 5.3D-F). As suspension cells are notoriously difficult to transfect, 
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we found these results encouraging. We further assessed the ability of 456 polymers to 
transfect non-transformed cell lines. The transfection efficiency of our nanopartcles in the 
WI-38 and IMR-90 human lung fibroblast lines was 13% and 11%, respectively; 
therefore, the 456 polymers appeared to be fairly selective for SCLC over non-
transformed cells (Figure 5.S2). To determine whether the transfection efficiency was 
limited by poor nanoparticle association and uptake by SCLC cells, we transfected H446 
cells with PBAEs complexed with a Cy5-labeled plasmid. We observed that >95% of 
cells were Cy5-positive (Figure 5.S3) suggesting that events downstream of nanoparticle 
uptake such as intracellular trafficking, endosomal release or nuclear uptake and 
processing may be additional determinants of PBAE transfection.  
 We next evaluated the ability of the 456 polymer to deliver functional p53. 
Transfection of H446 cells with 456:CMV-p53-GFP, but not 456:CMV-GFP, induced 
morphologic changes and punctate GFP localization (Figure 5.4A). At 48 hrs post-
transfection, 22% of cells transfected with 456:CMV-p53-GFP were strongly GFP-
positive, compared to 41% of those transfected with 456:CMV-GFP (Figure 5.4B-C). 
p53-GFP expression was seen as early as 2 hrs and peaked at 18-24 hrs post-transfection 
(Figure 5.4D). Consistent with functional p53 activity, we observed p21 induction at 18-
24 hrs, a significant increase of Annexin V positive cells at 48 hrs and cellular 
accumulation in sub-G1 at 72 hrs post-transfection with 456:CMV-p53-GFP (Figure 
5.4D-F). To ascertain the effect of WT p53 restoration in more homogeneous populations, 
we sorted H446 cells transfected with either 456:CMV-GFP or 456:CMV-p53-GFP into 
GFP-positive and GFP-negative populations (Figure 5.5A). Post-sort (20 hrs post-
transfection) flow cytometry confirmed that the sorted cells were relatively homogeneous 
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(>80%) and GFP expression was maintained over 72 hrs (Figure 5.5B). At 48 and 72 hrs, 
we observed robust p53-GFP expression and p21 induction in GFP-positive cells 
transfected with 456:CMV-p53-GFP (population 4), but in none of the other sorted 
populations (Figure 5.5C). Cell cycle analysis also revealed > 40% of the population 4 
cells had accumulated in sub-G1 at 48 and 72 hrs, consistent with functional p53 activity 
(Figure 5.5D-E). 
 Successful nanoparticle delivery of WT p53 would be expected to result in cell 
cycle arrest, induction of apoptosis and inhibition of tumor progression in vivo. To 
determine whether PBAE-mediated p53 delivery had antitumor activity in vivo, we 
administered nanoparticles carrying CMV-p53-LUC intratumorally (IT) into 
subcutaneous H446 xenografts. For this proof of principal analysis, we selected another 
leading PBAE polymer from our in vitro studies, 457, as this polymer appeared to better 
target subcutaneous tumors in pilot in vivo experiments (data not shown). Nude mice 
bearing H446 xenografts received twice weekly IT injections of 457:CMV-p53-LUC, 
457:CMV-LUC, or neither nanoparticle formulation, and the tumors were serially 
measured (Figure 5.6). We observed > 50% tumor growth inhibition with IT injection of 
457:CMV-p53-LUC relative to either 457:CMV-LUC or no treatment control (p ≤ 0.01 
for comparison to either control). Thus, when effectively delivered to tumors, PBAE-
mediated nanoparticle delivery and exogenous expression of WT p53 can inhibit tumor 
growth of human SCLC xenografts.  
 
5.4 Discussion 
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 Here we report on a non-viral, biodegradable PBAE nanoparticle that self-
assembles with DNA and can deliver WT TP53 to SCLC cells. Using a luciferase-based 
high throughput screening approach, we were able to identify PBAE polymers that could 
transfect SCLC lines at efficiencies comparable to commercially available transfection 
reagents. We showed that the 456 polymer could deliver functional p53 to SCLC cell 
lines resulting in p21 expression, induction of apoptosis and accumulation in sub-G1. 
Finally, we demonstrated that IT delivery of 457:CMV-p53-LUC significantly 
suppressed tumor growth while injection of the polymer with CMV-LUC had no effect. 
Thus, when effectively delivered, exogenously expressed WT p53 suppresses tumor 
growth of H446 xenografts.  
 Loss of p53 tumor-suppressor activity is a critical event in cancer development 
across multiple tumor types. In transgenic SCLC models, TP53 loss is required for tumor 
development [13, 36]. Re-expression of WT p53 has potent efficacy in established p53-
null lymphomas, sarcomas and hepatocellular carcinomas [10, 11, 37]. Nanoparticle 
delivery of TP53 using (D,L-lactide-co-glycolide) (PLGA) polymers caused growth 
inhibition in p53-null PC-3 prostate cancer xenografts [38].  
 In addition to p53 deletion or inactivation, some p53 mutations result in dominant 
negative (DN) or gain-of-function activities. The ability of WT p53 to overcome a gain-
of-function p53 mutation is unclear. In spontaneous p53-mutant lymphoma and sarcoma 
models, WT p53 restoration resulted in tumor growth arrest but not tumor regression [39]. 
In these experiments, p53 was restored to endogenous levels, and the authors suggested 
that the ability of p53 to overcome a DN p53 mutant may be dose-dependent. As an 
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alternative approach, small molecules that can restore mutant p53 to its WT conformation 
have been explored. One such molecule, PRIMA-1 (p53-dependent reactivation of 
massive apoptosis), is able to restore the transcriptional activity of mutant p53 and has 
efficacy in several preclinical cancers models including SCLC [40]. A primary limitation 
is the requirement for mutant p53; PRIMA-1 would not be effective in tumors harboring 
a null mutant or that are driven by overexpression of p53 binding proteins such as MDM2. 
The H446 SCLC cell line harbors a G154V alteration in the DNA binding domain of 
TP53 and expresses high basal levels of the mutant protein. We demonstrated that CMV-
driven expression of p53 was effective in this p53-mutant cell line; our cell sorting 
experiments show that H446 cells that expressed high-level exogenous WT p53 had 
robust p21 induction and accumulated in sub-G1.  
 This study demonstrates that PBAE-mediated gene transfection is feasible both in 
vitro and, importantly, in tumor-bearing animals. Further, this work shows that this 
approach can be used to restore activity of a silenced or absent tumor suppressor, 
resulting in specific inhibition of tumor growth. This same approach could be used to 
restore multiple silenced genes or to deliver other therapeutic agents. These polymers are 
amenable to a variety of modifications that may improve their efficiency in targeted 
delivery of an anti-cancer payload. 
 A better understanding of the limitations on DNA delivery is required to improve 
the utility of this non-viral gene transfer system. While nearly 100% of the cells take up 
the particles, about 40% of the cells successfully expressed the target protein in our initial 
experiments. This indicates that events downstream may be limiting transfection 
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efficiency PBAEs are able to successfully escape endosomes [41], thus cytosolic 
transport and nuclear import are possible barriers and are the subject of active 
investigation[23]. Delivery of therapeutic agents that are not reliant on 100% transfection, 
that can induce a bystander effect, may be well-suited for this system. For example, 
nanoparticle delivery of the tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) induces apoptosis and tumor regression in the A549 NSCLC cell line [42]. 
TRAIL-induced death, however, is reliant on host factors, including the presence of 
TRAIL receptors, DR4 or DR5, and caspase 8. Agents such as mitomycin C, doxorubicin, 
etoposide and epigenetic modulators are able to sensitize cells to TRAIL by upregulating 
of DR4/5 or caspase 8 [43-45]. Another approach, gene-directed enzyme prodrug therapy 
(GDEPT), is based on cell-specific delivery of an enzyme which can covert a 
systemically administered prodrug into a toxin. While the direct effects are cell-specific, 
this system could be adapted to induce a bystander effect by selecting a drug whose 
metabolite can traverse gap junctions. 
 Our in vivo data demonstrate that if effectively delivered to tumors, PBAE 
nanoparticles can successfully transfect SCLC xenografts and inhibit tumor growth. Our 
work is further supported by Huang et al. demonstrating that PBAE nanoparticles can 
deliver diptheria toxin and induce tumor regression when delivered locally in an ovarian 
cancer xenograft model [46]. Systemic delivery and in vivo stability are major challenges 
in the clinical development of these nanoparticles. PBAE particles are readily amenable 
to approaches to add electrostatic coatings to improve these properties [42, 47, 48]. In 
SCLC, cell-surface expression of CD56 is nearly universal and can be targeted 
effectively by antibodies. A mantaysinoid-conjugated anti-CD56 antibody is being 
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evaluated clinically in SCLC and other tumors [49, 50]. Coatings which incorporate 
NCAM-binding moieties may enhance SCLC specificity and improve in vivo stability of 
PBAE particles. 
 Therapeutic gene delivery has held great promise for decades but has been limited 
by the lack of stable, safe delivery vehicles. Here we report the first demonstration to our 
knowledge of effective non-viral polymeric delivery of therapeutic genes in SCLC in vivo. 
The ability to deliver high level gene expression utilizing a non-toxic biodegradable 
nanoparticle has multiple advantages over viral-based delivery systems, including 
flexibility in cargo capacity, ability to deliver mixed nucleic acids targets, lack of 
insertional mutagenesis and minimal immunogenicity. PBAEs fulfill all of these criteria 
and, with optimization of DNA delivery and systemic stability, may ultimately provide a 
powerful platform for therapeutic restoration of gene expression.  
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5.6 Figures 
 
 
Figure 5.1. Poly(β-amino ester) synthesis scheme depicting the conjugate addition of 
amines to diacrylates in two steps. The three R groups allow modifications to the polymer 
backbone (R), side chain (R’) and end-groups (R’’). Each monomer comprises a 
backbone (B), a side chain (S) or an end-group (E). 
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Figure 5.2. Nanoparticle characterization. The ability of the PBAEs to form 
nanoparticles was examined using NTA to determine the nanoparticle size. (A) and by 
gel electrophoresis. (B) Gel electrophoresis of the nanoparticles shows that at the proper 
PBAE:DNA weight:weight ratios, the DNA is completely complexed by the polymers. In 
general, the nanoparticle diameters range from 100 nm to 200 nm, with the range for the 
select polymers shown from 100 – 150 nm.  
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Figure 5.3. A GFP-based secondary screen identifies several PBAE polymers that can 
deliver genes to adherent and suspension SCLC cell lines at efficiencies comparable to 
commercially available reagents. (A-B) H446 cells were transfected with PBAEs 
complexed with CMV-GFP DNA then analyzed by microscopy and flow cytometry. (C) 
The transfection efficiency and geometric mean fluorescence of 15 PBAE polymers are 
shown; the PBAE polymers are indicated across the x-axis. Percent transfection is 
presented as the mean +/- SEM of triplicate runs and the geometric mean fluorescence is 
the geometric mean FL1 signal +/- SEM of triplicate runs. Fugene HD was used as a 
control. Statistical significance of geometric mean fluorescence was determined by one-
way ANOVA comparing each group with Fugene-HD (*: p ≤ 0.01). (D-F) Two SCLC 
suspension cell lines, H146 and H187 cells were transfected with 456:CMV-GFP and 
analyzed by fluorescence microscopy and flow cytometry.  
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Figure 5.4. Delivery of p53-GFP by 456 polymers induces morphologic changes, p21 
expression, apoptosis and sub-G1 accumulation in bulk transfected cells. (A-B) H446 
cells were transfected with 456 polymers complexed with either CMV-GFP plasmid or a 
CMV-p53-GFP and visualized by microscopy (A) and flow cytometry (B). (C) Percent 
transfection is presented as the mean +/- SEM of triplicate runs. (D) Cells were harvested 
at serial time points after transfection; lysates were examined for p53-GFP, p53 and p21 
expression using anti-p53, anti-p21, anti-GFP (to visualize p53-GFP) antibodies. Actin 
was used as a loading control. (E) Annexin V staining was performed at 48 hours after 
transfection, cisplatin treated cells were used as a positive control for the assay. (F) Cell 
cycle analysis at 72 hours post-transfection. 
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Figure 5.5. Cells sorted for p53-GFP expression exhibit marked morphologic changes, 
p21 induction and accumulation in sub-G1 consistent with functional p53 activity. (A) 
H446 cells were transfected with 456 polymers complexed with either CMV-GFP or 
CMV-p53-GFP and sorted for GFP positive and negative populations (populations 2-5) 
and plated in fresh media. Untreated, sorted cells were used as a control for changes due 
to the sorting procedure (population 1). (B) GFP expression was quantitated by flow 
cytometry immediately post-sort (20H), 48 and 72 hours post-transfection. (C) Western 
analysis confirmed p53-GFP expression and p21 induction primarily in the p53-GFP 
positive (4) population. (D-E) Morphologic changes were observed by brightfield 
microscopy and cell cycle analysis demonstrated accumulation of cells in sub-G1. 
Statistical significance was determined by one-way ANOVA comparing all groups at 48 
and 72 hours (***: p ≤ 0.0001 population 4 vs. 2 or 1)  
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Figure 5.6. Intratumoral delivery of 457:CMV-p53-LUC causes tumor growth inhibition. 
Nude mice bearing H446 xenografts received twice weekly IT injections of 457:CMV-
LUC nanoparticles (n=3), 457:CMV-p53-LUC nanoparticles (n=4), or neither agent 
(n=3). Tumors were measured twice weekly. Group means and SEM were calculated and 
are shown. (A) IT injection of 457:CMV-p53-LUC resulted in statistically significant 
tumor growth inhibition compared with controls. (B) Area under the tumor growth curve 
by day 18. Statistical significance was determined by two-way ANOVA at day 18 (**: p 
≤ 0.001 CMV-p53-LUC vs. CMV-LUC; 
#
: p ≤ 0.01 CMV-p53-LUC vs. untreated).  
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5.7 Supplementary Methods 
5.7.1 Cell lines 
All cell lines were obtained from American Type Culture Collection (ATCC). 
IMR-90 and WI38 cell lines were grown in complete EMEM supplemented with 10% 
fetal bovine serum, L-glutamine, pen/strep, sodium pyruvate, HEPES, and sodium 
bicarbonate.  
5.7.2 High-throughput screening of PBAE polymer library 
H446 cells were seeded at 15,000 cells/well in 96-well plates in 100 µL of 
complete RPMI one day prior to transfection. The nanoparticles were made as discussed 
in the nanoparticle preparation section, with luciferase (CMV-Luc) plasmid DNA at 30, 
60, 75, 100, 125, or 150 w/w of PBAE. Twenty µL of the nanoparticle solution was then 
added per well to the complete RPMI. Untreated wells served as negative controls, while 
Lipofectamine 2000 and FuGene HD, leading commercially available non-viral reagents, 
were used as positive controls as per the manufacturer’s instructions. After 4 hours, the 
transfection solution was removed and fresh media was added to the cells. Transfection 
efficacy was analyzed 2 days after transfection by measuring the luminescence using the 
BrightGlo luciferase assay as we have previously described using a BioTek Synergy 2 
plate reader. Luminescence was averaged within groups of quadruplicates and 
normalized by the untreated group. 
5.7.3 Transfection protocol 
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Adherent (DMS-114, WI-38, IMR-9) and suspension cells (H69, H82, H345, 
H1930) were transfected following the protocol described in the Material and Methods.  
5.7.4 Fluorescence microscopy 
GFP positive cells were analyzed using a Motic AE31 inverted microscope using 
a FITC 480nm filter. Cy5 labeled cells were visualized and analyzed using a Zeiss Axio 
Observer microscope fitted with a Cy5 specific filter (emission wavelength of 690nm).  
5.7.5 Flow cytometry 
GFP fluorescence was used to indicate successful transfection, propidium iodide 
(PI) was used for dead cell discrimination, and Cy5 fluorescence to indicate successful 
nanoparticle association using a FACSCalibur flow cytometer (BD Biosciences, 
Rockville, MD). Briefly, adherent cells were trypsinized, centrifuged and resuspended in 
500 µL of fresh media and analyzed by flow cytometry. A total of 10,000 cells were 
acquired per analysis. All analyses were run with triplicate samples. Data analysis was 
performed using BD CellQuest Pro software (BD Biosciences). 
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5.8 Supplementary Figures 
 
 
Figure 5.S1. High-throughput screen of a library of PBAE polymers. H446 cells were 
plated in 96-well plates and incubated with the indicated PBAE complexed with CMV-
LUC plasmids at multiple w/w combinations. The control samples are Lipofectamine 
2000, FuGene HD 3:1, FuGene HD 4:1, FuGene HD 5:1, and FuGene HD 6:1 
formulations, respectively from front to back. Luminescence was measured with a multi-
well plate reader and normalized to untreated cell. N = 4 wells per condition.  
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Figure 5.S2. The transfection efficiency of 456 polymers in two non-transformed human 
lung fibroblast cell lines. WI-38 and IMR-90 cell lines were transfected with 456 
polymers complexed with CMV-GFP DNA and then analyzed by flow cytometry. 
Percent transfection (% GFP positive) is presented as the mean +/- SEM of triplicate runs. 
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Figure 5.S3. The transfection efficiency of 456 polymers is limited by events 
downstream of binding and uptake. To address whether binding and uptake limit the 
transfection efficiency of 456 polymers, we transfected cells with Cy5-labeled DsRed 
DNA which allowed for visualization of cellular binding and uptake by flow cytometry 
without the requirement for downstream processing or protein expression. H446 cells 
were transfected with either 456:Cy5-DsRed or 456 polymers co-complexed with Cy5-
DsRed and CMV-GFP plasmids and evaluated by microscopy and flow cytometry (A-B). 
We observed that >99% cells transfected with 456:Cy5-DsRed were Cy5 positive while 
only 39% of cells transfected with 456:Cy5-DsRED + CMV-GFP were GFP positive (C). 
Analyses using Cy5-labeled DsRed with suspension cells, H146 and H187, also showed 
similar results (data not shown). 
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Chapter 6 
Gene Delivery Nanoparticles Specific for Human 
Microvasculature and Macrovasculature 
 
6.1 Introduction 
Endothelial cells play important roles in various ocular diseases, such as age-
related macular degeneration, diabetic retinopathy, and retinoblastoma [1]. The 
dysregulation and subsequent angiogenic proliferation of these ocular microvascular 
endothelial cells represents the key step in most retinal causes of blindness. Regulation of 
this angiogenesis by anti-angiogenic drugs such as ranibizumab is now the first-line 
therapy and there is continued interest in more effective anti-angiogenic therapies [2]. 
Gene delivery is one such alternative method for delivery of anti-angiogenic factors to 
endothelial cells, such as endostatin, angiostatin, and vascular endothelial growth factor-
binding protein [3, 4]. In addition, gene therapy can be used to correct specific genetic 
deficiencies within the endothelial cell population. In this strategy, therapeutic genes that 
can either add or block a function are delivered to a targeted cell population. Additionally, 
such gene delivery methods can also be very useful in the study of cellular biology and 
disease.  
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Non-viral transfection of human retinal endothelial cells (HRECs) remains a 
challenge as does transfection of many other cell types. For example, one recent report 
using lipid coated magnetic nanoparticles achieved only ~5% transfection efficacy [5]. 
Leading commercial reagents, such as Lipofectamine 2000, can improve the transfection 
of HRECs. One study found that this approach could lead to 42%-67% knockdown of a 
target receptor’s surface expression following plasmid transfection [6]. Macrovascular 
(human umbilical vein endothelial cells, HUVECs) are also generally difficult to transfect 
as a lead polymer (polyethylenimine) plus magnetofection yielded transfection efficacy 
of only 39% positive cells [7]. New nanomedicines are needed to further increase the 
effectiveness of non-viral gene delivery.  
Certain poly(β-amino esters) (PBAEs) have recently shown good transfection 
efficacy to a variety of cell types, including hard to transfect cell types like human 
mammary epithelium in 2D and 3D [8], human brain cancer cells [9], and HUVECs [10]. 
Particular polymers formulations have shown selectivity in terms of transfecting brain 
cancer cells as compared to normal astrocytes [9]. In addition, polymer end-group 
modification has been suggested as a tool to tune transfection efficacy [10-12]. The 
objectives of this study were to investigate the endothelial and retinal cell-type 
specificities of PBAE-based nanoparticles and also to identify novel nanoparticles that 
can achieve high transfection of human endothelial cells with minimal toxicity. A new 
PBAE combinatorial polymer library was synthesized and evaluated to discover 
nanoparticles that can transfect either macrovascular (HUVECs) or microvascular 
(HRECs) human endothelial cells or both.  
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6.2 Materials and Methods 
6.2.1 Materials 
All chemicals and solutions were used as received unless otherwise indicated. 
Monomers and vendors used for synthesis are the following:  from Acros Organics [1-(3-
aminopropyl)pyrrolidine (E8)], Alfa Aesar [3-amino-1-propanol (S3), 4-amino-1-butanol 
(S4), 5-amino-1-pentanol (S5), 1,4-butanediol diacrylate (B4), 1,6-hexanediol diacrylate 
(B6), 1-(3-aminopropyl)-4-methylpiperazine (E7)], Fluka [2-(3-
aminopropylamino)ethanol (E6)], Monomer-Polymer and Dajac Laboratories [1,3-
propanediol diacrylate (B3), 1,5-pentanediol diacrylate (B5)], Sigma-Aldrich [1,3-
diaminopropane (E1), 2,2-Dimethyl-1,3-propanediamine (E2), cystamine dihydrochloride 
(E10), 2-(1H-imidazol-4-yl)ethanamine (E12)], and TCI America [1,3-diaminopentane 
(E3), 2-methyl-1,5-diaminopentane (E4), (PEO)4-bis-amine (E5)]. Anhydrous DMSO 
and 3 M sodium acetate buffer were purchased from Sigma Aldrich. Sodium acetate 
buffer was diluted to 25 mM and filtered through 0.2 µm filter. pCMV-eGFP DNA was 
purchased from Aldevron. PBS, 0.25% trypsin-EDTA, Fu-Gene HD, and Lipofectamine 
2000 were purchased from Invitrogen. CellTiter 96® AQueous One MTS assay was 
purchased from Promega. 96-well TCP and non-TCP round-bottom plates were 
purchased from Sarstedt. Human Umbilical Vein Endothelial Cells (HUVECs) and 
EGM-2 Bullet Kit and Reagent Pack were purchased from Lonza. Human retinal 
endothelial cells (HRECs) were obtained from Cell Systems and cultured in EGM2-MV 
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(from Lonza), as previously described [13, 14]. The immortalized human RPE cell line, 
ARPE-19, was obtained from the Dr. James Handa [15]. 
6.2.2 Synthesis of Poly(beta-amino ester) (PBAE) 
The structures of these polymers were chosen so that there are ester linkages to 
ensure degradability of the polymers and amine groups to ensure the ability to bind DNA 
and form nanoparticles. The base polymers were synthesized by mixing diacrylates, 
labeled as ‘B#’ in the text, and amino alcohols, ‘S#’, at a molar ratio of 1.2:1 in glass 
scintillating vials with teflon stir bars, forming ‘B#-S#’ base polymers. The reaction was 
run at 90
o
C for 24 hours. The base polymer was then dissolved at 167mg/mL in DMSO. 
In the last step of the reaction, 480 µL containing 80 mg of the base polymer and 320 µL 
of 0.5 M end-capping amine, ‘E#’, were mixed in a 1.5 mL eppendorf tubes in a shaker 
for 1 hour. Completed polymers were aliquoted into smaller volumes and stored at 4
o
C. 
The completed polymers are designated as ‘B#-S#-E#’; for example, B3-S5-E1 is an end-
modified PBAE formed from the B3-S5 base polymer which is then end-modified with 
the end-capping amine E1. Polymer molecular weights were typically ~10 kDa as we 
previously have reported and among these polymers we have found that molecular weight 
is not correlated to transfection efficacy.[16] We have recently published the polymer 
characterization of these synthetic biomaterials including 
1
H-NMR and Gel Permeation 
Chromatography of each polymer [16]. 
6.2.3 Nanoparticle Sizing 
DNA was diluted in 25 mM sodium acetate buffer to 0.01 mg/mL. Polymer was 
diluted in sodium acetate buffer to either 30 or 60 times that concentration (30 and 60 
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weight to weight, w/w, ratios), added to the DNA solution and incubated at room 
temperature for 10 minutes. Nanoparticles were then diluted 20 fold into PBS and loaded 
into NS500 nanosight tracking analysis (NTA) system. Nanosight videos were captured 
for 60 seconds and then analyzed used the NTA software, version 2.2. 
6.2.4 Transmission Electron Microscopy (TEM) imaging 
Nanoparticles were prepared the same way as for sizing by NTA. 10 uL of sample 
was dropped onto carbon coated copper grids and left to dry in chemical hood for 2 hours. 
Unstained TEM imaging was then performed using the Philips CM120 system. 
Nanoparticle sizing was performed using ImageJ software. 
6.2.5 Green Fluorescent Protein (GFP) transfection 
HUVECs and HRECs were seeded at 2,500-5,000 cells/well onto 96-well plates 
and allowed to adhere overnight, in 100 µL of the appropriate media per well (EGM-2 for 
HUVECs and EGM-2 MV for HRECs). Immediately before transfection, media in plates 
were replaced with 10% supplemented FBS HUVEC media, 100 µL per well. For RPE 
transfections, ARPE-19 cells were seeded at 15,000 cells/well and allowed to grow to 
confluence over 3 days, and then transfected in DMEM with 10% supplemented FBS. 
Polymers and pCMV-eGFP DNA were diluted in 25mM sodium acetate buffer. The final 
DNA concentration of the mixture was 0.03 mg/mL, with PBAEs at either at 0.9 or 1.8 
mg/mL (30 w/w and 60 w/w ratios, respectively). Solution was mixed, incubated for 10 
minutes at room temperature and then 20 µL were added per well. FuGene HD and 
Lipofectamine 2000 were screened to find best formulation by following the 
manufacturer’s guidelines. FuGene HD-DNA ratio of 4-1 was used, with 10 µL added 
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per well, while Lipofectamine 2000-DNA ratio of 1.5-1 was used, with 10 µL added per 
well. Plates then incubated for 4 hours, after which nanoparticle loaded media was 
removed and fresh EGM-2 and EGM-2 MV media were added, 100 µL/well. Each 
experimental condition was evaluated in quadruplicate. Duplicate plates were made for 
each experimental group to use one each for cell viability and transfection efficiency 
measurements. 
6.2.6 Cell metabolism/viability 
Twenty-four hours after transfection, designated plates were used for the CellTiter 
96® AQueous One MTS assay. 10 µL of the aliquoted assay solution was added per well. 
Plates were incubated for 1-4 hours, after which absorbance at 490 nm was measured 
using the BioTek Synergy 2 Plate Reader. Absorbance measurements were corrected 
from background media signal and normalized by untreated groups. Each experimental 
condition was evaluated in quadruplicate. 
6.2.7 Flow cytometry 
Forty-eight hours after transfection, flow cytometry was performed using the 
Accuri C6 flow cytometer with IntelliCyt high-throughput attachment. Cells were washed 
with 1x PBS and trypsinized with 30 µL/well of 0.25% trypsin-EDTA. 170 µL FACS 
buffer (2% FBS, 1x PBS) was added to cells and 200 µL/well transferred to 96-well 
round-bottom plates. The plates were centrifuged at 1000 rpm for 5 minutes, after which 
170 µL/well of the supernatant was removed. The pellets were re-suspended in the 
remaining 30µL of buffer. Plates were then placed onto the IntelliCyt high-throughput 
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attachment and HyperCyt software was to acquire and process data. FlowJo was used to 
analyze the flow cytometry data. 
 
6.3 Results 
6.3.1 Polymer and Nanoparticle Synthesis 
A polymer library was synthesized for gene delivery, such that a large diversity of 
structures could be investigated, each with small differential structural changes from each 
other. The structures of these polymers were chosen so that there are ester linkages to 
ensure degradability of the polymers and amine groups to ensure the ability to bind DNA 
and form nanoparticles. These polymers were synthesized from a pool of 4 acrylate 
monomers, 3 side chain monomers, and 12 end-chain capping molecules as described in 
the methods. The synthetic polymers are referred to by a ‘B’ number, a ‘S’ number, and 
an ‘E’ number, each referring to their constituent monomers. The number following the 
‘B’ or the ‘S’ corresponds to the number of carbons between functional groups in the 
diacrylate or amino-alcohol monomers; thus ‘B4-S5’ is a polymer formed from a base 
diacrylate with 4 carbons between each acrylate group, and an amino-alcohol with 5 
carbons between the amine and the alcohol functional groups. 
Nanoparticles are formed through electrostatic self-assembly, due to attractive 
interactions between cationic polymers and anionic DNA. We use relatively high 
polymer to DNA weight ratios (w/w) such that the polymers encapsulate 100% of the 
DNA as we have recently described [17]. Representative polymers of interest were 
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chosen for sizing measurements. Even though polymer structure varied, nanoparticle size 
was found to be similar with these different types of polymers (Figure 6.2A). 
Hydrodynamic diameter of the nanoparticles was approximately 150 nm, with a range of 
110-190 nm in the particle distributions that was dependent on polymer to DNA weight-
to-weight (w/w) formulation ratio. The average diameter of a nanoparticle formed from 
B3-S5-E1 at 60 w/w as measured by TEM was 147 nm (Figure 6.2B), which closely 
matches the results found from NTA. There was no correlation between the sizes of 
nanoparticles that transfected the cells well (B3-S5-E# and B4-S4-E# series) as compared 
to those that transfected the cells less well (B3-S4-E# series). Therefore, we hypothesize 
that chemical structure, not nanoparticle physical properties, is the driver of the 
differences seen in transfection efficacy. 
6.3.2 Nanoparticle-mediated Gene Delivery  
Leading polymeric nanoparticles were found to be very effective for gene 
delivery to human microvascular and macrovascular endothelial cells. Significantly, 
transfection efficiencies of up to 85% for HRECs and 65% for HUVECs were observed 
as opposed to 49% (HREC) and 32% (HUVEC) with a leading commercially available 
reagent, Lipofectamine 2000 (Figures 6.3A-B). Lipofectamine 2000 was also more toxic 
than the PBAE nanoparticles (Figures 6.3C-D). The polymeric nanoparticles were found 
to display a wide range of transfection efficacies with both HRECs and HUVECs, which 
was dependent on polymer structure. Both the choice of base polymer and end-capping 
groups had a large effect on the transfection efficacy. The B4, B5, and B6 diacrylates 
differ by one carbon, yet there are significant differences in toxicity and transfection 
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efficacy. A similar effect was observed when changing the side-chain amines. For 
example, B3-S4-based polymeric nanoparticles had very low transfection (< 10%), but a 
single carbon added to each of the side-chain monomers (B3-S5-based polymeric 
nanoparticles) resulted in highly effective gene delivery for both HRECs (up to 76%) and 
HUVECs (up to 64%). The end-group of the polymer made a big difference to 
endothelial cell gene delivery as well, where the best formulations usually contained E5, 
E6, and E7. 
In order to better isolate the effects from changing each component of the 
polymer, the data were averaged together across two of the three polymer elements that 
compose each synthetic polymer. In general, B4 and B5 based polymers had the highest 
gene delivery efficacy (Figure 6.4A) and reveal an optimal base diacrylate length. On the 
other hand, we observe an increasing monotonic trend with increasing length for the 
various side-chain amines used in this experiment, with S5 based polymers performing 
best (Figure 6.4B). Unlike with the structure of the base polymers, a clear trend in the 
structure of the end-group with transfection efficacy is not observed (Figure 6.4C). 
However, there are some end-capping amines, such as E6, which dramatically improve 
delivery, and others, such as E12, that are much less effective. These results motivate 
further studies on how polymer structure affects endothelial cell gene delivery.   
6.3.3 Endothelial Cell-specific Gene Delivery  
Comparing the transfection efficiencies between the different cell types and 
tissues revealed interesting trends (Figure 6.5). In this study, the HREC and HUVEC 
transfection profiles were positively correlated (linear regression, R
2
= 0.81), with greater 
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transfection efficiencies for HRECs overall. Similar viability profiles were also observed 
between HUVECs and HRECs. On the other hand, using the same set of nanoparticles, 
there is very little correlation between the transfection efficacies for gene delivery to 
HRECs as compared to retinal pigment epithelium (RPEs, linear regression, R
2
 = 0.21), 
or HUVECs as compared to RPEs (linear regression, R
2
 = 0.23). Polymers that 
performed better on the endothelial cell types as compared the regression line include B4-
S4 and B3-S5, as well as some B4-S5-based polymers (upper left hand corner of Figures 
5B and 5C). As a group, these polymers were synthesized by diacrylate monomers that 
were less hydrophobic and contained 3 or 4 carbons between diacrylate monomer groups. 
On the other hand, there are some polymers that work better on the epithelial cells, such 
as B6-S5 (lower right hand corner of Figures 5B and 5C). This polymer is more 
hydrophobic than the polymers that tend to be better at transfecting endothelial cells and 
this polymer contains 6 carbons between its diacrylate monomer groups. The polymers 
that work well on both endothelial and epithelial cell types include B5-S5 based-
polymers (upper right hand corner of Figures 5B and 5C), which have an intermediate 
level of hydrophobicity and 5 carbons between its diacrylate monomer groups. Strikingly, 
these structural changes are quite subtle and they do not influence nanoparticle size 
(Figure 6.2). 
 
6.4 Discussion 
Synthesis and testing of a PBAE library resulted in the identification of polymeric 
nanoparticles that can transfect human endothelial cells, HRECs and HUVECs, with high 
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efficiency as compared to current commercially available standards. The best polymers 
(both good transfection and viability), B3-S5-E# and B4-S4-E# series, are new PBAE 
structures that were able transfect at least as well as the commercially available reagents 
and in some cases with less toxicity. Additionally, Small molecular changes to polymer 
backbone, side chain or end-group structure dramatically changed transfection efficiency. 
The best polymers were ones that contained B4 and B5, and S4 and S5, with a few 
different E# groups. The most hydrophilic polymers, such as B3-S4, were not good at 
transfecting the cells, while their toxicity was also minimal. On the other hand, the most 
hydrophobic polymers, such as the B6-S5 series, were usually relatively toxic to the 
endothelial cells, subsequently also reducing the transfection efficiency. This trend is 
mirrored when looking at the effects of the different diacrylate monomers used (Figure 
4A), where B4 and S5 performed best. While among certain structures, high 
hydrophobicity correlated to increased cytotoxicity and reduced transfection, overall, 
when all the data is evaluated together, there is not a strong correlation between 
transfection efficiency and viability (R
2
 =0.06, data not shown).   
Interestingly, the gene delivery efficacy across the entire polymer library was 
highly correlated between transfection of HREC and HUVEC cells – nanoparticle 
formulations that performed well for HRECs also performed well for HUVECs (R
2
 = 
0.81). This is dramatically different when compared to the performance of the same 
nanoparticles with retinal pigment epithelium, indicating that formulations could 
potentially be found which selectively transfect one ophthalmic cell type and not the 
other, as can be observed in Figures 5B and 5C. To our knowledge this phenomenon, that 
specific ocular cell types can be targeted directly by fine-tuning of the polymer structure 
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that composes nanoparticles, is striking and surprising. This finding also suggests that 
biomaterial-mediated targeting from this class of materials may be able to be combined 
with other methods of gene delivery targeting such as ligand or coating-mediated cell 
uptake [18-20] and transcriptional targeting [21, 22] to further improve specificity and 
efficacy to only one specific type of cell. 
In particular, we show that the polymers in the middle of the hydrophobicity scale 
for this PBAE library worked very well for the endothelial cells, but much less so for the 
epithelial cells. On the other hand, those that were more hydrophobic, such as the B6-S5, 
worked well for the epithelial cells. Taken together, these correlations indicate that there 
may be natural cell type specificity for polymeric nanoparticles of this class.  
Safe and effective gene delivery vehicles can have a large impact on biological 
studies and for the treatment of diseases. For example, researchers have developed a 
system for gene delivery of sFLT using adeno-associated virus (AAV) to bind VEGF in 
monkeys as a potential treatment for age-related macular degeneration [23]. However, 
viral gene therapy has limitations that may preclude many clinical applications due to 
carrying capacity constraints and safety concerns [24]. In contrast, our study reveals 
premiere non-viral nanoparticles that are enabling technologies for transfection of 
endothelial cells in vitro and are promising for use in vivo as delivery vehicles for genetic 
nanomedicines. We also show that polymer structure itself, may enable cell-specific non-
viral gene delivery. 
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6.6 Figures 
 
 
Figure 6.1. (A) Polymers were synthesized by reacting a diacrylate, ‘B#’, with an amino 
alcohol, ‘S#’; (B) These were then reacted with an end-group, ‘E#’; (C) Monomer 
structures. 
 
 
Figure 6.2. (A) Hydrodynamic diameter by nanoparticle tracking analysis. (B) 
Transmission Electron Microscopy of nanoparticles formed from B3-S5-E1 (60 w/w); 
scale bar is 200nm. 
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Figure 6.3. (A) HUVEC and (B) HREC transfection percentage. (C) HREC and (D) 
HUVEC metabolic activity relative to untreated control. Controls: Gray=untreated, 
Green=FuGene HD, Yellow=Lipofectamine 2000. 
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Figure 6.4. Panel of monomer effects on transfection %. Collapsing (averaging) two of 
three types of monomers attempt to isolate effects of each monomer change. (A) 
Diacrylate base, (B) Side-chain amine base, (C) End-group amine. 
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Figure 6.5. (A) There is a strong correlation between transfection of HUVEC and 
HRECs and (B-C) a much weaker correlation when compared to transfection of RPEs. 
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Chapter 7 
Long-Term Suppression of Choroidal Neovascularization by 
Microparticle Peptide Delivery 
 
7.1 Introduction 
Pathologic angiogenesis plays an important role in several classes of diseases. In 
cancer, angiogenesis supports the growth of tumors [1]. In patients with neovascular age-
related macular degeneration (NVAMD), angiogenesis leads to the loss of central vision 
[2]. There are several angiogenic factors that contribute to pathologic angiogenesis, such 
as vascular endothelial growth factor (VEGF-A), platelet-derived growth factor (PDGF-
BB), and stromal derived factor (SDF-1) and neutralization of one or more of these can 
provide therapeutic benefits [3]. Patients with NVAMD have experienced improved 
visual outcomes from intraocular injections of various types of VEGF antagonists 
including ranibizumab (Lucentis®), an Fab; bevacizumab (Avastin®), a full-length 
antibody; and aflibercept (EYLEA®), a fusion protein consisting of the binding domains 
of VEGF receptors 1 and 2 and Fc fragment [4, 5], but frequent injections over a 
prolonged period are needed to maintain visual benefits. Failure to return for follow up 
which can occur for a variety of reasons such as illness, travel, or transportation 
difficulties can result in permanent loss of vision. More durable treatments are needed to 
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mitigate these risks. Biomaterials for controlled drug delivery can potentially facilitate 
both protection of sensitive biological molecules from quick clearance and degradation as 
well as provide a mechanism for sustained and long-term release. 
We have discovered classes of peptides with very strong anti-angiogenic 
properties, including collagen IV-derived, thrombospondins, CXC chemokines, 
somatotropins and serpins [6]. These peptides have been developed by combining 
experimental and computational approaches and several have been validated by inhibiting 
tumor growth in cancer models [7]. One class of these peptides, the serpin-derived 
peptides, are able to inhibit angiogenesis by both inducing endothelial cell apoptosis as 
well as decreasing their migration by increasing adhesion [8]. One of these serpin-derived 
peptides, which we refer to as SP6001, more specifically derived from DEAH box 
polypeptide 8 protein, was selected and evaluated unencapsulated, in nanoparticles, and 
in microparticles in the mouse model of laser-induced choroidal neovascularization. 
Generally, small peptides possess many advantageous characteristics as 
therapeutic agents, such as high specificity and low toxicity [9]; the main disadvantage is 
their short half-life. Biomaterials, nanoparticles, and microparticles have the potential to 
significantly impact medicine as delivery systems for diverse biological molecules, 
including peptides. A long-term controlled release system can help overcome problems 
associated with current AMD treatments. A number of different polyester polymers, such 
as poly(lactic-co-glycolic acid) (PLGA), have been commonly used in long-term release 
systems. PLGA has been used in several FDA approved devices such as sutures and drug 
delivery devices. It is a material that is biodegradable in water and is generally 
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recognized as safe. PLGA nanoparticles have been used to increase the half-life of 
therapeutics, such as in the encapsulation of a peptide integrin antagonist in PLA/PLA-
PEO nanoparticles [10], as well as encapsulation of the antibody bevacizumab [11]. In 
contrast to nanoparticles, which generally act short-term, larger implantable devices are a 
drug delivery strategy that has been investigated to enable controlled long-term delivery 
[12, 13]. By using polymers such as PLGA, implantable devices can be designed to be 
biodegradable so that they do not need to be surgically removed at a future time [14]. 
In order to protect the SP6001 peptide from degradation and to extend its delivery, 
the peptide can be complexed and/or encapsulated by biodegradable polymers. The 
SP6001 peptide is negatively charged due to a number of glutamic acid residues. 
Therefore, a cationic polymer, such as a poly(beta-amino ester), PBAE, can be used to 
self-assemble with the peptide. PBAEs are also hydrolytically degradable due to the ester 
bonds in the polymer backbone. As such, these polymers have been previously used to 
self-assemble with DNA and RNA to form effective gene delivery nanoparticles [15-17]. 
To further extend release, these polymer-peptide nanoparticles can be encapsulated into 
PLGA microparticles. These microparticles can degrade over time to release the 
nanoparticles and peptide into the eye and create a new treatment for NVAMD.  
 
7.2 Materials and Methods 
7.2.1 Chemicals 
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PLGA [Poly(D,L-lactide-co-glycolide); lactide:glycolide (65:35); Mw 40,000-
75,000] and DCM [Dichloromethane] were purchased from Sigma (St. Louis, MO). We 
synthesized PBAE [Poly(beta-amino ester)], as previously described [18], from the 
following monomers: 3-amino-1-propanol (S3) purchased from Alfa Aesar (Ward Hill, 
MA), 1,3-propanediol diacrylate (B3) purchased from Dajac laboratories (Trevose, PA), 
and 2-(3-aminopropylamino)ethanol (E6) purchased from Fluka/Sigma. The PBAE 
polymer, 2-(3-aminopropylamino)ethanol end-capped 1,3-propanediol diacrylate-co-3-
amino-1-propanol (abbreviated based on its constituent monomers as B3-S3-E6), was 
synthesized at a B3 to S3 molar ratio of 1.05:1. Polymer B3-S3-E6 was kept stored in 
anhydrous DMSO at 100 mg/mL with desiccant at -20°C. Peptides (SP6001 and FITC-
SP6001) were purchased from American Peptide (Sunnyvale, CA). Sodium Acetate 
buffer (NaAc) (pH=5) was purchased from Invitrogen (Grand Island, NY). PVA 
[Poly(vinyl alcohol); Mw 25,000] was purchased from Polysciences (Warrington, PA). 
7.2.2 Nanoparticle formation 
For sizing with a Nanosight NS500: In an eppendorf tube, SP6001 peptide (20 
µg/µL in DMSO) was diluted to 1.2 µg/µL in milli-Q water. In a second tube, 25 mM 
NaAc was added to the PBAE to obtain the desired PBAE concentration. For example, 
for 5:1 weight/weight (w/w) of PBAE to peptide, 125.3 µL NaAc was added to 8 µL (100 
µg/µL) of B3-S3-E6. 100 µL of PBAE solution was added to 100 µL of peptide solution, 
vortexed, and incubated at room temperature for 10 min to allow for nanoparticle 
formation. To characterize nanoparticle size by nanoparticle tracking analysis, 100 µL of 
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nanoparticle solution was diluted into 400 µL milli-Q water and run on a Nanosight 
NS500. 
For in vivo injections: In separate eppendorf tubes 1.25 µL (100 µg/µL) B3-S3-E6 
+ 8.75 µL NaAc was prepared as was 1.25 µL (20 µg/µL) SP6001 + 8.75 µL PBS. The 
solutions were mixed together and then an additional 5 µL PBS was added to bring the 
total peptide concentration to 1.0 µg/µL. For corresponding controls: Buffer only 
contained 2.5 µL DMSO + 13.75 µL PBS + 8.75 µL NaAc; Peptide only contained 1.25 
µL (20 µg/µL) peptide + 13.75 µL PBS mixed with 1.25 µL DMSO + 8.75 µL NaAc; 
Polymer only contained 1.25 µL (100 µg/µL) PBAE + 8.75 µL NaAc mixed with 1.25 
µL DMSO + 13.75 µL PBS. For all samples of nanoparticles containing peptide and 
corresponding peptide controls, 1 µL of 1 µg/µL peptide solutions were intravitreally 
injected into each mouse eye. 
7.2.3 Microparticle formulation 
One hundred mg of PLGA was first dissolved into 2.5 mL of DCM in a test tube 
and vortexed to fully dissolve. The aqueous phase was prepared by mixing peptide 
(SP6001 or FITC-SP6001), PBAE (B3-S3-E6), and milli-Q water in an eppendorf tube. 
First 12.5 µL (20 µg/µL) SP-6001 + 8.33 µL water were mixed, then 2.5 µL (100 µg/µL) 
B3-S3-E6 1.05:1 + 18.33 µL water was added, and then this was diluted with an 
additional 26.67 µL water. For blank microparticles, the aqueous phase was 41.67 µL 
water. The aqueous phase was micropipetted to the PLGA/DCM solution and vortexed 
on high. The mixture was sonicated with the test tube on ice to create the first w/o 
emulsion. Sonication was performed with an amplitude setting of ‘30’, which equals 
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approximately 10 W for 20 seconds. The primary emulsion was poured into 50 mL of 1% 
PVA solution and homogenized at 3.6-3.8 krpm for 1 minute to create the w/o/w 
secondary emulsion. The full volume was transferred into 100 mL of 0.5% PVA solution 
and stirred in a chemical hood for 3 hours. Three wash steps were then performed. For 
each wash step, the microparticle solution was centrifuged at 4
o
C, 4 krpm, for 5 minutes, 
and then the supernatant was removed. Subsequently, 40 mL of refrigerated water was 
added, the microparticle pellet was resuspended and the washing steps were repeated. 
After the last centrifugation step, 5 mL of water was added. Samples were snap frozen in 
liquid nitrogen and immediately placed in a lyophilizer. Following lyophilization, all 
microparticles were stored at -20
o
C. For release and in vivo studies, an appropriate 
amount of microparticles were weighed out and suspended in an appropriate amount of 
PBS to reach the desired concentration. 
7.2.4 SEM imaging of microparticles and ImageJ quantification 
Lyophilized particles were placed on carbon tape (Electron Microscopy Sciences, 
Hatfield, PA) placed on aluminum mounts. Samples were sputtered with gold-palladium, 
and SEM imaging was performed with a LEO/Zeiss FESEM at the JHU School of 
Medicine MicFac. 
7.2.5 Microparticle loading and release profiles 
Microparticles were prepared as described with 10% or 100% of the peptide 
labeled with FITC. Loading efficiency was quantified by dissolving the microparticles in 
DMSO and adding to PBS. The solution was centrifuged to separate out the PLGA 
precipitate and the supernatant was collected for fluorescence measurement. For release 
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studies, microparticles were diluted in PBS at 40 mg/mL in a 1.5 mL tube and incubated 
at 37
o
C with light shaking. At the specified time points, samples were vortexed, spun 
down, supernatant was collected, and new PBS added to the microparticle pellet. DMSO 
was added to the supernatant so that the final solution for fluorescence measurements was 
constant 5% v/v DMSO/PBS. Fluorescence measurements were obtained using a BioTek 
Synergy 2 plate reader with an excitation filter of 485 +/- 20 nm and an emission filter of 
528 +/- 20 nm. Peptide concentration was obtained by comparison to a standard curve for 
6001-FITC in 5% v/v DMSO/PBS. 
7.2.6 In vitro assays for determination of peptide effects 
Human retinal endothelial cells (HRECs) (all cells used were P8-P12) were tested 
in three separate assays. SP6001’s effect on HREC apoptosis was tested by the caspase-
glo 3/7 assay purchased from Promega (Madison, WI). Cells were plated at 5,000 
cells/well in opaque 96-well plates to minimize well-to-well cross-talk. After 24 h, 
complete endothelial cell media was replaced with serum free media. Next, media with 
30/10 ng/mL (bFGF/VEGF) was added with or without peptide at 10 µM. After 48 h, 
caspase-glo luminescent reagent was added at 100 µL/well, and luminescence measured 
with a Victor V plate reader (Perkin Elmer). The experiment was repeated twice. 
We used the ACEA cell migration assay to assess SP6001 effect on cell adhesion, 
SP6001 was added to complete endothelial cell medium at 12.5 μM, and cells allowed to 
adhere in special E-plate (Roche, IN), suitable for cell culture with sensing electrodes. 
Impedance, correlated to cell adhesion, was measured using a RT-CIM system (ACEA 
Biosciences, Inc., San Diego, CA). HRECs were trypsinized and plated at 25,000 
 
178 
cells/well. Cells settled for 30 minutes before being loaded into the ACEA machine. 
Values are scaled to percent increase above the negative control (complete endothelial 
cell media), at 10 h time point. 
HREC migration was tested using the Platypus migration assay. Specialized plates 
with stoppers were purchased from Platypus Technologies (Madison, WI). HRECs were 
plated at 20,000 cells/well in the presence or absence of SP6001 at 10 μM in complete 
endothelial cell media for 2 h, then stoppers were removed and cells allowed to migrate. 
After 20 h cells were stained with calcein AM (Invitrogen, Carlsbad, CA) and read with a 
Victor V plate reader (Perkin Elmer, Waltham, MA). Digital micrographs were taken 
using a Nikon Inverted Scope Eclipse T-100 scope (Nikon Instruments, Inc., Melville, 
NY), and are representative of each image. 
7.2.7 Mouse model of choroidal neovascularization 
Choroidal NV was induced by laser photocoagulation-induced rupture of Bruch’s 
membrane, as previously described [19]. Briefly, 5- to 6-wk-old female C57BL/6 mice 
were anesthetized with ketamine hydrochloride (100 mg/kg body weight) and pupils were 
dilated. Laser photocoagulation was performed in the 9, 12, and 3 o’clock positions of the 
posterior pole of each eye with the slit lamp delivery system of an OcuLight GL diode 
laser (Iridex, Mountain View, CA, USA) and a coverslip as a contact lens to view the 
retina. Production of a tissue bubble by the laser, which indicates rupture of Bruch’s 
membrane, is an important factor in obtaining choroidal NV; therefore, only burns in 
which a bubble was produced were included in the study. After 14 days, the mice were 
perfused with 1 ml of PBS containing 50 mg/ml of fluorescein-labeled dextran (2×10
6
 Da 
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average molecular mass; Sigma-Aldrich, St. Louis, MO, USA) and choroidal flat mounts 
were examined by fluorescence microscopy. Image analysis software (Image-Pro Plus; 
Media Cybernetics, Silver Spring, MD, USA) was used to measure the area of choroidal 
NV at each rupture site. To measure the long-term efficacy, Bruch’s membrane was 
ruptured at various time points after intravitreous injection (of 1.0 µL of peptide, buffer 
without peptide, nanoparticles containing peptide, polymer without peptide, 
microparticles containing peptide, or empty microparticles). Intravitreous injections were 
done under a dissecting microscope with a Harvard Pump Microinjection System 
(Harvard Apparatus, Holliston, MA, USA) and pulled glass micropipettes, as previously 
described [20]. 
7.2.8 Mouse model statistical comparisons 
Data are presented graphically as mean+s.e.m. Experiments were designed so that 
there were fellow-eye controls and comparisons were done using a two-way analysis of 
variance or paired t test. P-values are two-tailed, * indicates p < 0.05 and ** indicates p < 
0.01. 
 
7.3 Results 
The serpin-derived peptide, SP6001 (sequence shown in Figure 7.1), has been 
previously shown to have anti-angiogenic properties in macrovascular endothelial cells 
and in a cancer model [8]. However, its potential inhibitory effect on retinal 
microvascular endothelial cells, its effects on ocular NV, and whether or not a sustained 
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delivery formulation could be achieved were unknown. SP6001 statistically significantly 
increases both apoptosis and adhesion in HRECs, as well as inhibits the migration of 
these cells (Figure 7.2). Biodegradable materials were used to construct a long-term 
peptide delivery system. In the first step, a peptide-polymer nanoparticle was formed with 
a PBAE, a biodegradable and cationic polymer. In the second step, these nanoparticles 
were encapsulated into larger PLGA microparticles that serve as a reservoir for long-term 
release. The polymer structures, peptide structure, and particle diagram are shown in 
Figure 7.1. The negatively charged peptide forms nanoparticles with the positively 
charged, biodegradable polymer through electrostatic self-assembly. Polymer B3-S3-E6 
was chosen due to its biodegradability, positive charge, biocompatibility with cells, and 
for its ability to form self-assembled particles with SP6001. The size of the self-
assembled peptide-polymer nanoparticles formed was determined by use of the 
Nanosight Nanoparticle Tracking Analysis instrument and software. The B3-S3-
E6/SP6001 nanoparticles had a mode size of 119 nm as shown in Figure 7.3A. 
In the next step, microparticles were formed using PLGA via a standard double 
emulsion method. The resulting microparticles were observed using SEM and sizes were 
quantified using imageJ (Figure 7.3B). The number fraction average size was 
approximately 6 µm and the volume fraction weighted size was approximately 12 µm. 
Addition of peptide-polymer nanoparticles did not affect microparticle size or 
morphology of the microparticles. The presence or absence of labeled peptide as 
compared to unlabeled peptide also did not affect particle size or morphology. The 
encapsulation efficiency of the labeled peptide was determined to be approximately 70% 
of the initially loaded peptide amount. The microparticle fabrication process was also 
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evaluated for endotoxin level to ensure that the particles were appropriate to use for 
subsequent in vivo experiments. According to the LAL endotoxin assay, all polymer and 
particle samples contained less than the 0.1 EU/mL of the lowest control sample (Figure 
7.3F). The release of labeled peptide from the microparticles was quantified in situ under 
physiological conditions and observed to last for over 200 days, as seen in Figure 7.4. 
The release curve demonstrates that there is near linear release for approximately 140 
days at ~0.008 µg peptide / mg particle released per day. This is followed by slightly 
slower release phase at additional 60 days. The full release extends over 7 months under 
physiological conditions in situ. 
After developing the peptide release system, we sought to compare its effects with 
the naked peptide in vivo. Free SP6001 was injected at different concentrations on the 
same day as rupture of Bruch’s membrane and after 2 weeks, there was significant 
suppression of choroidal NV in eyes that had been injected with 0.01 µg or 0.1 µg 
(Figure 7.5A). The 0.1 µg dose was chosen as the total peptide dose to use in all 
subsequent experiments. Next, the SP6001/B3-S3-E6 nanoparticles were tested for 
activity as compared to a scrambled control peptide. While none of the controls (buffer, 
scrambled peptide, PBAE polymer) had any anti-angiogenic effect, both the free peptide 
and nanoparticle-complexed peptides caused significant suppression (Figure 7.5B).  
Next, we tested the effect of encapsulating the peptide-containing nanoparticles 
into microparticles. At short time points (2-4 weeks), both the free peptide and the 
peptide in nanoparticles and microparticles significantly suppresses choroidal NV; 
however, at time points longer than 1 month, there was good suppression by the 
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encapsulated peptide but not the free peptide (Figure 7.6). A single injection of the 
encapsulated peptide inhibited choroidal NV for at least 14 weeks. It is important to note 
that even though the microparticle groups contain the same total peptide dose as the free 
peptide dose, and only release a small fraction of peptide at a given time point, the 
microparticle group performed similarly to free peptide at the early time points (<1 
month). This demonstrates both that the peptide is potent at low doses and that controlled 
constant release, rather than injection of a bolus, may be especially advantageous for 
treating NVAMD. Fundus photographs showed slow disappearance of the microparticles 
from mouse eyes that correlated well with the duration of bioactivity (Figure 7.7).  
 
7.4 Discussion 
The eye is a relatively isolated tissue compartment and local delivery can 
facilitate high drug levels within the eye and low systemic levels in other tissues. 
Systemic administration of VEGF antagonists in patients with cancer provides some 
benefits, but also has potential complications including hypertension, thromboembolic 
events, and renal damage [21, 22]. These problems have been largely circumvented in 
patients with NVAMD by intravitreous injections of VEGF antagonists, which neutralize 
VEGF in the eye for 1-2 months in most patients with little effect on systemic VEGF 
levels. However, a month after injection of ranibizumab and possibly as long as 2 months 
after an injection of aflibercept, VEGF is no longer neutralized causing recurrent leakage 
and collection of fluid in the macula that reduces vision. Timely reinjection of a VEGF 
antagonist can stop leakage allowing vision to be regained, but failure to re-inject allows 
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growth of the NV, recruitment of retinal pigmented epithelial cells and glia, and scarring 
that damages photoreceptors resulting in permanent reduction in vision. Attempts to 
reduce follow up and frequency of anti-VEGF injections have resulted in poorer visual 
outcomes than those achieved with monthly injections. Therefore, sustained suppression 
of choroidal NV is needed to achieve the best long-term outcomes in patients with 
NVAMD, and this is difficult to sustain with current treatments that require very frequent 
follow up and injections.  
In this study, we have demonstrated sustained suppression of choroidal NV for at 
least 14 weeks after a single injection of an anti-angiogenic peptide encapsulated in 
nanoparticles and microparticles. Specifically, we report on the efficacy of an anti-
angiogenic serpin-derived peptide, SP6001, to treat AMD and its improved long-term 
efficacy in vivo when released from a biodegradable drug delivery system composed of 
PBAE nanoparticles in PLGA microparticles. The peptide SP6001 shows anti-angiogenic 
efficacy comparable to a recently approved AMD therapeutic, aflibercept, using the same 
mouse model [23]. Statistically significant suppression of choroidal NV was caused by 
the microparticles encapsulating peptide compared to empty control microparticles for at 
least 14 weeks after a single intravitreal injection. The degradation rate of the particles in 
vivo was observed to be faster (approximately twice as fast) as what was observed in situ. 
This is not unexpected as the in vivo microenvironment in the eye contains additional 
degradative enzymes and clearance mechanisms that are not captured in an in situ 
degradation experiment. Biomaterial modification (i.e. PLGA copolymer composition) 
can be used to further slow degradation rate if needed. 
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PLGA, a biodegradable polymer that has been used in FDA approved devices, has 
been used to deliver a number of different drugs in the eye and has been shown to be 
generally well tolerated [11, 24, 25]. For example, Shelke et al. have observed safe and 
sustained release of an encapsulated hydrophilic drug in vivo [24]. Mordenti et al. 
delivered a humanized antibody encapsulated in PLGA to rabbit eyes and observed some 
initial immune response, but no resulting safety issues [26]. Pan et al. have shown long-
term release of PLGA-encapsulated bevacizumab in a similar laser photocoagulation 
model in rats over the course of a few weeks [27]. In this study they observed a 
statistically significant decrease in CNV area at four weeks and at eight weeks post-
injection, but not at six weeks post-injection. In another example, Xu et al. delivered 
dexamethasone acetone loaded PLGA nanoparticles using a rat laser photocoagulation 
model and observed inhibition of CNV [28]. However, here we show a peptide controlled 
release system that maintains anti-angiogenic activity in this laser-induced choroidal 
neovascularization model that lasts for at least 14 weeks following a single injection. In 
this manuscript, we report a potent anti-angiogenic peptide for NVAMD, SP6001, and a 
biodegradable polymeric particle delivery system able to maintain long-term peptide 
efficacy in the eye. 
 
7.5 Conclusion 
We have demonstrated that the combination of a novel serpin-derived peptide and 
its polymeric delivery system is promising as a potential therapeutic for NVAMD. The 
peptide is able to inhibit angiogenesis through multiple mechanisms including interfering 
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with proliferation, adhesion, and migration. The peptide has anti-angiogenic efficacy in 
mice with choroidal NV that peaks at ~50% inhibition at 2 weeks and persists for an 
additional two weeks. By complexing the serpin-derived peptide with a poly(beta-amino 
ester) to form nanoparticles and then encapsulating these nanoparticles within PLGA 
microparticles, inhibition of angiogenesis using the same peptide dose can be extended to 
at least 14 weeks following a single intravitreal injection. The particles are made of safe, 
hydrolytically degradable polymers and have low endotoxin. By delivering the peptide in 
a long-term release system, this treatment may potentially be able to improve patient 
outcomes, both by sustaining suppression of choroidal NV for long periods and through 
the action of a multimodal anti-angiogenic therapeutic. 
 
7.6 Acknowledgements 
The authors thank the Edward N. & Della L. Thome Memorial Foundation (Bank 
of America, Trustee) Awards Program in AMD Research, the NIH (1R21EY022986-01 
and R01EY012609), and the Wallace H. Coulter Foundation for support of this work.  
 
7.7 Disclosure 
JJG and ASP are co-founders and officers of AsclepiX Therapeutics, LLC; 
Potential conflicts of interest are managed by the Johns Hopkins Medical Institutions 
Committee on Outside Interests.  
 
186 
7.8 Figures 
 
Figure 7.1. Polymer, peptide, and particle structures. Structure of PBAE (B3-S3-E6), 
structure of PLGA, SP6001 peptide sequence, and the peptide particle delivery system. 
 
 
Figure 7.2. SP6001 effects on HRECs. (A) SP6001 evaluated in the caspase-glo 3/7 
assay to measure apoptosis, normalized to the negative control. (B) ACEA cell migration 
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assay. Values are scaled to percent increase above the negative control (complete 
endothelial cell media), at the 10 hour time point, (C) Platypus cell migration assay. 
Digital micrographs are shown representative of each condition. Scale bars represent 500 
μm. (D) Quantification from the cell migration assay. Values are significant for *p<0.05. 
 
 
Figure 7.3. Peptide delivery system characterization. (A) Nanoparticle formation 
between the SP6001 peptide and PBAE B3-S3-E6, as measured by NanoSight NTA. The 
mode of the particle distribution is 119 nm. SEM of microparticles, (B) ImageJ size 
quantification. Error bars represent standard deviations of the mean of each sample, (C) 
Empty microparticles with aqueous phase only, (D) Microparticles encapsulating peptide 
SP6001/PBAE B3-S3-E6 nanoparticles, (E) Microparticles encapsulating peptide FITC-
SP6001/PBAE B3-S3-E6 nanoparticles, (F) Limulus amebocyte lysate endotoxin assay 
test performed on LPS controls, as well as polymer and microparticle samples. All 
polymeric samples contained less than the 0.1 EU/mL control and are comparable to 
sterile PBS. Error bars represent standard deviation of the mean of each sample. 
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Figure 7.4. Microparticle release profile. Microparticles are loaded with FITC-
SP6001/B3-S3-E6 nanoparticles and release experiments are performed in phosphate 
buffered saline at 37
o
C on a shaker.  
 
 
Figure 7.5. In vivo efficacy of peptide and nanoparticles. In vivo fluorescein 
isothiocyanate-dextran stained mouse eyes were analyzed in the laser-induced CNV 
model. (A) Free peptide injections, * = p < 0.05, ** = p < 0.01. (B) Polymer, peptide, and 
nanoparticle injections including polymer = B3-S3-E6, nanoparticle = B3-S3-E6 + 
SP6001, control nanoparticle = B3-S3-E6 + scrambled SP6001. (C) Representative 
fluorescence micrographs from buffer injected and peptide injected conditions. 
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Figure 7.6. In vivo efficacy of microparticles. In vivo fluorescein isothiocyanate-dextran 
stained mouse eyes were analyzed in the laser-induced CNV model. “Control 
microparticles” do not contain peptide whereas “0.1 µg/µl microparticles” contain 0.1 µg 
of peptide per injection. * = p < 0.05, ** = p < 0.01. 
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Figure 7.7. Persistence of microparticles in vivo. Fundus photographs showed slow 
degradation of the microparticles in the mouse eyes over 18 weeks. 
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Chapter 8 
Biodegradable Particles Containing a Collagen IV-Derived 
Peptide for Treatment of Ocular Neovascularization and 
Macular Edema 
 
8.1 Introduction 
Aberrant angiogenesis plays an important role in a number of eye diseases, 
including neovascular age-related macular degeneration (NVAMD) and macular edema 
(ME). While a host of genetic and environmental factors may lead to the development of 
such diseases, much of the vision loss occurs during advanced phases when aberrant 
angiogenesis causes leakage and subsequent damage to the macula. Diabetic macular 
edema (DME) is the leading cause of vision loss and blindness in the working-age 
population [1]. In the case of DME, if left untreated, 25% to 30% of patients suffer at 
least moderate vision loss, with many eventually going blind [2]. NVAMD is the leading 
cause of severe vision loss in patients over the age of 60 [3]. In both cases, a number of 
molecular factors may be involved, with vascular endothelial growth factor (VEGF) 
playing a critical role [4]. Therefore, blocking the action of VEGF has been widely 
investigated to treat these diseases. Currently approved therapeutics for NVAMD and ME, 
such as ranibizumab (along with off-label use of bevazicumab), and aflibercept, all work 
through this mechanism. While these therapies can halt the progression of the disease, 
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they require monthly, or bi-monthly, intravitreal injections to prevent further loss of 
vision. 
There are a number of endogenous anti-angiogenic proteins that balance the 
actions of VEGF, and other pro-angiogenic factors [4]. Using a combination of 
computational and experimental techniques, groups have discovered, and then further 
developed, anti-angiogenic proteins and peptides with these various anti-angiogenic 
properties [5, 6]. One class of these peptides, the serpin-derived peptides, have been 
shown to be effective for inhibiting choroidal neovascularization (CNV) in a clinically 
relevant laser-induced CNV-AMD mouse model [7-9]. In order to reduce the number of 
injections required for therapy, one of these serpin-derived peptides was encapsulated in 
a biodegradable polymeric microparticle system [9]. Long-term efficacy up to 14-weeks 
was demonstrated with a single injection. This long-term efficacy is important since 
frequent intravitreal injections can both reduce patient compliance and increase the 
probability of damage due to intravitreal injections [10]. 
Another class of peptides, the collagen-IV derived peptides, has been shown to 
have very strong anti-angiogenic effects both in vitro and in vivo in mouse cancer models 
[11]. These peptides have a few advantages over the previously published serpin-derived 
peptide work. The biological pathway by which the collagen-IV derived peptides work 
has been partly elucidated. This is important for translating a therapeutic to the clinic. In 
this case, these peptides are able to interact with both integrin and integrin-connected 
complexes that leads to altering of cellular proliferation, adhesion, and migration [5, 12-
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14]. Here it will be shown that these peptides also show additional anti-angiogenic 
properties in the eye in a number of relevant and important animal models. 
In order to incorporate these peptides in a long-term release system, they are 
encapsulated into biodegradable polymeric microparticles. As previously described, these 
peptides are encapsulated using poly(lactide-co-glycolide) (PLGA) [9], a generally 
regarded as safe (GRAS) substance as defined by the FDA. Different versions of PLGA 
are tested in order to extend the release window of the peptide. This long-term release 
strategy further enhances the clinical relevance of the system described here, allowing for 
fewer injections of a potentially more efficacious anti-angiogenic therapy. 
 
8.2 Materials and Methods 
8.2.1 Materials 
PLGA [Poly(D,L-lactide-co-glycolide); lactide:glycolide (65:35), Mw 40k–75k; 
lactide:glycolide (75:25), Mw 76k-115k; lactide:glycolide (85:15), Mw 190k-240k], 
DMSO [Dimethylsulfoxide], DCM [Dichloromethane], and acriflavine were purchased 
from Sigma (St. Louis, MO). PVA [Poly(vinyl alcohol); Mw 25,000] was purchased from 
Polysciences (Warrington, PA). Peptide (SP2043) was purchased from New England 
Peptide (Gardner, MA). 
8.2.2 Microparticle formation 
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PLGA was first dissolved into DCM, at 20 mg/mL in a test tube and vortexed to 
fully dissolve. Peptide stock in DMSO (20 mg/mL) was micropipetted to the 
PLGA/DCM solution. The initial mass ratio of peptide to PLGA can vary; common 
formulations are 1:50 and 1:20 peptide:PLGA. Similarly, for the test microparticles 
loaded with acriflavine, acriflavine in DMSO was added to the PLGA/DCM solution. For 
blank microparticle, equivalent volume of DMSO only was pipetted. The mixture was 
sonicated with the test tube on ice. Sonication (Misonix) was performed with an 
amplitude setting of ‘30’, which equals approximately 5-10 W, for 20 seconds. This 
primary emulsion was immediately poured into 50 mL of 1% PVA solution and 
homogenized (Ika T25 digital Ultra-Turrax) at 3.6-3.8 krpm for 1 minute. The full 
volume was then transferred to 100 mL of 0.5% PVA solution and stirred in a chemical 
hood for about 3.5 hours. Three wash steps were then performed. For each wash step, the 
microparticle solution was centrifuged at 4°C, 4 krpm, for 5 minutes, and then the 
supernatant was removed. Subsequently, 40 mL of refrigerated Milli-Q water was added, 
the microparticle pellet was resuspended and the washing steps were repeated. After the 
last centrifugation step, 5 mL of water was added to resuspend the sample. Samples were 
snap frozen in liquid nitrogen and immediately placed in a lyophilizer. Following 
lyophilization, all microparticles were stored at -20°C. 
8.2.3 Scanning electron microscopy (SEM) characterization 
Lyophilized particles were placed on carbon tape (Electron Microscopy Sciences, 
Hatfield, PA) placed on aluminum mounts. Samples were sputtered with gold-palladium, 
and SEM imaging was performed with a LEO/Zeiss FESEM at the JHU School of 
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Medicine MicFac. Sizing of microparticle samples was performed with ImageJ analysis 
of SEM images. 
8.2.4 Microparticle loading and release quantification 
To measure loading, a known mass of microparticles was dissolved in DMSO. 
For acriflavine loaded microparticles, the fluorescence of the dissolved sample was 
measured using a BioTek Synergy 2 plate reader with an excitation filter of 485 +/- 20 
nm and an emission filter of 528 +/- 20 nm. Quantification was performed by comparison 
with an acriflavine standard in DMSO. For peptide loaded microparticles, and 
corresponding blank microparticles, quantification was performed by running gel 
electrophoresis (Bio-Rad Mini-PROTEAN system ) and silver stain analysis (Invitrogen). 
A 12-well 10-20% Mini-PROTEAN tris-tricine gel was used (Bio-Rad), along with 10x 
tris/tricine/SDS running buffer (Bio-Rad) diluted to 1x in Milli-Q water. Each gel 
contained a standard series of a known amount of peptide. The peptide standard series 
included 0, 62.5, 125, 250, and 500 ng of peptide per well. The remaining wells included 
a protein standard, and the microparticle samples, both peptide loaded and blanks as 
controls. The DMSO samples were mixed 1:1 by volume with sample buffer. Sample 
buffer was made of 24% glycerol in 1x PBS. Gel electrophoresis was run until the 2.5 
kDa band of the protein standard traveled approximately two-thirds of the way down the 
gel. The silver stain protocol was followed for gel staining. For the development step, the 
stop solution was added once the lowest peptide standard (in this case 62.5ng) began to 
appear. Gel images were captured with a digital camera and analyzed with ImageJ using 
gel band intensity quantification functionality. 
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To measure release, a known mass of microparticles was suspended in 1x PBS, 
placed on a shaker in a 37 ºC oven. At various time points, samples were centrifuged for 
5 min at ~2.5 krcf. Supernatant was collected and stored at -80 ºC, and fresh PBS was 
added to samples. For acriflavine loaded microparticles, released acriflavine was 
quantified by measuring fluorescence as described above. For peptide loaded 
microparticles, released peptide was quantified using gel electrophoresis and silver 
staining, as described above. For peptide loaded microparticles, two different release 
experiments were performed. The first release experiment contained only 65/35 PLGA, 
and microparticles were suspended in PBS at 100 mg/mL. In the second release 
experiment, with both 65/35 and 85/15 PLGA, microparticles were suspended at 20 
mg/mL in 1x PBS with 0.01% sodium azide and 0.01% polysorbate 20 (w/v %). 
8.2.5 Laser-induced choroidal neovascularization mouse model 
Choroidal NV was induced by laser photocoagulation-induced rupture of Bruch's 
membrane, as previously described [9, 15]. Briefly, 5- to 6-wk-old female C57BL/6 mice 
were anesthetized with ketamine hydrochloride and pupils were dilated. Laser 
photocoagulation was performed in the 9, 12, and 3 o'clock positions of the posterior pole 
of each eye. Only burns in which a bubble was produced, indicating a ruptured Bruch’s 
membrane, were included in the study. Laser photocoagulation was performed at various 
time points after intravitreous injection (of 1.0 μL of peptide, alfibercept, buffer without 
peptide/aflibercept, microparticles containing peptide, or empty microparticles; for 
peptide groups at 1 μg/μL, for aflibercept at standard concentration), 14 days before the 
final end-point. After 14 days, at the final end-point time, the mice were perfused with 1 
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mL of PBS containing 50 mg/mL of fluorescein-labeled dextran (2 × 10
6
 Da average 
molecular mass; Sigma–Aldrich, St. Louis, MO, USA) and choroidal flat mounts were 
examined by fluorescence microscopy. Image analysis software (Image-Pro Plus; Media 
Cybernetics, Silver Spring, MD, USA) was used to measure the area of choroidal NV at 
each rupture site. Intravitreous injections were done under a dissecting microscope with a 
Harvard Pump Microinjection System (Harvard Apparatus, Holliston, MA, USA) and 
pulled glass micropipettes, as previously described [16]. 
8.2.6 Macular edema mouse model 
See reference [17] for full details on both development of the transgenic mouse 
model, as well as mouse disease model induction. Briefly, 1 μL of either peptide, 
aflibercept, buffer without peptide/aflibercept, microparticles containing peptide, or 
empty microparticles, was injected into transgenic mice. Three days before final assay 
time point, mice were given drinking water containing doxycycline. At final time points, 
eyes were evaluated by fundus photography, ocular coherence tomography (OCT), and 
histological analysis. 
 
8.3 Results 
Collagen-IV derived peptides have previously been shown to have potent anti-
angiogenic effects in vitro and in vivo in mouse cancer models [11, 14]. Here, the specific 
biomimetic peptide SP2043 was first tested for its anti-angiogenic efficacy in various eye 
disease models. Further, the efficacy over time of both peptide and a slow-release 
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formulation of the peptide were tested. Long-term release was achieved by encapsulating 
the peptide into PLGA microparticles. These microparticles were made by a double 
emulsion technique commonly employed. Initially, 65/35 PLGA was used to make 
microparticles. Figure 8.1A-C shows SEM images of these microparticles made with an 
initial peptide:PLGA mass ratio of 0, 1:50, and 1:20. Loading quantification indicated a 
loading efficiency of about 20%. The number average diameter of all of these 
microparticles was about 5 µm as quantified by ImageJ analysis (Figure 8.1D).  
Release of the peptide in an in vitro system was measured and found to last 
around 10 months (Figure 8.2). The release experiment was performed in 
microcentrifuge tubes with PBS, placed in a 37ºC oven on a shaker. The release profile 
showed a relatively linear portion over the first few months, followed by a slow-down of 
release, and ending with a final burst. This profile is not uncommon for PLGA-based 
release systems [18]. 
Peptide, peptide encapsulated in microparticles, and aflibercept were then tested 
for their ability to inhibit CNV in a laser-induced CNV mouse model (Figure 8.3). 
Samples were intravitreally injected on day 0, with laser-induction performed two weeks 
before the final assay time point. Representative images, as well as quantification of 
corresponding CNV, are shown in Figure 8.3A. These results show that after two weeks, 
SP2043 inhibits CNV better than aflibercept at a standard dose. Additionally, the amount 
of peptide released has a statistically significant effect compared to blank microparticles 
and seems to have a comparable effect to aflibercept at this time point. In figure 8.3B-D, 
free and encapsulated peptide were injected and CNV was quantified at various time 
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points. As expected, free peptide efficacy decreases over time, while peptide released 
from microparticle maintains its efficacy over time. However, by 12 weeks, the efficacy 
disappears. Fundus images (not shown here) seem to indicate that microparticles are no 
longer around in the eye, matching this activity result. 
In order to increase the residence time of the microparticle samples in the eye, 
PLGA with different lactide:glycolide ratios were investigated. PLGA with L/G ratios of 
65/35, 75/25, and 85/15 were used to make microparticles encapsulating the fluorescent 
molecule acriflavine. Release was quantified over time (Figure 8.4). Release over the 
first few months was similar across groups, after which a separation can be observed 
between the groups, with the 85/15 microparticles released acriflavine most slowly, as 
expected. 
85/15 PLGA was then used in order to encapsulate SP2043 for further 
experiments. SEM imaging was performed to confirm microparticle formation (Figure 
8.5). These microparticles, along with free peptide and aflibercept, were again tested in 
the laser-induced CNV mouse model. As expected, efficacy of free peptide and 
aflibercept decreased over time. On the other hand, the efficacy of the microparticle 
sample maintains efficacy over time, and some efficacy lasts until 16 weeks. Note that 
the total initial dose of the peptide in the free and encapsulated case is the same. In order 
to test the ability of the free and encapsulated peptide to treat macular edema, a 
doxocyclin-induced, tet/VEGF/opsin genetic mouse model was used. This is a 
particularly aggressive model where induction of VEGF causes complete retinal 
detachment in the mice. Free peptide strongly inhibits retinal detachment (data to be 
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shown in future publication). Encapsulated peptide also can inhibit retinal detachment at 
the two week, and to some extent also the two month time point (Figure 8.7). 
For larger animal testing, a functional rabbit assay was developed by Dr. 
Campochiaro’s lab. Data in a future publication will show that the peptide inhibits this 
NV at least as well as aflibercept. In the next step, blank 85/15 PLGA microparticles 
were injected into the rabbit eye in order to see how these microparticles might distribute 
throughout the eye, as well as to track these particles over time. The goal was to inject the 
microparticles inferiorly so that they form a depot out of the visual axis so as not to 
prevent vision. Figure 8.8 shows that this is possible, with a microparticle mass observed 
in the inferior region, while none in the visual axis of the rabbit eye. In one of two rabbits 
tested, the microparticle mass can be observed one month after injection in the same 
place. The rabbits are allowed to move freely during this time. The rabbits were 
sacrificed after one month, with various parts of the eye, including the microparticle mass 
collected. The microparticle mass was taken in order to visualize with SEM (Figure 8.9) 
One can still observe the microparticles intact and comparable to pre-injected 
microparticles. As can be seen in Figure 8.9, the sizes of the microparticle groups are 
similar. 
 
8.4 Discussion 
 The ability to translate a therapeutic to the clinic is dependent on a number of 
factors. Efficacy must be validated on multiple scales, from in vitro cell cultures, to in 
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vivo pre-clinical models, and finally in clinical trials. The biological pathway of activity 
should also be elucidated. Additionally, the therapeutic needs to be active at a level where 
there is minimal toxicity. Ideally, the therapy is also one that is easy for patients to 
comply with and reduces any side-effects of the therapy itself or the route by which it is 
administered. In this chapter, a delivery system is described that was developed in a 
collaborative effort with the labs of Dr. Popel and Dr. Campochiaro, one that attempts to 
address all of these important criteria. 
 The peptide, SP2043, was previously shown to have potent anti-angiogenic 
effects in a number of in vitro assays [14]. SP2043 was shown to decrease human 
umbilical vein endothelial cell (HUVEC) viability, inhibit HUVEC migration, as well as 
inhibit tube formation of HUVECs, microvascular endothelial cells (MECs), and 
lymphatic endothelial cells (LECs). The study also revealed some of the biological 
pathways that this peptide affects. In MECs, SP2043 blocks both HGF- and IGF-induced 
receptor tyrosine kinase activities, pathways involved in various angiogenic effects. The 
peptide does this by interfering with the various protein complexes required to form for 
the activation of these receptor tyrosine kinases. One such partner in these complexes is 
integrin β1, previously also shown to be a target of an earlier version of this peptide [19]. 
In relation to the earlier collagen-IV peptide, SP2043 was designed to be easier to 
manufacture, while retaining its biological properties. 
 The activity of SP2043 is shown here to extend to in vivo models. Importantly, the 
mouse models used are clinically relevant ones. For example, the laser-induced CNV 
model was used to accurately predict efficacy of the most recently approved therapy 
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aflibercept [8]. Here it is shown that SP2043 has efficacy at least as potent as aflibercept 
(Figure 8.3). In addition to inhibiting CNV, these peptides show the ability to prevent 
retinal detachment in a particularly aggressive model of macular edema [17].  
 In order to further improve the therapy, SP2043 was encapsulated into PLGA 
microparticles. Currently approved therapeutics need to be injected intravitreally monthly 
or bi-monthly. Such a procedure reduces patient compliance, which is a problem since 
repeated dosing is required to prevent further vision loss [4]. Further, repeated injections 
can potentially cause adverse events to the patients [10]. Peptide therapeutics are known 
to have shorter half-lives, and, as can be seen in Figure 8.3, efficacy of free peptide 
decreases over time. Therefore, a long-term releasing peptide system can be an important 
advance in the treatment of ocular diseases such as AMD and ME. 
 PLGA is used in a many biomedical applications, has a long track record of being 
safe in humans, and is therefore a GRAS substance as classified by the FDA for various 
applications. Previous work has shown that PLGA can be well tolerated in the eye with in 
vivo models [20]. Other research has shown that there can be an initial inflammation 
response to particles and this response dissipates over a few weeks [21]. It is likely the 
case that the amount and extent of inflammation will depend on the amount of PLGA in 
the eye, the way it is injected, the version of PLGA used, and the type of particle that is 
made. Therefore, while PLGA has been shown to be safe in the eye in some cases, 
toxicity tests are of course still necessary. While no overall signs of toxicity were noticed 
in the described experiments, further safety studies are required. One other issue is that 
the injected particle system should not remain in the visual axis so that vision would not 
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be blocked. While there have been some observed cloudiness in nanoparticle injections, 
this can be avoided in microparticle injections [22]. Here, in a more physiologically 
relevant rabbit model [23], the microparticles are injected inferiorly in the eye (Figure 
8.8). Although the rabbits are free to move around, the microparticle bolus remains in the 
same position as where it was injected, and, most importantly, out of the visual axis. The 
microparticles retain their approximate shape and size over the course of one month in 
the rabbit (Figure 8.9), indicating the potential for long-term release in the rabbit, and 
then possibly also in human patients. 
 The microparticle delivery system showed release of the peptide in vitro over the 
course of many months (Figure 8.2). However, in vitro release systems might not always 
recapitulate the in vivo environment well enough. While efficacy of both free peptide and 
aflibercept decrease over time in the laser-induced CNV model (Figure 8.3, and Figure 
8.6), a single injection of microparticle encapsulated peptides retains efficacy over time 
(Figure 8.3 and Figure 8.6). The extent of efficacy can be modulated by altering the 
structure of PLGA used to make the microparticles. Increasing the L:G ratio extended the 
efficacy over time as seen in Figure 8.6. Efficacy was also observed at the two month 
time point in the aggressive macular edema mouse model (Figure 8.7). Future 
experiments will include testing the long-term improvements in efficacy in rabbit models. 
 An important point is that in all of these experiments, the total injected dose of 
peptide in the microparticle case was the same as for the free peptide groups. Therefore, 
for the controlled release formulations, there is less peptide available to the eye at any 
given time compared to bolus injection. Future experiments will investigate higher 
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loading and the effect of dosage. Peptide releasing microparticles may be a viable 
treatment strategy for NVAMD and ME. 
 
8.5 Conclusion 
A collagen-IV derived peptide, SP2043, was shown to have potent anti-
angiogenic effects in various relevant animal models. In a CNV mouse model, SP2043 
significantly inhibits NV, while also showing an ability to regress already formed NV. In 
a VEGF-inducible model, an aggressive macular edema model, SP2043 is able to prevent 
retinal detachment. Additionally, this peptide efficacy was shown to be at least as good as 
that of the leading approved therapeutic, aflibercept. The peptide was also successfully 
encapsulated in PLGA microparticles. These microparticles were able to release the 
peptide over many months in vitro. Optimization of the biomaterial was performed with 
the purpose of extending long-term release of the peptide. The peptide release in vivo was 
also evaluated in the multiple animal models described and showed efficacy over long 
time points. Therefore, this therapy shows promise for the treatment of NVAMD as well 
as ME. 
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8.7 Figures 
 
Figure 8.1. 65/35 PLGA MPs encapsulating SP2043. (A) 0% SP2043, (B) Initial 1:50 
SP2043:PLGA, (C) Initial 1:20 SP2043:PLGA. (D) ImageJ based size quantification, 
error bars represent sample standard deviation. 
 
 
Figure 8.2. SP2043 release from 65/35 PLGA microparticles suspended in PBS at 
~100mg/mL on shaker in 37ºC oven. At indicated time points, supernatant collected and 
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peptide quantified. Error bars represent standard deviation of sample (n = 3 at each time 
point). 
 
 
Figure 8.3. Microparticle effects in a laser-induced CNV mouse model. CNV induction 
was performed at different times in order to test long-term release and efficacy of the 
peptide in inhibiting angiogenesis. CNV inhibition is quantified by measuring area of 
FITC-dextran in back of the eye. Groups include MP control, MP loaded with peptide, 
peptide only and aflibercept. (A) Two week time point representative images and 
corresponding quantification. (B-D) Long-term time points in CNV mouse model. 
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Figure 8.4. Microparticles loaded with acriflavine using 65/35, 75/25, and 85/15 L/G 
PLGA. Release quantified by measuring fluorescence of collected supernatant over time 
from MPs suspended in PBS at 37ºC on shaker. Error bars represent standard deviation at 
each time point (n = 3). 
 
 
Figure 8.5. MPs made with 85/15 PLGA and 2043, using same double emulsion 
technique as described previously. Lyophilized samples then imaged with SEM. (A) 0% 
loading; (B) 0.6% final peptide loading by weight; (C) 1% final loading. 
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Figure 8.6. 85/15 PLGA microparticle effects in a laser-induced CNV mouse model. 
(Left) Peptide loaded microparticles; (Right) Aflibercept. 
 
 
Figure 8.7. Leakage, retinal detachment model of ME. (Left) Retinal detachment after 
two weeks; (Right) Retinal detachment of two months. 
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Figure 8.8. Persistence of 85/15 MPs intravitreally injected inferiorly in rabbit eye. Use 
fundus imaging to track the injected MP mass over time. Visual axis remains clear, with 
MP mass remaining in bottom of eye for one of two rabbit. 
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Figure 8.9. SEM analysis of persistence of 85/15 MPs intravitreally injected inferiorly in 
rabbit eye. (A) Zoomed out image of MPs from rabbit eye. (C) and (D) Zoomed in 
images of that sample. (E) SEM image of pre-injected MPs. (B) Quantification of size for 
MP samples with and without peptide and pre- and post-injected (after one month) into 
rabbit eye. Quantification performed with ImageJ. Error bars represent sample standard 
deviations. 
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Chapter 9 
Nanoparticle Formulations for the Targeting and Treatment of 
Tumor Vasculature 
 
9.1 Introduction 
Tumors depend on angiogenesis in order to grow beyond a certain size and spread 
throughout the body [1, 2]. Inhibiting tumor angiogenesis can help prevent tumor growth 
[3]. A number of therapeutics, such as bevacizumab and sunitinib, have been developed 
to inhibit tumor angiogenesis that are now clinically approved. These therapeutics usually 
are active against vascular endothelial growth factor (VEGF) or its receptor. However, 
while these therapies have been shown to extend survival in many types of cancers, very 
often the tumors grow back and clinical benefit is reduced [4]. The limitations of such 
therapies might be due to a few factors. At least some of these angiogenic inhibitors, such 
as sunitinib, have been shown to have biphasic dose-response curves [5, 6]. It is also 
hypothesized that tumors can develop or take advantage of alternate pathways to VEGF 
in order to recruit and develop tumor angiogenesis. This might be either in response to 
anti-VEGF or anti-VEGFR therapy or even as a base case in some patients [7]. In order 
to further anti-angiogenic cancer therapy, the development of alternative anti-angiogenic 
agents, controlling the delivery profile of such agents, and combining these agents into 
combination therapies are being pursued [8]. 
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Dr. Popel’s lab has discovered and developed a number of classes of anti-
angiogenic peptides [9]. These peptides have been shown to have potent anti-angiogenic 
activity in vitro and in vivo in cancer animal models [10, 11]. One such class is the 
collagen-IV derived peptides, which have shown to be able to inhibit tumor growth in a 
number of models, including a metastatic tumor model by inhibiting both angiogenesis 
and lymphangiogenesis [12, 13]. The collagen-IV derived peptides have been shown to 
bind to and disrupt integrin and integrin-dependent protein signaling pathways [9, 13, 14]. 
Therefore, not only have these peptides shown very promising pre-clinical data, but they 
also target pathways alternative to VEGF, thereby expanding the arsenal of anti-cancer 
therapies. 
In general, peptides have certain ideal properties as therapeutics, such as high 
specificity [15]. However, peptides can also be difficult to translate to the clinic, for 
example due to short half-lives [16]. One way this can be overcome is by the use of 
nanoparticle (NP) formulations. Nanoparticle formulations have been used to deliver a 
number of therapeutics in various cancer models [17].  Nanoparticle formulations can 
allow for extended half-life by avoiding certain clearance mechanisms, such as enzymatic 
or renal removal. Nanoparticles can also increase biodistribution to the tumor by taking 
advantage of the enhanced permeation and retention (EPR) effect [18]. Enhanced 
permeation is due to the fact that the vasculature recruited by tumors is often irregular 
and poorly formed, with larger pores than normal vasculature. Similarly, the enhanced 
retention is due to irregularly formed lymph vessels that don’t drain fluid as well as 
normal lymph vessels do. 
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 There are various nanoparticle parameters that can be altered to affect their 
efficacy. Altering the size and shape can alter how cells interact with the particles [19, 
20]. Particles can be made of different materials, which can affect how particles degrade 
and release their cargo, how they distribute in the body, and play a role in a number of 
other ways [8]. One other strategy is coating of nanoparticles in an attempt to improve 
targeting to specific tissues or cell types [21]. Nanoparticles can be coated with elements 
that can target specific receptors on cancer cells, or endothelial cells lining tumor 
vasculature. 
 In this chapter, various nanoparticle systems are investigated as possible delivery 
vehicles for the collagen-IV derived peptides. The biomaterials used include poly(beta-
amino esters) (PBAEs), poly(lactide-co-glycolide) (PLGA), and poly(lactide-co-
glycolide)-poly(ethylene glycol) (PLGA-PEG) block copolymers in order to encapsulate 
the peptides. Preliminary evidence to be discussed includes the possibility of the peptides 
used in a dual role as both therapeutic and targeting ligand. 
 
9.2 Materials and Methods 
9.2.1 Materials 
PLGA [Poly(D,L-lactide-co-glycolide); lactide:glycolide (65:35)], DMSO 
[Dimethylsulfoxide], DCM [Dichloromethane], 3M NaAc [Sodium acetate] buffer, 
sucrose, and Sephadex G75 superfine beads were purchased from Sigma (St. Louis, MO). 
PVA [Poly(vinyl alcohol); Mw 25,000] was purchased from Polysciences (Warrington, 
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PA). Peptides (SP2012, SP2024, SP2024-TAMRA, SP2043, and SP2043-IRD800) were 
purchased from New England Peptide (Gardner, MA). The monomers for the PBAEs 
[Poly(β-amino esters)] were purchased as follows: from Acros Organics [1-(3-
aminopropyl)pyrrolidine (E8)], Alfa Aesar [3-amino-1-propanol (S3), 4-amino-1-butanol 
(S4), 5-amino-1-pentanol (S5), 1,4-butanediol diacrylate (B4), 1-(3-aminopropyl)-4-
methylpiperazine (E7)], Fluka [2-(3-aminopropylamino)ethanol (E6)], Monomer-
Polymer and Dajac Laboratories [1,3-propanediol diacrylate (B3), 1,5-pentanediol 
diacrylate (B5), 2-(benzoyloxymethyl)-2-ethylpropane-1,3-diyl diacrylate (BL1), 
ethoxylated bisphenol A diacrylate (BL2), glycerol 1,3-diglycerolate diacrylate (BH1)], 
Sigma-Aldrich [1,3-diaminopropane (E1), 2,2-Dimethyl-1,3-propanediamine (E2)], and 
TCI America [1,3-diaminopentane (E3), 2-methyl-1,5-diaminopentane (E4), (PEO)4-bis-
amine (E5)]. PBAEs were synthesized and characterized as previously described [22]. 
9.2.2 PBAE-peptide complexes 
Each type of PBAE and peptide (SP2043) was diluted in NaAc buffer at varying 
concentrations depending on desired PBAE:SP2043 mass ratios (from 1:1 to 100:1). The 
PBAE solution was pipetted to the SP2043 solution and incubated at room temperature 
for 5 minutes.  
9.2.3 Solid PLGA nanoparticles 
PLGA was first dissolved into DCM, at desired concentration (usually 20 mg/mL 
or 40 mg/mL), in a test tube and vortexed to fully dissolve. Peptide stock in DMSO 
(usually 20 mg/mL) was micropipetted to the PLGA/DCM solution. The mass ratio of 
peptide to PLGA can vary; a common formulation is 1:50 peptide:PLGA. For blank 
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nanoparticle, an equivalent volume of DMSO only was pipetted. The mixture was 
sonicated with the test tube on ice. Sonication (Misonix) was performed with an 
amplitude setting of ‘30’, which equals approximately 5-10 W, for 20 seconds. This 
primary emulsion was immediately poured into 50 mL of 1% PVA solution and sonicated 
at an amplitude setting of anywhere from ‘30’ to ‘100’ for 2 minutes on ice. The full 
volume was then transferred to 100 mL of 0.5% PVA solution and stirred in a chemical 
hood for ~3.5 hours. Three wash steps were then performed. For each wash step, the 
microparticle solution was centrifuged at 4°C, 17 krpm, for 10 minutes, and then the 
supernatant was removed. Subsequently, 30 mL of refrigerated Milli-Q water was added, 
the microparticle pellet was resuspended and the washing steps were repeated.  After the 
last centrifugation step, 5 mL of water was added to resuspend the sample. Samples were 
snap frozen in liquid nitrogen and immediately placed in a lyophilizer. Following 
lyophilization, all microparticles were stored at -20°C. 
Solid PLGA nanoparticles were also stretched, as previously described [20]. 
Briefly, lyophilized nanoparticle mass was weighed out and suspended in water, which 
was then added to a PVA/glycerol solution and mixed thoroughly. The solution was 
added to a mold and allowed to dry into a film. The film was then stretched via a custom 
made stretching device, after which the film is dissolved and the nanoparticles are 
collected and stored for future use.  
9.2.4 PLGA-PEG nanoparticles 
PLGA-PEG-methoxy was first dissolved in DMF at 10 mg/mL (or other desired 
concentration). Then peptide (SP2043 or SP2043-IRD800; stocks at 20 mg/mL in 
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DMSO) were added to the polymer/DMF solution for initial peptide w/w% of 2% (or 
other desired ratio). For blank nanoparticles, an equivalent volume of DMSO only was 
added to polymer solution. The polymer/peptide/DMF solution was added dropwise to 
Milli-Q water spinning on stir plate for final volume ratio of organic:aqueous at 1:10.  
The mixture was spun in the chemical hood for about 4 hours. Particles were washed 
twice using Amicon Ultra-15 centrifuge tubes (Millipore) at 4°C, for 10 min each spin. 
Concentrated particles were stored either in water at 4°C, or lyophilized with different 
amounts of sucrose. 
9.2.5 NP characterization – Sizing and Loading 
For sizing, nanoparticles were first diluted to 1 mg/mL in water or PBS and then 
sized by Nanoparticle Tracking Analysis (NTA, Nanosight NS500), and Dynamic Light 
Scattering (DLS, Malvern Zetasizer Nano ZS90), or transmission electron microscopy 
(TEM). For TEM, 10 uL of sample was dropped onto carbon coated copper grids and left 
to dry in chemical hood for 2 hours. Unstained TEM imaging was then performed using 
the Philips CM120 system.  
For loading quantification, particles were first dissolved in DMSO. For labeled 
peptide, a Biotek Synergy 2 plate reader was used to measure fluorescence of the samples 
and of a labeled peptide only standard. For non-labeled SP2043 samples, quantification 
was performed by running gel electrophoresis (Bio-Rad Mini-PROTEAN system) and 
silver stain analysis (Invitrogen). A 12-well 10-20% Mini-PROTEAN tris-tricine gel was 
used (Bio-Rad), along with 10x tris/tricine/SDS running buffer (Bio-Rad) diluted to 1x in 
Milli-Q water. Each gel contained a standard series of a known amount of peptide. The 
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peptide standard series included 0, 62.5, 125, 250, and 500 ng of peptide per well. The 
remaining wells included a protein standard, and the nanoparticle samples, both peptide 
loaded and blanks as controls. The DMSO samples were mixed 1:1 by volume with 
sample buffer. Sample buffer was made of 24% glycerol in 1x PBS. Gel electrophoresis 
was run until the 2.5 kDa band of the protein standard traveled about two-thirds of the 
way down the gel. The silver stain protocol was followed for gel staining. For the 
development step, the stop solution was added once the lowest peptide standard (in this 
case 62.5ng) just began to appear. Gel images were captured with a digital camera and 
analyzed with ImageJ using gel band intensity quantification functionality. 
9.2.6 In vitro assays 
Human umbilical vein endothelial cells (HUVECs) and EGM-2 Bullet Kit and 
Reagent Pack were purchased from Lonza, and cultured as recommended. Cells were 
grown on a 96-well plate. Proliferation assay was performed using CellTiter 96® AQueous 
One MTS assay, one day after adding either peptide only, polymer only, or peptide plus 
polymer. 10 µL of the aliquoted assay solution was added per well. Plates were incubated 
for 1-4 hours, after which absorbance at 490 nm was measured using the BioTek Synergy 
2 Plate Reader. Absorbance measurements were corrected from background media signal 
and normalized by untreated groups. Each experimental condition was evaluated in 
quadruplicate. 
9.2.7 Biodistribution experiment 
 MDA-MB-231 cells were orthotopically injected into the mammary fat pads of 
athymic nude mice, as previously described [23]. Once tumors reached the appropriate 
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size, samples were injected intravenously. The total peptide (SP2043-IRD800) injected 
was 20 µg per mouse and was kept constant across the different groups that contained 
peptide. The groups included PBS only, free peptide, solid spherical PLGA NPs loaded 
with peptide, solid ellipsoidal PLGA NPs loaded with peptide, and PLGA-PEG NPs 
loaded with peptide. The total injected peptide amount was determined according the 
ability to load the peptide into solid PLGA nanoparticles. In order to collect blood from 
the mice, retro-orbital bleeding was performed at the pre-specified time points and blood 
was collected into heparinized capillaries. After 24 hours, the mice were sacrificed and 
the organs were collected. Fluorescence imaging was performed on all blood and organ 
samples using a Xenogen imager. 
Quantification of the images was performed using ImageJ analysis on the 
“luminescent” Xenogen images. Comparisons were made after normalizing the 
fluorescence signal within each mouse. First, the organ background fluorescence, as 
measured from the PBS only injected group, was subtracted from the fluorescence signal 
obtained in the other groups. Second, for the “Per organ area” plots, the fluorescence of 
each organ per mouse was divided by the total fluorescent signal summed from all the 
collected organs within each mouse, while for the “Total signal” plots, the all 
fluorescence values were multiplied by the area of that organ, as measured by ImageJ. 
For the blood clearance quantification, the Xenogen “luminescent” images were also 
quantified by ImageJ analysis. 
 Note, injections for experiment were performed on different days, with one mouse 
per group injected each day. There were, however, some differences between the 
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protocols used on different days. The mice used on days 1 and 2 were originally injected 
with cancer cells in media, while the mice used on days 3 and 4 were injected with cancer 
cells mixed with matrigel. The PLGA-PEG NPs were prepared all injections of day 2, 
whereas they were prepared right before the specific mouse injection on days 3 and 4. 
Statistical analysis was performed using Graphpad’s Two-way ANOVA test with a 
Bonferroni post-test. 
 
9.3 Results 
 Various nanoparticle systems were developed and explored with the eventual 
purpose of improved delivery of collagen-IV derived anti-angiogenic peptides. It has 
previously been shown that a serpin derived peptide, SP6001, can be complexed by 
certain PBAEs [24]. However, that peptide was negatively charged due to glutamic acid 
residues, allowing for the potential to complex with a positively charged polymer. The 
collagen-IV derived peptides are more hydrophobic and much less charged, with some in 
this class with a slight positive charge, such as SP2012, and some that are neutral, such as 
SP2043. 
In order to see if these peptides can self-assemble with PBAEs, they were mixed 
together in solution and sized with DLS and NTA in order to check for NP formation. 
Figure 9.1A seems to indicate that SP2012 does not readily, or obviously, form NPs 
when mixed with some PBAEs. For the less hydrophobic PBAEs, those without the “L” 
designation, the size is found to be similar to the SP2012 only in solution. In the case of 
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the more hydrophobic “L” PBAEs, the size was similar to the PBAE only sizes. This is to 
say that the NPs observed in each case were similar to the peptide or polymer only cases, 
and so it is difficult to tell if anything new is happening when mixing the two together. 
However, a further in vitro efficacy test was performed in order to see if any changes 
could be observed there when mixing SP2012 and PBAE, Figure 9.1B. Peptide only, 
polymer only, and peptide-polymer mixes were added to HUVECs in a 96-well plate. A 
metabolic assay was used to determine the relative effects on the cells. The signal from 
the peptide-polymer samples were normalized by the polymer only and peptide only 
effects. While there were no statistically significant effects, there were some conditions 
where there might be some increased effect (decreased cellular activity) as compared to 
peptide only, for example with some of the B3S5 polymers. However, this could be due 
to independent effects of the polymer and peptide on the cells, for example, if the 
presence of the (free) PBAEs allowed for better interaction of the peptide with the cells. 
 Next, SP2043 was tested to see if it can form NPs with PBAEs, with data for two 
such PBAEs shown in Figure 9.2. Both the mean and mode of the NP distributions 
increased when comparing the PBAEs mixed with peptide as compared to PBAEs only. 
This difference seemed to decrease as the mass ratio of PBAE to peptide increased. The 
relative concentration of NPs, as well as the relative maximum brightness of the NPs, 
also seemed to increase when adding in the peptides. This seems to suggest that there is 
some interaction between some PBAEs and SP2043. However, another PBAE tested, 
B3S5E1, didn’t show these changes upon addition of the peptide (data not shown). It 
should also be noted that the light scattering observed through the Nanosight seemed to 
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flicker to some extent, possibly indicating non-spherical complexes. Further experiments, 
such as TEM imaging, might reveal more about any possible NP formation. 
 Other, more developed, NP systems were then explored. PLGA NPs were made 
using a commonly employed double emulsion protocol. The sonication settings and 
surfactant concentration were varied in an attempt to modulate the size of the PLGA NPs, 
Figure 9.3. If the sonication setting was too low, such as at 30A, the particles formed in 
the few micron range (data not shown). Increasing the sonication setting to 60A produced 
NPs in the 200-300nm range, with only moderate reductions in size when increasing the 
sonication power past 60A. Increasing the PVA concentration a few fold also did not 
reduce the NP size much. SEM images of the NPs can be seen in the inset of Figure 9.3. 
The shape of NPs has been previously shown to have effects on the biological response to 
these particles. Using previously developed methods, these PLGA NPs were also 
stretched to create ellipsoidal PLGA NPs, as seen in TEMs in Figure 9.4. Loading 
efficiency of the peptide into these PLGA NPs was generally found to be in the 20%-30% 
range. 
 Further, PLGA-PEG NPs were also made to provide yet another option for the 
encapsulation and delivery of these peptides. These NPs were made with a 
nanoprecipitation/emulsion technique that is commonly used with PLGA-PEG block co-
polymers. Here, NPs with sub-100nm size were made, Figure 9.5. Loading SP2024-
TAMRA into the NPs increased their size to an extent, and in all cases, these NPs are 
stable in water at 4ºC for up to a week, Figure 9.5A. These NPs could also be formulated 
with SP2043-IRD800, as seen in Figure 9.2B. These NPs were stable in both water, as 
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well as to an extent in PBS and FBS, but the polydispersity index increaseds as stability 
did begin to decrease over time, especially in 100% FBS. It was observed that the 
concentration at which these NPs were lyophilized, as well as the addition of a 
lyoprotectant, in this case sucrose, could affect the stability of the NPs during 
lyophilization, Figure 9.6. When no sucrose was added, NPs aggregated into larger 
particles after lyophilization. Increasing the amount of sucrose maintained a particle size 
closer to the original pre-lyophilization size. However, it appears that when loaded with 
the peptide it is more difficult to maintain the exact original size. Similarly, increasing the 
NP concentration before lyophilization can also result in aggregation, especially when no 
lyoprotectant is added. 
 A biodistribution experiment was then performed using a number of these NP 
systems. An orthotopic xenograft breast cancer mouse model was used for this 
experiment, using a near infrared fluorescent tagged peptide, SP2043-IRD800. The 
injected groups were PBS only, free peptide, spherical PLGA NPs with peptide, 
ellipsoidal PLGA NPs with peptide, and PLGA-PEG NPs with peptide. In all peptide 
groups, the total amount of peptide injected was the same, at 20µg per mouse. There were 
two groups of mice that were injected. The first group was inoculated with MDA-MB-
231 cells in media, whereas the second group was inoculated with same cells mixed with 
matrigel. Due to potential differences, the plots in Figure 9.7 show data from the 
cell/matrigel inoculated mice. 
In Figure 9.7A, the relative distribution of the fluorescence across the different 
organs within each mouse is shown. While the free peptide was more likely to be end up 
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in the kidneys, the NPs were more likely to end up in the liver. There were no statistically 
significant differences between the groups in terms of accumulation in the tumor after 24 
hours. However, it is interesting that the free peptide was able to match the NP 
accumulation of 10%. Another interesting point is that the ellipsoidal NPs might have 
some extra preference to go to the spleen. The blood clearance was more difficult to 
determine due to weaker signals over background (Figure 9.7B), however, an attempt 
was made to quantify the half-lives using a simple, single exponential decay fitting 
function with GraphPad. The half-lives were each estimated to be approximately 10 
minutes. Further experiments are need to increase the sample size to determine the half-
lives with greater precision. 
 
9.4 Discussion and Future Directions 
 Many promising therapeutics have been discovered that have various limitations 
when attempting to translate to the clinic. For example, while peptides have very good 
specificity, they usually have short half-lives and poor bioavailability [25]. The use of 
nanoparticles to improve delivery has therefore been investigated. Encapsulating 
therapeutics in NPs helps protect the cargo while altering the biodistribution profile in a 
way that can enhance the delivery of the cargo to the appropriate physiological space. In 
the case of treating cancer, in addition to cargo protection, NPs can help targeting to 
tumors in two general ways. NPs can passively target tumors due to the EPR effect. The 
pore size in the leaky tumor vasculature can range from 200 nm – 2,000 nm, depending 
on the tumor type and its particular environment [21]. NPs that are in the range of 10 nm 
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– 200 nm might be optimal since they can take advantage of the EPR effect, while 
reducing renal and reticulo-endothelial system (RES) clearance [26].  NPs can also 
provide active targeting either due specifically to the biomaterial that is encapsulating the 
cargo, or by coating the NP surface with a targeting ligand. 
 Here, a number of NP systems are discussed with the purpose of delivery a potent 
anti-angiogenic class of peptide. PBAEs have displayed some innate cellular targeting in 
vitro, both in the case of cancer and endothelial cell specificity [27, 28]. Initial attempts 
were made to see if some PBAEs could then self-assemble with some of the collagen-IV 
derived peptides. The SP2043 peptide seems to be able to self-assemble with PBAEs, 
Figure 9.2. However, further characterization is required to explore these as potential 
therapeutic NPs. Additionally, a larger library of PBAEs can be tested for the ability to 
form NPs. 
 PLGA is a commonly used biomaterial, and one that is recognized as generally 
regarded as safe (GRAS) by the FDA for certain applications. The peptides were 
successfully encapsulated in a number of PLGA NPs, including solid spherical NPs, solid 
ellipsoidal NPs, and PEG coated NPs. These formulations allow for the exploration of 
both shape and surface properties on the ability of the NPs to deliver to the tumor. Some 
research indicates that increasing the aspect ratio of the NPs could increase tumor 
targeting [21]. It has also been shown that PEGylation can increase the half-life of a 
number of particles [21], which can increase the likelihood that the NPs can be passively 
targeted to the tumor. A biodistribution experiment was then performed with these 
various systems and with free peptide (SP2043 tagged with a near infrared dye was used 
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in all cases). The largest observed difference in the organ distribution after 24 hours was 
that, as expected, the free peptide is more likely to end up in the kidney, while the NPs 
are more likely to end up in the liver. It was interesting to see that there was at least some 
signal in the kidneys of mice injected with the NPs, however, it is not currently clear if 
this is released peptide, or NPs of a certain size that got stuck in the kidney. 
 In all cases, including the free peptide, around 5% - 10% of the measured signal 
ended up in the tumors, Figure 9.7. This is comparable to other reports in the field [29]. 
Another interesting finding is that the free peptide appears to have active targeting to the 
tumor. This suggests that the peptide can be used not only as the active therapeutic, but 
also as a targeting element for the NP system. It would be of interest to perform efficacy 
studies with these various NP systems. 
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9.6 Figures 
 
Figure 9.1. (A) Malvern sizing of polymer only, polymer with SP2012, or polymer with 
plasmid DNA. For polymer only, if no bar, no particles detected. For polymer + DNA, if 
no bars, no sample was measured. (B) Place mixtures of polymer and SP2012 onto 
HUVECs in cell culture and measure effects with use of cell titer metabolic assay. Y-axis 
represents the signal of polymer + peptide after normalizing to both polymer only and 
peptide only effects. 
 
 
 
233 
Figure 9.2. PBAE-SP2043 conjugation attempts, as measured with Nanosight NTA. (A) 
and (C) Using PBAE B4S4E7; (B) and (D) Using PBAE B6S5E7. (A) and (B) Measures 
of mean, mode, and standard deviation of complexes with and without SP2043; (C) and 
(D) Measures of relative concentration and maximum brightness of complexes with and 
without peptide. 
 
 
Figure 9.3. PLGA nanoparticles made with varying sonication settings and PVA 
concentrations. Sizing measured with DLS and NTA. Inset shows SEM of PLGA NPs 
made at 60A loaded with initial 2% by mass SP2024-TAMRA. 
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Figure 9.4. TEM images of PLGA NPs nonstretched (left) or 2x stretched (right). 
 
 
Figure 9.5. PLGA-PEG NPs sizing with Malvern Zetasizer. (A) Varying the initial 
loading w/w% of SP2024-TAMRA, and tracking NPs stored over a few days at 4ºC. (B) 
Varying media in which NPs are stored. These NPs loaded with SP2043-IRD800, 
initially 2% by mass. 
 
 
Figure 9.6. PLGA-PEG stability after lyophilization depends on NP concentration before 
lyophilization and on lyoprotectant concentration. (A) Pre-lyophilization NP 
concentration at 2.5 mg/mL, varying sucrose concentration. (B) Pre-lyophilization NP 
concentration at 6 mg/mL, varying sucrose concentration. For both 0 mg/mL sucrose 
samples, NP size in the micron range. 
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Figure 9.7. Biodistribution experiment; naked = free peptide, sphere = solid spherical 
PLGA NP, ellipse = solid ellipsoidal PLGA NP, PEG = PLGA-PEG NPs. NPs all loaded 
with SP2043-IRD800. (A) Sample organ biodistribution normalized by organ background 
fluorescence and normalized to total signal within each mouse. Two-way ANOVA with 
Bonferroni posttest, * < 0.05. (B) Blood clearance plot and (C) zoomed in for three of the 
groups listed in legend. 
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